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Haematopoiesis is controlled by complex signal transduction pathways and transcription 
regulators which may become dysregulated in acute myeloid leukaemia (AML). Activating 
mutations in FLT3 and c-KIT receptor tyrosine kinases (RTKs) are commonly found in AML 
and can impact on prognosis. Different types of FLT3 mutations are known to have distinct 
biological activities and prognostic implications. The presence of c-KIT mutations has been 
shown to increase the risk of relapse, but there has been no direct comparison of the 
biological activity of AML specific c-KIT mutations occurring in different receptor domains. 
In addition to prognostic information, RTKs are attractive potential targets for therapy using 
small molecule inhibitors.  
To evaluate their biological activity and response to targeted therapies, human UT-7 cells 
were transduced with wild-type and mutant c-KIT isoforms - c-KIT-Δ417-419>Y 
(extracellular domain [ECD]), c-KIT-L576P (juxtamembrane domain [JMD]), c-KIT-D816V 
and c-KIT-N822K (both in the activating loop domain [ALD). There were intrinsic 
differences in signal strength between the mutants examined - only c-KIT-Δ417-419>Y and 
c-KIT-D816V expressing cells had detectable constitutive c-KIT activation and showed 
ligand-independent growth. The response of transduced UT-7 cells to c-KIT inhibitors was 
assessed by treating the cells with dasatinib and masitinib. Cells expressing ALD c-KIT 
mutations were more resistant to dasatinib or masitinib-mediated cell killing in comparison 
to cells expressing c-KIT mutations in the ECD and JMD. Western blotting revealed that 
although c-KIT phosphorylation was potently inhibited, there was residual mTOR and/or 
PI3K/AKT activation in these cells. The resistance to dasatinib observed in c-KIT-D816V or 
c-KIT-N822K expressing cells could be overcome by co-blockade of c-KIT and 
PI3K/mTOR and blockade of c-KIT and PI3K/mTOR was synergistic in all c-KIT mutant 
cell lines at inducing cell death. Blockade of FLT3 and PI3K/mTOR in FLT3-ITD AML cell 
lines also showed similar results.  
During the screening of AML cell lines for c-KIT and FLT3 mutations a novel FLT3-T820N 
point mutation was identified in the ME-1 cell line. Expression of FLT3-T820N in 32D cells 
constitutively activated FLT3 and conferred ligand-independent growth. 32D FLT3-T820N 
cells were most sensitive to the FLT3 inhibitor AC220 with regard to growth inhibition, cell 
killing and decreased phosphorylation of FLT3 compared to FLT3-WT and FLT3-D835Y 
expressing cells. This work highlights the differences in biological outcomes and TK 
inhibitor-sensitivity between different RTK mutants found in AML and shows that 
simultaneous blockade of RTKs and PI3K/mTOR may provide a novel therapeutic approach 




The completion of this thesis would not have been possible without the help and support of 
numerous people including colleagues, friends and family.  
I would like to thank Prof. Asim Khwaja and Prof. Rosemary Gale for their support, 
knowledge and patience throughout the duration of my thesis. I am extremely grateful to 
several colleagues including: Simon Brooks for answering the endless barrage of questions 
and whose technical expertise has been invaluable, Koremu Meja for teaching me about 
drugs and always making me laugh and to Rob Sellar, Glenda Dickson and Maria Virgilio 
who listened to me ranting when things were challenging but always managed to keep me 
optimistic.  
I am forever grateful to Mark Newton, Pam Dhadda and Kirsty Asquith who provided 
endless reassurance, encouragement and were always there for a cocktail or three in the more 
trying moments.  
Finally I would like to say a huge thank you to my dad, mum, brother and sister who have 











TABLE OF CONTENTS: 
1.1 Haematopoiesis .......................................................................................... 18 
1.2 AML Leukaemogenesis ............................................................................. 20 
1.3 Clinical presentation ................................................................................. 21 
1.4 AML Classification .................................................................................... 21 
1.4.1 French-American-British (FAB) classification and cytogenetics ...................... 21 
1.4.2 WHO classification ............................................................................................ 21 
1.5 Prognostic factors in AML ....................................................................... 24 
1.5.1 Clinical factors ................................................................................................... 24 
1.5.2 Cytogenetics ....................................................................................................... 25 
1.5.3 Recurrent gene mutations in AML ..................................................................... 25 
1.5.4 Chemotherapy .................................................................................................... 30 
1.6 Core binding factor leukaemias ............................................................... 31 
1.7 c-KIT ........................................................................................................... 33 
1.7.1 c-KIT structure and function .............................................................................. 33 
1.7.2 c-KIT isoforms ................................................................................................... 35 
1.7.3 c-KIT mutations in AML.................................................................................... 35 
1.7.4 Impact of c-KIT mutations in AML models ....................................................... 36 
1.7.5 Prognostic impact of c-KIT mutations ............................................................... 39 
1.7.6 c-KIT inhibitors ................................................................................................. 40 
1.8 FLT3 ........................................................................................................... 43 
TITLE PAGE ........................................................................................ 1 
DECLARATION .................................................................................. 2 
ABSTRACT ........................................................................................... 3 
ACKNOWLEDGEMENTS ................................................................. 4 
TABLE OF FIGURES: ...................................................................... 10 
LIST OF TABLES:............................................................................. 14 
COMMONLY USED ABBREVIATIONS ....................................... 16 
1. INTRODUCTION ........................................................................ 18 
6 
 
1.8.1 FLT3 structure and function .............................................................................. 43 
1.8.2 FLT3 mutations in AML .................................................................................... 45 
1.8.3 FLT3-ITD mutations .......................................................................................... 45 
1.8.4 Clinical impact of FLT3-ITDs ........................................................................... 45 
1.8.5 FLT3-TKD mutations ........................................................................................ 46 
1.8.6 Clinical impact of FLT3-TKD mutations ........................................................... 49 
1.8.7 Clinical impact of FLT3-WT over expression ................................................... 49 
1.8.8 FLT3 inhibitors .................................................................................................. 49 
1.9 AML and PI3K/ AKT, mTOR and MEK signalling .............................. 53 
1.9.1 PI3K /AKT ......................................................................................................... 53 
1.9.2 mTOR ................................................................................................................ 53 
1.9.3 MEK ................................................................................................................... 54 
1.9.4 PI3K/AKT/ mTOR and MEK activation in AML ............................................. 57 
1.9.5 Mechanisms for PI3K/AKT/mTOR and MEK activation in AML ................... 57 
1.9.6 The use of PI3K/mTOR/AKT and MEK inhibitors in AML ............................. 58 
1.9.7 Dual PI3K/mTOR inhibition .............................................................................. 61 
1.9.8 MEK inhibitors .................................................................................................. 62 
1.9.9 Novel therapeutic approaches ............................................................................ 64 
1.10 Aims ............................................................................................................ 64 
2.1 Cell culture ................................................................................................. 65 
2.1.1 Cell lines ............................................................................................................ 65 
2.1.2 Cell culture reagents .......................................................................................... 66 
2.1.3 Cell culture plastics ............................................................................................ 66 
2.1.4 Small molecule inhibitors .................................................................................. 67 
2.1.5 Recombinant Growth Factors ............................................................................ 67 
2.1.6 Thawing of cells and cryo-preservation ............................................................. 67 
2.1.7 Cell counting and cell viability using the Casy Counter system ........................ 68 
2.1.8 Ficoll centrifugation ........................................................................................... 68 
2.2 Retroviral production ............................................................................... 69 
2.2.1 Reagents for retroviral production ..................................................................... 69 
2.2.2 Transfection of 293T cells ................................................................................. 69 
2.3 Immunoblotting ......................................................................................... 70 
2.3.1 Reagents for immunoblotting............................................................................. 70 
2.3.2 Antibodies .......................................................................................................... 71 
2.3.3 DCTM protein assay ............................................................................................ 72 
2.3.4 Western blotting ................................................................................................. 73 
2.4 Flow cytometry .......................................................................................... 74 
2.4.1 Reagents for flow cytometry .............................................................................. 74 
2.4.2 Annexin V / PI staining ...................................................................................... 74 
2. MATERIALS AND METHODS ................................................ 65 
7 
 
2.4.3 Flow cytometry examining BFP expression ...................................................... 74 
2.4.4 Staining of cells with PE-conjugated antibodies ................................................ 75 
2.4.5 Cell sorting ......................................................................................................... 75 
2.5 Molecular Biology ...................................................................................... 75 
2.5.1 Molecular biology reagents ................................................................................ 75 
2.5.2 DNA extraction .................................................................................................. 77 
2.5.3 RNA extraction .................................................................................................. 77 
2.5.4 Generation of cDNA .......................................................................................... 77 
2.5.5 Polymerase Chain Reaction (PCR) .................................................................... 77 
2.5.6 Principle of overlapping extension PCR ............................................................ 78 
2.5.7 Fragment size separation using the Capillary Electrophoretic Genetic Analysis 
System (CEQ)
TM
 8000 ................................................................................................... 80 
2.5.8 Agarose gel electrophoresis ............................................................................... 80 
2.5.9 Agar plates and LB broth ................................................................................... 80 
2.5.10 Restriction enzyme digests............................................................................... 81 
2.5.11 Sequencing ....................................................................................................... 81 
2.5.12 Cloning ............................................................................................................. 81 
3.1 Introduction ............................................................................................... 83 
3.2 Methods ...................................................................................................... 84 
3.2.1 Cell lines ............................................................................................................ 84 
3.2.2 Screening of pCMV6-XL5-c-KIT (NM_000222 OriGene) ............................... 84 
3.2.3 Quantification of the c-KIT GNNK+ isoform transcript in samples from AML 
patients ........................................................................................................................... 85 
3.2.4 Screening of samples from AML patients for the presence of c-KIT CAG repeat
 85 
3.2.5 Preparation of c-KIT-WT construct lacking the GNNK+ insert and CAG repeat
 86 
3.2.6 Cloning of corrected c-KIT-WT into SFG-xm.eGFP.I2.eBFP2 vector .............. 86 
3.2.7 Generation of c-KIT mutant constructs .............................................................. 90 
3.2.8 Generation of SFG-EMPTY vector ................................................................... 91 
3.2.9 Retroviral production ......................................................................................... 93 
3.2.10 Transduction of UT-7 cells with SFG-c-KIT constructs .................................. 93 
3.2.11 Examination of CD117 expression .................................................................. 93 
3.2.12 Proliferation assay ............................................................................................ 93 
3.2.13 Cytotoxicity assay ............................................................................................ 93 
3.2.14 Data analysis .................................................................................................... 94 
3.3 Results ......................................................................................................... 95 
3.3.1 Sequencing of the pCMV6-XL5-c-KIT (OriGene) construct ............................ 95 
3.3.2 Detection of c-KIT GNNK +/- isoforms in samples from patients with AML .. 95 
3. CHAPTER 3: FUNCTIONAL CONSEQUENCE OF C-KIT 
MUTATIONS IN THE UT-7 AML CELL LINE ............................ 83 
8 
 
3.3.3 Sequencing of samples with AML for the additional CAG (Q) repeat .............. 96 
3.3.4 Transduction of UT-7 cells with SFG-c-KIT and SFG-EMPTY constructs ...... 97 
3.3.5 Impact of c-KIT mutations on proliferation ..................................................... 100 
3.3.6 Impact of c-KIT mutations on downstream signalling ..................................... 103 
3.3.7 Effect of dasatinib treatment on UT-7 cells expressing c-KIT ........................ 104 
3.3.8 Response of UT-7 cells expressing c-KIT to dasatinib and BEZ-235 ............. 108 
3.3.9 Impact of dasatinib and BEZ-235 on c-KIT and downstream signalling in c-KIT 
transduced UT-7 cells .................................................................................................. 109 
3.3.10 Effect of masitinib treatment on UT-7 cells expressing c-KIT ...................... 113 
3.4 Discussion ................................................................................................. 115 
4.1 Introduction ............................................................................................. 120 
4.2 Methods .................................................................................................... 121 
4.2.1 Cell lines .......................................................................................................... 121 
4.2.2 Identification of FLT3 T820N mutation .......................................................... 121 
4.2.3 RNA extraction and cDNA amplification from ME-1 cells ............................ 122 
4.2.4 PCR of FLT3 WT and T820N from ME-1 cDNA ........................................... 122 
4.2.5 Cloning of FLT3 WT and T820N cDNA into the SFG-xm.eGFP.I2.eBFP2 
retroviral vector ............................................................................................................ 124 
4.2.6 Removal of the D7G polymorphism in the SFG-FLT3-WT construct ............ 124 
4.2.7 Generation of SFG-FLT3-D835Y construct .................................................... 127 
4.2.8 Retroviral production. ...................................................................................... 127 
4.2.9 Transduction of 32D cells ................................................................................ 127 
4.2.10 Examination of CD135 expression ................................................................ 129 
4.2.11 Proliferation assay .......................................................................................... 129 
4.2.12 Cytotoxicity assay .......................................................................................... 129 
4.2.13 Detection of Reactive Oxygen Species (ROS)............................................... 129 
4.3 Results ....................................................................................................... 131 
4.3.1 Screening of ME-1 cells for c-KIT and FLT3 mutations ................................. 131 
4.3.2 Response of ME-1 cells to the FLT3 inhibitor AC220 .................................... 132 
4.3.3 Transduction of 32D cells with SFG-FLT3 and SFG-EMPTY constructs ...... 134 
4.3.4 Impact of FLT3-T820N on proliferation.......................................................... 135 
4.3.5 Impact of FLT3-T820N on downstream signalling ......................................... 139 
4.3.6 Effect of AC220 treatment on 32D FLT3-expressing cells ............................. 140 
4.3.7 Response of FLT3-expressing cells to ponatinib ............................................. 145 
4.3.8 Level of Reactive Oxygen Species (ROS) in FLT3-expressing cells .............. 145 
4.4 Discussion ................................................................................................. 149 
4. CHAPTER 4: IDENTIFICATION AND FUNCTIONAL 
ANALYSIS OF A NOVEL FLT3 ACTIVATING MUTATION IN 
CBFL .................................................................................................. 120 
9 
 
5.1 Introduction ............................................................................................. 154 
5.2 Materials and methods ............................................................................ 155 
5.2.1 Cell lines .......................................................................................................... 155 
5.2.2 Screening of AML cell lines and primary AML cells for c-KIT and FLT3 
mutations ...................................................................................................................... 155 
5.2.3 Annexin V/ PI assay ......................................................................................... 155 
5.2.4 Protein detection using western blotting .......................................................... 155 
5.2.5 Immunoprecipitation of FLT3 from MV4-11 and MOLM-13 cells ................ 155 
5.2.6 Data analysis .................................................................................................... 156 
5.3 Results ....................................................................................................... 157 
5.3.1 Confirmation of reported mutations in cell lines ............................................. 157 
5.3.2 Cytotoxic effects of dasatinib in Kasumi-1 and HMC1.2 cells ....................... 157 
5.3.3 The effect of dasatinib on signalling in c-KIT mutant cell lines ...................... 161 
5.3.4 Cytotoxic effect of combining dasatinib with other small molecule inhibitors in 
Kasumi-1 and HMC1.2 cells ........................................................................................ 163 
5.3.5 Evaluation of synergy between dasatinib and PI3K/mTOR inhibitors ............ 165 
5.3.6 Impact of combined inhibition of c-KIT and PI3K/mTOR on downstream 
signalling in Kasumi-1 and HMC1.2 cells ................................................................... 169 
5.3.7 A combination of dasatinib and inhibitors of PI3K/mTOR induces apoptosis 171 
5.3.8 Time course effect of dasatinib on c-KIT autophosphorylation in Kasumi-1 and 
HMC1.2 cells ............................................................................................................... 173 
5.3.9 Cytotoxic effect of dasatinib in SKNO.1 cells ................................................. 174 
5.3.10 Effect of dasatinib on signalling in SKNO.1 cells ......................................... 174 
5.3.11 Synergistic cell killing meditated by c-KIT and PI3K/mTOR blockade is 
limited to c-KIT mutant cells ....................................................................................... 177 
5.3.12 MV4-11 and MOLM-13 cells treated with AC220........................................ 179 
5.3.13 Cytotoxic effect of combining AC220 and BEZ-235 in FLT3-ITD mutant cells
 180 
5.3.14 Impact of combined FLT3 and PI3K/mTOR blockade on cell signalling ..... 182 
5.3.15 Primary CBFL cells ....................................................................................... 183 
5.3.16 Impact of dasatinib and BEZ-235 on cell growth and cell survival in primary 
CBFL cells ................................................................................................................... 183 
5.3.17 The effect of dasatinib and BEZ-235 on downstream signalling in primary 
CBFL cells ................................................................................................................... 187 
5.4 Discussion ................................................................................................. 189 
5. CHAPTER 5: THE IMPACT OF DASATINIB AND OTHER 
SMALL MOLECULE INHIBITORS ON AML CELL LINES 
AND PRIMARY AML CELLS ....................................................... 154 
6. CONCLUSIONS AND FUTURE DIRECTIONS ................... 194 
10 
 
Table of Figures:  
Chapter 1: Introduction  
Figure 1.1 The current hierarchical model of lineage differentiation from a HSC to mature 
progenitors, including some of the known transcription factors and key signalling 
molecules required for haematopoiesis. ............................................................................ 19 
Figure 1.2 Schematic diagrams showing the functional domains of c-KIT in its inactive 
and active form. ................................................................................................................ 34 
Figure 1.3 A diagram highlighting the domains in which c-KIT mutations commonly 
occur in CBFL .................................................................................................................. 34 
Figure 1.4 Schematic diagrams showing the functional domains of FLT3 in its active and 
inactive form. .................................................................................................................... 44 
Figure 1.5 Diagrams of the two most frequent FLT3 mutations in AML. ........................ 44 
Figure 1.6 The protein signalling networks of PI3K/AKT, mTOR and MEK and their 
respective downstream targets. ......................................................................................... 56 
 
Chapter 2: Materials and Methods 
Figure 2.1 A schematic illustrating the principle of overlapping extension PCR. ............ 79 
 
 Chapter 3: Functional consequence of c-KIT mutations in the UT-7 AML cell 
line 
Figure 3.1 Amplification of c-KIT removing the GGTAACAACAAA insert and CAG 
repeat. ................................................................................................................................ 88 
Figure 3.2 Schematic of the cloning strategy used to introduce c-KIT-WT into the SFG 
vector. ............................................................................................................................... 89 
Figure 3.3 Schematic of the cloning strategy used to introduce c-KIT mutations into the 
SFG vector. ....................................................................................................................... 92 
Figure 3.4 Sequencing chromatograms of c-KIT from the pCMV6-XL5-c-KIT construct 
showing the presence of the GNNK insert and CAG repeat. ............................................ 95 
Figure 3.5 Chromatograms showing size separation of the GNNK- and GNNK+ isoforms.
 .......................................................................................................................................... 96 
Figure 3.6 Sequencing chromatogram illustrating the additional CAG repeat isoform in a 
sample with AML. ............................................................................................................ 97 
Figure 3.7 Examination of (a) BFP and (b) CD117 expression within UT-7 transduced 
cells. .................................................................................................................................. 99 
11 
 
Figure 3.8 Western blotting of transduced UT-7 cells examining total c-KIT expression.
 .......................................................................................................................................... 99 
Figure 3.9 The impact of c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-419>Y, c-KIT-D816V, 
c-KIT-L576P and c-KIT-N822K on proliferation in UT-7 cells. ................................... 102 
Figure 3.10 UT-7 cells transduced with c-KIT-WT and mutant constructs treated with or 
without 50ng/mL SCF for 8 hours. ................................................................................. 104 
Figure 3.11 Response of transduced UT-7 cells to dasatinib in the presence of 100ng/mL 
SCF after 72 hours. ......................................................................................................... 106 
Figure 3.12 Western blots of UT-7 transduced cells treated with 0.1-1000nM of dasatinib, 
in the presence of 50ng/mL SCF for 24 hours. ............................................................... 107 
Figure 3.13 Response of transduced UT-7 cells to combinations of dasatinib and BEZ-
235 in the presence of 100ng/mL SCF after 72 hours. ................................................... 111 
Figure 3.14 Effect of dasatinib and BEZ-235 on c-KIT and downstream signalling in UT-
7 transduced cells. ........................................................................................................... 112 
Figure 3.15 Response of transduced UT-7 cells to masitinib in the presence of 100ng/mL 
SCF after 72 hours. ......................................................................................................... 114 
 
Chapter 4: Identification and functional analysis of a novel FLT3 activating 
mutation in CBFL 
Figure 4.1. Amplification of FLT3 and subsequent cloning into the SFG vector backbone.
 ........................................................................................................................................ 123 
Figure 4.2 Cloning FLT3-WT and FLT3-T820N into the SFG vector. .......................... 125 
Figure 4.3 Removal of D7G SNP from the SFG-FLT3-WT construct. .......................... 126 
Figure 4.4 Cloning of FLT3-D835Y into the SFG vector. ............................................. 128 
Figure 4.5 Analysis of FLT3-ITD and FLT3-TKD PCR products from HL60 and ME-1 
cells highlighting the identification of the FLT3 T820N mutation in ME-1 cells. ......... 131 
Figures 4.6 Growth inhibition and cell killing of MV4-11, MOLM-13, PL-21, HMC1.2 
and ME-1 cells treated with AC220 for 72 hours. .......................................................... 133 
Figure 4.7 Effect of AC220 on signalling downstream of FLT3 in the HMC1.2, MV4-11, 
MOLM-13, PL-21 and ME-1 cells. ................................................................................ 134 
Figure 4.8 Examination of (a) BFP and (b) CD135 expression within 32D transduced 
cells. ................................................................................................................................ 137 
Figure 4.9 Western blotting of transduced 32D cells examining total FLT3 expression.137 
Figure 4.10 The impact of FLT3-T820N on proliferation in 32D cells in comparison to 
FLT3-WT, FLT3-D835Y and SFG-EMPTY expressing cells. ...................................... 138 
Figure 4.11 Examining FLT3 signalling in 32D FLT3-T820N, FLT3-WT, FLT3-D835Y 
and SFG-EMPTY cells ± 3.125ng/mL FL for 4 hours. .................................................. 139 
Figure 4.12 32D SFG-EMPTY, FLT3-WT, FLT3-T820N and FLT3-D835Y cells treated 
with AC220 in the presence or absence of 2ng/mL mIL3 with or without 10ng/mL FL for 
48 hours. ......................................................................................................................... 141 
12 
 
Figure 4.13 Response of 32D FLT3 WT, FLT3-T820N and FLT3-D835Y cells to a 
narrower dose range of AC220 in the presence of 10ng/mL FL after 48 hours. ............ 143 
Figure 4.14 Western blots of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y expressing 
cells treated with 6.25-100nM of AC220, in the presence of 10ng/mL FL for 24 hours.143 
Figure 4.15 Response of 32D FLT3 WT, FLT3-T820N and FLT3-D835Y cells to a 
narrower dose range of AC220 in the absence of FL after 48 hours. ............................. 144 
Figure 4.16 Western blots of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y expressing 
cells treated with 6.25-100nM of AC220, in the absence of FL for 48 hours. ............... 144 
Figure 4.17 Response of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y expressing 
cells to ponatinib in the presence or absence of 10ng/mL FL after 48 hours. ................ 147 
Figure 4.18 Examining the level of ROS in 32D FLT3-WT, FLT3-T820N, FLT3-D835Y 
and SFG-EMPTY cells pre-incubated with or without 10ng/mL FL for 8 hours and 
subsequently treated with H2O2. ..................................................................................... 148 
 
 Chapter 5: The impact of dasatinib and other small molecule inhibitors on 
AML cell lines and primary AML cells 
Figure 5.1 Sequencing chromatograms showing the presence of c-KIT mutations in 
HMC1.2, SKNO.1 and Kasumi-1 cells. .......................................................................... 158 
Figure 5.2 Identification of FLT3-ITD mutations in MV4-11, MOLM-13 and PL-21 cells.
 ........................................................................................................................................ 159 
Figure 5.3 Fragment analysis of FLT3–ITD mutations in the MV4-11, MOLM-13 and 
PL-21 cells. ..................................................................................................................... 159 
Figure 5.4 Response of Kasumi-1 cells to dasatinib after 72 hours ................................ 160 
Figure 5.5 Response of HMC1.2 cells to dasatinib after 48 hours ................................. 160 
Figure 5.6 Effect of dasatinib on signalling downstream of c-KIT in Kasumi-1 cells after 
4 hours. ........................................................................................................................... 162 
Figure 5.7 Effect of dasatinib on signalling downstream of c-KIT in HMC1.2 cells after 4 
hours. .............................................................................................................................. 162 
Figure 5.8 Effect of expanded dose range of dasatinib on c-KIT phosphorylation in 
HMC1.2 cells after 4hours. ............................................................................................. 163 
Figure 5.9 Response of Kasumi-1 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 after 48 hours. ......................................................... 164 
Figure 5.10 Response of HMC1.2 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 after 48 hours. ......................................................... 164 
Figure 5.11 Response of Kasumi-1 cells to combinations of dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 ................................................................................................... 166 
Figure 5.12 Response of HMC1.2 cells to combinations of dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 ................................................................................................... 167 
Figure 5.13 Effect of dasatinib and WYE-354, ZSTK-474 or BEZ-235 on c-KIT and 
downstream signalling in Kasumi-1 and HMC1.2 cells after 4 hours. ........................... 170 
13 
 
Figure 5.14 Effect of dasatinib and WYE-354, ZSTK-474 or BEZ-235 on apoptotic 
regulators in Kasumi-1 and HMC1.2 cells after 48 hours of treatment. ......................... 172 
Figure 5.15 Time course effect of dasatinib on c-KIT autophosphorylation and 
downstream target proteins in Kasumi-1 and HMC1.2 cells. ......................................... 173 
Figure 5.16 Response of SKNO.1 cells to dasatinib in the presence or absence of 
10ng/mL GM-CSF for 48 hours. .................................................................................... 175 
Figure 5.17 Response of SKNO.1 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 in the absence of GM-CSF after 48 hours ............... 176 
Figure 5.18 Effect of dasatinib on c-KIT and downstream signalling in SKNO.1 cells 
after 4 hours. ................................................................................................................... 176 
Figure 5.19 Response of PL-21, MV4-11 and MOLM-13 cells to combinations of 
dasatinib and BEZ-235 after 72 hours. ........................................................................... 178 
Figure 5.20 Effect of AC220 on phosphorylation of FLT3 and downstream target proteins 
in MV4-11 and MOLM-13 cells. .................................................................................... 179 
Figure 5.21 Response of MV4-11, MOLM-13 and PL-21 cells to combinations of AC220 
and BEZ-235 after 72 hours. ........................................................................................... 181 
Figure 5.22 Effect of AC220 and BEZ-235 on phosphorylation of FLT3 and downstream 
target proteins in MV4-11 and MOLM-13 cells after 4 hours. ....................................... 182 
Figure 5.23 Response of primary CBFL samples to combinations of dasatinib and BEZ-
235 after 48 hours. .......................................................................................................... 186 
Figure 5.24 Impact of dasatinib and BEZ-235 on cell signalling in primary CBFL samples 
after 4 hours. ................................................................................................................... 188 
14 
 
List of Tables:  
Chapter 1: Introduction 
Table 1.1 The French-American-British classification of AML ....................................... 22 
Table 1.2 The revised 2008 WHO AML classification system. ....................................... 23 
Table 1.3. The MRC risk group classification of patients with AML based on 
cytogenetics. ..................................................................................................................... 26 
Table 1.4 The 10-year survival outcome of patients entered into MRC AML 10, 12 and 
15. ..................................................................................................................................... 26 
Table 1.5 Genes commonly mutated in AML listing their frequency, potential role and 
prognostic impact. ............................................................................................................. 27 
Table 1.6 The docking sites in c-KIT that are phosphorylated upon receptor activation 
and the proteins that subsequently bind to specific residues. ........................................... 33 
Table 1.7 c-KIT mutations reported in CBFL and the domains they target. ..................... 37 
Table 1.8 FLT3 mutations currently reported in AML. .................................................... 48 
Table 1.9 Clinical trials using FLT3 inhibitors in patients with AML. ............................ 50 
Table 1.10 PI3K, AKT, mTOR, PI3K+mTOR and MEK inhibitors currently available 
illustrating their targets, the mechanisms of binding to their targets and current clinical 
status of each inhibitor. ..................................................................................................... 63 
 
Chapter 3: Functional consequence of c-KIT mutations in the UT-7 AML cell 
line 
Table 3.1 Primers used to sequence the coding region of c-KIT from the pCMV6-XL5-c-
KIT plasmid construct. ..................................................................................................... 84 
Table 3.2 PCR primers used to identify the presence or absence of the GNNK isoform 
and the additional CAG repeat. ......................................................................................... 85 
Table 3.3 c-KIT primers used to remove the GGTAACAACAAA insert and CAG repeat.
 .......................................................................................................................................... 90 
Table 3.4 c-KIT primers used to introduce the ∆417-419>Y, L576P, D816V and N822K 
mutations. .......................................................................................................................... 91 
Table 3.5 Live cell number and live cell fraction IC50 values from UT-7 transduced cells 
treated with dasatinib. ..................................................................................................... 106 
Table 3.6 CI values for the cell killing data of transduced UT-7 cells treated with 
dasatinib  and BEZ-235. ................................................................................................. 111 
Table 3.7 Live cell number and live cell fraction IC50 values from UT-7 transduced cells 




Chapter 4: Identification and functional analysis of a novel FLT3 activating 
mutation in CBFL 
Table 4.1 PCR primers used to screen for common FLT3 and c-KIT mutations. ........... 121 
Table 4.2 PCR primers used to clone FLT3 and to introduce the FLT3-D835Y point 
mutation. ......................................................................................................................... 122 
Table 4.3 Primers used to sequence the entire FLT3 gene within the plasmid constructs.
 ........................................................................................................................................ 124 
 
Chapter 5: The impact of dasatinib and other small molecule inhibitors on 
AML cell lines and primary AML cells 
Table 5.1 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell 
killing data of Kasumi-1 and HMC1.2 cells treated with dasatinib and WYE-354, ZSTK-
474 or BEZ-235. ............................................................................................................. 168 
Table 5.2 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell 
killing data of PL-21, MV4-11 and MOLM-13 cells treated with dasatinib and BEZ-235.
 ........................................................................................................................................ 177 
Table 5.3 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell 
killing data of MV4-11, MOLM-13 and PL-21 cells treated with AC220 and BEZ-235.












Commonly used abbreviations 
ALD  Activating loop domain  
ALL  Acute lymphoblastic leukaemia  
Allo-SCT Allogeneic stem cell transplantation 
AML  Acute myeloid leukaemia 
APL  Acute promyelocytic leukaemia 
ATRA  All-trans-retinoic acid 
Auto-SCT Autologous stem cell transplantation 
BFP2  Blue fluorescent protein 2 
BM  Bone marrow 
bp  Base pairs 
CBF  Core binding factor 
CBFL  Core binding factor leukaemia  
cDNA  Complementary DNA 
CIR  Cumulative incidence of relapse 
CLP  Common lymphoid progenitor 
CML  Chronic myeloid leukaemia  
CMP  Common myeloid progenitor 
CN-AML Cytogenetically normal AML 
CR  Complete remission 
DFS  Disease-free survival 
DNA  Deoxyribonucleic acid 
ECD  Extracellular domain 
EFS  Event-free survival 
FAB  French-American-British 
FL  FLT3 ligand  
FLT3  Fms-like tyrosine kinase-3 
gDNA  Genomic DNA 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GMP  Granulocyte/macrophage progenitor 
GVHD  Graft-versus-host disease 
GVL  Graft-versus-leukaemia 
HLA  Human leukocyte antigen 
HSC  Haematopoietic stem cell 
ITD  Internal tandem duplication 
JMD  Juxtamembrane domain  
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LSC  Leukaemic stem cell 
MDR-1  Multi-drug resistant protein 
MDS  Myelodysplasia  
MEP  Megakaryocyte/erythroid progenitors 
mIL3  Murine Interleukin 3 
MLL  Myeloid/lymphoid leukaemia 
MRC  Medical Research Council 
MRD  Minimal Residual Disease 
NK  Normal karyotype 
OS  Overall survival 
PB  Peripheral blood 
PCR  Polymerase chain reaction 
RFS  Relapse-free survival 
RTK  Receptor tyrosine kinase 
SCT  Stem cell transplantation 
SEM  Standard error of the mean 
SNP  Single nucleotide polymorphism 
TKD  Tyrosine kinase domain 
TMD  Transmembrane domain  
TRM  Treatment-related mortality 
WBC  White blood cell count 
WHO  World Health Organization 











Within the bone marrow (BM) of an adult human approximately one trillion new cells are 
generated daily. To maintain this high turnover in cell production, haematopoietic stem cells 
(HSCs) are required to replenish the system through a process called haematopoiesis. HSCs 
are rare cells that reside in the BM and form the apex of a cellular hierarchy, with the 
terminally differentiated cells at the bottom (Figure 1.1). HSCs are pluripotent, giving rise to 
all cell lineages whilst also possessing the ability to self-renew. The HSCs divide via 
asymmetric cell division, giving rise to a daughter cell committed to differentiation and a 
daughter cell that maintains the pool of HSCs. This process is controlled by the BM 
microenvironment and complex genetic interactions, with some of the key transcription 
factors and signalling molecules highlighted in Figure 1.1. As the HSCs differentiate they 
form intermediate progenitor cells, e.g. the common myeloid progenitor (CMP), that 
gradually commit to a specific cell lineage. Blood cells fall into two main branches,  the 
myeloid lineage comprised of red blood cells (RBCs), megakaryocytes, mast cells, 
eosinophils, neutrophils, monocytes/macrophages and platelets, and the lymphoid lineage 
made up of B and T lymphocytes and natural killer cells (Orkin & Zon, 2008;Doulatov et al., 
2012). A number of transcriptional regulators and/or signalling molecules are dysregulated 
in acute myeloid leukaemia (AML). AML is characterised by an expansion of immature 
myeloid cells (blast cells) within the BM and peripheral blood that have lost their ability to 





LT-HSC = long term HSCs, ST-HSCs = short term HSCs, CMP = common myeloid 
progenitor, MEP = megakaryocyte-erythroid progenitor, GMP = granulocyte-macrophage 
progenitor, CLP = common lymphoid progenitor, AK2 = adenylate kinase 2, GATA2 = 
GATA binding protein 2, RUNX1 = Runt-related transcription factor 1, PU.1 = ETS domain 
transcription factor, C/EBPα = CCAAT/enhancer protein alpha, IRFs = interferon regulatory 
factors, BCL11A = B-cell lymphoma/leukaemia 11A protein, GFI.1 = zinc finger protein, 
NOTCH1 = Notch homolog 1, translocation-associated (Drosophila) and PAX5 = paired box 
protein. 
 
Figure 1.1 The current hierarchical model of lineage differentiation from a HSC to 
mature progenitors, including some of the known transcription factors and key 
signalling molecules required for haematopoiesis. c-KIT and/or FLT3 expression have 
been illustrated based on reports of surface expression on specific cell populations or of 








1.2 AML Leukaemogenesis 
Within AML, a subset of cells known as leukaemic stem cells (LSCs) are thought to be 
responsible for the initiation, progression and relapse of the disease. The first report of 
leukaemia-initiating cells was by Dick and colleagues demonstrating that primitive human 




 expression were capable of recapitulating 
AML within non-obese diabetic mice with severe combined immuno-deficiency disease 
(NOD/SCID mice) (Bonnet & Dick, 1997). The exact origin and definition of LSCs is, 
however, widely debated. Subsequent studies have shown that mice with enhanced 









cell compartments have leukaemia-initiating properties, highlighting that 
LSCs are not restricted to one specific cell subset (Taussig et al., 2008;Yoshimoto et al., 
2009). A recent report examining BM from patients with CD34
+
 AML revealed that 
approximately 80% of patients have two distinct leukaemia progenitor cell populations as 






















 (GMP-like cells). Analysis of these cell populations 
revealed that both compartments had LSC activity and were more closely related to their 
normal progenitor cell type than to normal stem cells (Goardon et al., 2011). Interestingly, 
the LMPP-like cells were able to give rise to the GMP-like population but not the contrary. 
Mouse models of human AML have demonstrated that murine LSCs are phenotypically 
downstream of the GMP, which opposes the view of LSCs being equivalent to HSCs in 
regards to their cellular hierarchy (Huntly et al., 2004;Somervaille & Cleary, 2006). This 
demonstrates the heterogeneity of LSCs both between and within individual patients.     
Although the exact origin of LSCs is debatable, the biological function of LSCs is similar to 
HSCs as demonstrated by their ability to self renew and reside in a state of quiescence 
(Bjerkvig et al., 2005). Quiescence may contribute to resistance to cytotoxic chemotherapy 
as a result the majority of patients with AML relapse. This is supported by emerging data 
suggesting that patients with AML that express higher levels of stem-cell related genes have 
a worse prognosis (Eppert et al., 2011). LSCs show a number of features that differ from 
normal HSCs including constitutive activation of nuclear factor B (NF-κB), active Wnt/β 
catenin signalling, increased expression of interferon regulatory factor-1 (IRF-1)/death 
associated protein kinase (DAPK)/Bcl-2, and abnormal cell surface marker expression of 
CD44, CD47, CD123 and CD96 (Zhang et al., 2013;Lagadinou et al., 2013). Several groups 
have exploited these differences and shown selective eradication of LSCs and not normal 
HSCs using the Bcl-2 inhibitor ABT-263, fenretinide (a synthetic retinoid which inactivates 
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NF-κB) and blocking monoclonal antibodies targeting CD47 (Majeti et al., 2009;Lagadinou 
et al., 2013;Zhang et al., 2013).  
1.3  Clinical presentation 
AML is characterised by the accumulation of immature myeloid cells within the BM. This 
interferes with normal haematopoiesis, leading to a reduction in both red and white blood 
cells and a decrease in platelets. Symptoms of AML include breathlessness, fatigue, ease of 
bruising, bleeding and an elevated risk of infection. In 2000-2003 the incidence of AML in 
younger patients (<65 years of age) was reported to be 1.8 per 100,000 persons which 
increased to 17 per 100,000 persons in people ≥ 60 years of age (Deschler & Lubbert, 2006). 
1.4 AML Classification  
1.4.1 French-American-British (FAB) classification and cytogenetics 
The first comprehensive classification of AML was using the French-American-British 
(FAB) sub-type system (Bennett et al., 1976;Bennett et al., 1985). The FAB system stratifies 
AML according to morphology and histochemistry, with a blast threshold of 30% within the 
BM. It stratifies AML into nine subtypes, M0-M7, based on the degree of maturity of the 
leukaemic cells, defined in Table 1.1. Within this classification system specific cytogenetic 
abnormalities are generally found within particular subgroups, including t(15;17), t(8;21) 
and inv(16) which fall into the subtypes M3, M2 and M4Eo respectively. In 1998 Grimwade 
and colleagues showed conclusively that specific cytogenetic abnormalities can impact on 
clinical outcome in AML and therefore provide a framework for risk-adapted therapy 
(Grimwade et al., 1998). In 2010 this was refined further to include rarer abnormalities and 
is illustrated in Table 1.3 (Grimwade et al., 2010). The use of cytogenetics is now considered 
the gold standard for risk-adapted therapy in AML. However, 40-50% of patients with AML 
are cytogenetically normal (CN). In recent years somatic mutations have been identified in 
specific genes in CN-AML, allowing for risk-adapted stratification of patients within this 
subgroup.   
 
1.4.2 WHO classification  
More recently, specific genetic and chromosomal abnormalities within AML have been 
identified as important prognostic factors. This led the World Health Organisation (WHO) to 
a more stringent classification system combining cytogenetic, immunophenotypic, 
morphological, genetic and clinical features (Vardiman et al., 2002). This system identifies 
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AML using a lowered blast cell threshold of 20% in the BM or peripheral blood (PB). 
However, AML is still considered if patients present with recurrent genetic abnormalities, 
even though this blast cell criterion may not be met. Table 1.2 gives the recently revised 
scheme showing 6 groups: AML with recurrent genetic abnormalities, AML with 
myelodysplasia-related changes, AML with therapy related neoplasms, AML not otherwise 
specified, myeloid sarcomas and myeloid proliferations related to Down syndrome. Current 
revisions have added two provisional AML entities including mutated nucleophosmin 1 
(NPM1) or mutated CCAAT/enhancer-binding protein alpha (CEPBA) (Vardiman et al., 
2009). Mutations in FLT3 are not currently given a distinct classification as they can be 
associated with other recurrent cytogenetic abnormalities, e.g. t(15;17)(q22;q12) and the 
t(6;9)(p23;q34). Approximately a third of patients with AML fall into the ‘AML not 
otherwise specified’ subgroup. However, the identification of new molecular markers such 
as NPM1 and CEPBA are likely to allow this group to be stratified further.   
 
FAB subtype  Description  
M0  Undifferentiated acute  myeloblastic leukaemia 
M1  Acute  myeloblastic leukaemia without maturation  
M2  Acute  myeloblastic leukaemia with minimal maturation  
M3  Acute promyelocytic leukaemia 
M4  Acute myelomonocytic leukaemia 
M4Eo Acute myelomonocytic leukaemia with eosinophilia 
M5  Acute monocytic leukaemia 
M6  Acute erythroleukaemia  
M7  Acute megakaryoblastic leukaemia   
Table 1.1 The French-American-British classification of AML  
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AML subgroup AML characteristics  
Recurrent genetic 
abnormalities 
AML with t(8;21)(q22;q22); (RUNX1T1;RUNX1) 
AML with inv(16)(p13q22) or t(16;16)(p13;22); (CBFB;MYH11) 
Acute promyelocytic leukaemia with t(15;17)(q22;q11-21);(PML;RARA)  
AML with t(9;11)(p22;q23); (MLLT3-MLL) 
 
AML with t(6;9)(p23;q34); (DEK-NUP214) 
 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); (RPN1-EVI1) 
AML (megakaryoblastic) with t(1;22)(p13;q13); (RBM15-MKL1) 
 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukaemia with myelodysplasia-related changes 





AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations 
related to Down 
syndrome  
 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down syndrome 
Table 1.2 The revised 2008 WHO AML classification system.  Adapted from Vardiman et 
al (2009).  
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1.5 Prognostic factors in AML 
1.5.1 Clinical factors  
Numerous clinical features in patients with AML have a prognostic impact including age, a 
high white blood cell count at diagnosis and secondary or therapy-related AML. Increasing 
age is an independent adverse prognostic factor in AML showing a decrease in overall 
survival (OS) (Appelbaum et al., 2006;Juliusson et al., 2009). Data from the Medical 
Research Council (MRC) trials has shown that patients >60 years of age, fit enough for 
intensive chemotherapy, had an OS of just 14% at 5 years from trial entry (Smith et al., 
2011). The poor prognosis of elderly patients is proposed to be the result of a multitude of 
factors including adverse cytogenetics, increased expression of multidrug resistance protein 
(MDR-1), prior myelodysplasia (MDS), reduced tolerance to cytotoxic chemotherapy and 
intrinsic chemoresistance (Slovak et al., 2000;Appelbaum et al., 2006;Erba, 2007;Smith et 
al., 2011).  
In conjunction with the above, the response to induction therapy and the level of minimal 
residual disease (MRD) are also important prognostic factors. Following treatment complete 
remission (CR) is defined as a bone marrow aspirate containing <5% leukaemic blasts with 
evidence of normal maturation of other marrow elements (Grimwade et al., 2010). An MRC 
study showed that if the BM blast count following the first and second courses of 
chemotherapy were greater than 15% and 5% respectively then this was associated with a 
poorer survival and an increased risk of relapse (RR) (Wheatley et al., 1999). Patients falling 
above these threshold limits should therefore have their therapy re-evaluated. Following 
induction or consolidation therapy patients may achieve a morphological CR but still retain a 
proportion of cells with an abnormal karyotype. Such patients have an increased RR and a 
reduced OS (Marcucci et al., 2004;Balleisen et al., 2009). As MRD is an important 
prognostic marker, techniques are now used to detect it. Flow cytometry can be used to 
identify specific aberrant cell immunophenotypes and real-time quantitative polymerase 
chain reaction (RQ-PCR) can be used to identify leukaemia-specific targets such as fusion 
proteins or particular mutations associated with AML (Smith et al., 2011).    
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1.5.2 Cytogenetics  
The use of cytogenetic abnormalities has become a powerful prognostic tool for risk-adapted 
treatment stratification in AML (Mrozek et al., 2004). The MRC recently updated its risk 
stratification based on these cytogenetic abnormalities using a cohort of 5876 patients with 
AML aged 16-59 years enrolled on the MRC AML10 (n=1238), AML12 (n=2241) and 
AML15 trials (n=2397) (Grimwade et al., 2010). Karyotype analysis of these patients 
showed 55.5% of cases fell into the intermediate risk group of which 41% had a normal 
karyotype, 25% had recurrent favourable cytogenetic abnormalities including t(15;17) 
(q22;21)/PML-RARA, t(8;21)(q22;q22)/RUNX1-RUNX1T1 or 
inv(16)(p13q22)/(t(16;16)(p13;22)/CBFB-MYH11 and 19.5% cases had adverse risk 
cytogenetics including -7 del(7q), -5/del(5q), t(9;22) and inv(3)/t(3;3). The survival outcome, 
10 years from trial entry, of these patients based on their cytogenetic abnormalities is 
summarised in Table 1.4, showing 55-81% survival for the favourable risk group, 24-39% 
for the intermediate and 3-11% for those in the adverse risk group.     
1.5.3 Recurrent gene mutations in AML 
Cytogenetic abnormalities are established as diagnostic and prognostic markers in AML. 
However, approximately 50% of leukaemias are CN (Frohling et al., 2005). This has led to 
targeted sequencing of dysregulated growth factor receptors, signal transduction proteins, 
transcription factors, chromatin remodelers and apoptosis regulators in patients with AML. 
Mutations in some of these genes such as FLT3, NPM1 and CEPBA have shown an impact 
on prognosis and are now being used at diagnosis as independent risk factors (Beran et al., 
2004;Boissel et al., 2006;Grimwade et al., 2010;Green et al., 2010b). Table 1.5 summarises 
some of the genes commonly mutated in AML. For some of these genetic lesions the impact 
on prognosis has not been fully elucidated. Therefore these markers require further study 
before they can be used for risk-adapted therapy. Two genes not included within the table are 







Risk group  Incidence 
(%)  
Cytogenetic abnormalities  
Favourable  25 t(15;17) (q22;21)/PML-RARA 
t(8;21)(q22;q22)/RUNX1-RUNX1T1 
inv(16)(p13q22)/(t(16;16)(p13;22)/CBFB-MYH11 
Intermediate  41 Normal karyotype  
14.5 Other non-adverse karyotype  
Adverse  19.5 inv(3)(q2,1q26)/t(3;3)(q21;q26)  
 del(5q), -5, add(5q) 
 -7, add(7q)/del(7q) (excluding AML with favourable karyotype) 
 t(6;11)(q27;q23) 
 t(10;11)(p11~13;q23) 
 t(11q23) (excluding t(9;11)(p21_22;q23) and t(11;19)(q23;p13) 
 t(9;22)(q34;q11) 
 -17/abn(17p) and complex  
 abn(3q) (excluding t(3;5)(q21_25;q31_35) 
 (≥4 unrelated abnormalities) 
 
Table 1.3. The MRC risk group classification of patients with AML based on 
cytogenetics. Adapted from Grimwade et al (1998) and Grimwade et al (2010). 
 
Cytogenetic abnormality  Risk group 10-year overall 
survival (%)  
t(15;17) Favourable  81 
t(8;21) Favourable 61 




Intermediate  39 
t(3;5) Intermediate 34 
t(6;9) Intermediate 27 
Other t(11q23) Intermediate 22 
AML with other MDS-related Intermediate 24 
t(9;22) Adverse 11 
-7/del(7q) Adverse 10 
-5/del(5q) Adverse 6 
Inv(3) Adverse 3 
 
Table 1.4 The 10-year survival outcome of patients entered into MRC AML 10, 12 and 
15. Adapted from Grimwade et al (2010).   
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Table 1.5 Genes commonly mutated in AML listing their frequency, potential role and prognostic impact. 
Gene Normal function Incidence Type of mutation and importance Prognostic effect References  
NPM1 NPM1 is a 
phosphoprotein that 
shuttles between the 
nucleus and the 
cytoplasm. It is involved 
in ribosome biogenesis 
and thought to have a 
tumour suppressive role 
42-62% 
(CN-AML) 
Most mutations reside in exon 12. ~75-
80% of the mutations are characterised 
by heterozygous tetranucleotide 
duplications (TCTG) which result in a 
frameshift disrupting the C terminus of 
the protein. This causes aberrant 
localisation of NPM1 to the cytoplasm 
NPM1 mutations, in the absence of a 
FLT3-ITD, have a favourable outcome 
in CN-AML. Patients with an NPM1 
mutation are twice as likely to have a 
FLT3-ITD or FLT3-TKD mutation 
when compared to those with WT 
NPM1. The presence of an NPM1 
mutation with a FLT3-ITD does not 
negate the poor outcome of FLT3-ITD 
positive AML. The impact of a FLT3-
TKD and an NPM1 mutation is 
unclear; some groups have reported an 
association towards a better OS and 











et al., 2010)  
CEBPA CEBPA functions as a 
tumour suppressor and is 
implicated in the 
regulation of granulocyte 
development 




Mutations are heterozygous, primarily 
residing at the N-terminus (frameshift 
mutations) or at the C-terminus (in-
frame insertion/deletions). N-terminal 
mutations lead to loss of the full length 
p42 protein but preserve the p30 
isoform which has an inhibitory 
dominant-negative effect on the 
remaining wild type p42. Mutations at 
the C-terminus occur in the leucine 
zipper region which disrupts DNA 
binding or dimerisation. ~55% of 
patients have two mutations usually one 
N-terminal and one C-terminal 
mutation.  
CN-AML patients with CEBPA 
double mutations, but not CEBPA 
single mutations, are associated with a 
favourable prognosis. The presence of 
a FLT3-ITD in conjunction with a 
CEPBA double mutation loses its 
favourable outcome. Coincidence of 
CEBPA double and NPM1 mutations 
is infrequent. The presence of a 
CEBPA WT or a CEBPA single 
mutation in conjunction with a NPM1 
mutation does not impact on the 
favourable prognosis associated with 
an NPM1 mutation. 





Gene Normal function Incidence Type of mutation and importance Prognostic effect References  
TET2 The TET family are a 
group of enzymes 
involved in catalysing 5-




8-27 % AML Mutations are spread throughout the 
gene. Mutations normally cause loss of 
function via missense, frameshift or 
nonsense mutations. The exact effects 
of TET mutations are unknown. 
The prognostic impact of TET2 
mutations is unclear. Some studies 
have reported an unfavourable 
prognosis for intermediate risk patients 
with a TET2 mutation while others 
have reported no significant prognostic 
effects. 
(Chou et al., 
2011;Gaidzik et 
al., 2012) 
DNMT3a DNMT3a is a 
methyltransferase enzyme 
that converts cytosine to 
5-methylcytosine and is 






Point mutations are most frequent at 
residue R882 but frameshift, nonsense 
and splice-site mutations have been 
identified across the gene. The 
consequence of DNMT3a mutations 
remains unclear. 
DNMT3a mutations are associated 
with an adverse prognosis in patients 
with intermediate risk cytogenetics. 
(Ley et al., 
2010;Thol et 
al., 2011) 
IDH1/2 IDH1/2 are isocitrate 
dehydrogenase enzymes 
that convert isocitrate to 
α-ketoglutarate in an 
NADP-dependent manner 





Mutations lead to accumulation of the 
oncometabolite 2-hydroxglutarate 
which suppresses TET2 activity and 
promotes HIF1α expression. This is 
proposed to be involved in driving 
leukaemogenesis. 
The prognostic impact of IDH1/2 
mutations is unclear. Some studies 
have reported no difference in outcome 
in regards to IDH mutational status, 
others have demonstrated that the 
presence of an IDH1 mutation in the 
absence of a FLT3-ITD confers an 
independent adverse prognosis, while 
mutations in IDH2 at residue R140 are 
associated with a favourable prognosis. 
(Green et al., 
2010a;Green et 
al., 2011;Naoe 
& Kiyoi, 2013) 
ASXL1 Implicated in activation 
and silencing of HOX 
genes, which are involved 
in chromatin remodelling. 
3-11% AML Mutations are commonly found in 
exon 12. They are often frame-shift, 
missense or non-sense mutations 
associated with a loss of function. 
Evaluation of prognostic significance 
is still under review. 
(Naoe & Kiyoi, 
2013) 
Table 1.5 (continued)  
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Gene Normal function Incidence Type of mutation and importance Prognostic effect References  
TP53 TP53 is a tumour 
suppressor gene involved 
in cycle arrest, apoptosis 
and DNA repair. 
10-15% 
AML 
Mutations are normally characterised 
by loss of function. Mutations are 
predominately found in patients with a 
complex karyotype.  




MLL-PTD Mixed lineage leukaemia 
protein is a DNA binding 




MLL partial tandem duplication (PTD) 
is an in-frame gain of function 
mutation that drives proliferation and 
maintains self renewal. 




WT1 Wilms tumour 1 (WT1) is 
a transcriptional regulator 





15% AML Mutations are predominantly 
frameshift or nonsense changes 
resulting in loss of function. 
The presence of a WT1 mutation in 
CN-AML has an unfavourable 
outcome compared to patients with 
WT WT1. 
(Paschka et al., 
2008) 
K/N-RAS K/N-RAS are a family of 
membrane bound proteins 






K/N RAS are usually deregulated by 
point mutations rendering RAS 
constitutively active. 
K/N-RAS mutations do not impact on 
OS. 
(Bowen et al., 
2005) 




Although there have been improvements in therapeutics and supportive care, the majority of 
patients with AML eventually succumb to the disease. An exception to this is acute 
promyelocytic leukaemia (APL), which occurs in approximately 10% of patients with AML. 
The treatment of APL has dramatically improved with >75% of patients achieving a cure 
when treated with a combination of all-trans retinoic acid (ATRA) with anthracycline-based 
protocols (Roboz, 2011). The induction treatment for all other subtypes of AML has largely 
remained unchanged for the last 30 years. Standard induction therapy consists of cytarabine 
(AraC), a cytotoxic agent, in combination with an anthracycline such as daunorubicin or 
idarubicin (Tallman, 2005). Overall, 60-80% patients <60 years of age achieve a CR, but 
only 30-40% of patients are still alive and disease-free after 5 years (Tallman, 
2005;Fernandez et al., 2009). It has been reported that 48.5% of patients >60 years of age 
achieve CR from induction therapy, however elderly patients have a dismal 5 year survival 
of <10% (Farag et al., 2006). Attempts to improve the induction regime include increasing 
the dose of AraC, the use of alternative anthracyclines or anthracenediones compounds, or 
the use of additional drugs such as etoposide, fludarabine or cladribine, however they have 
all failed to show a significant advantage compared to the standard therapy. In contrast, the 
addition of gemtuzumab ozogamicin, a monoclonal antibody to CD33, to cytarabine and 
daunorubicin induction therapy in patients <60 years of age has been shown to significantly 
improve survival in patients with favourable risk cytogenetics and 70% of patients with 
intermediate risk cytogenetics (Burnett et al., 2011).  
Following induction therapy the optimal treatment choice in AML is still unclear. There are 
currently three treatment options including intensive chemotherapy for 3-4 cycles, high dose 
chemotherapy in conjunction with autologous stem-cell transplantation (auto-SCT) or 
allogeneic stem cell transplantation (allo-SCT). The current consensus following the first CR 
(CR1) suggests that patients with good-risk cytogenetics should receive chemotherapy or an 
auto-SCT, while patients with poor-risk cytogenetics should be recommended for a allo-SCT, 
regardless of response to induction therapy (Koreth et al., 2009;Schmid et al., 2012). For 
patients with intermediate-risk cytogenetics, the benefit of an allo-SCT over auto-SCT or 
chemotherapy is highly debated. Allo-SCT administered after CR1 has demonstrated the 
lowest RR rates and the best anti-leukaemic effect, as a result of the graft-versus-leukaemia 
(GvL) effect, when compared to auto-SCT or consolidation therapy. However, it is 
associated with increased treatment-related mortality (TRM) and therefore has shown limited 
benefit on OS (Burnett et al., 1998;Cassileth et al., 1998). Auto-SCT negates some of the 
toxicities associated with allo-SCT, and has been shown to reduce the RR in several trials. 
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However, due to prolonged marrow aplasia and TRM associated with the procedure, there 
has been no observable improvement in OS (Vellenga et al., 2011). Auto-SCT also does not 
elicit the immunological response of the GvL effect and there is the risk of re-transplanting 
residual LSCs.  
1.6 Core binding factor leukaemias  
Core binding factor leukaemia (CBFL) is characterised by the chromosomal rearrangements  
t(8;21)(q22;q22) or inv(16)(p13;q22)/t(16;16)(p13;q22) which generate the fusion proteins 
RUNX1-RUNX1T1 (AML1-ETO) and CBFβ-MYH11 respectively. These fusion proteins 
disrupt the normal function of core binding factor (CBF). The CBF factor is a heterodimeric 
transcription factor composed of a DNA-binding CBFα subunit (RUNX1, RUNX2 or 
RUNX3) and a non-DNA binding counterpart subunit CBFβ. RUNX1 (AML-1) binds to 
core enhancer sequences (TGT/cGGT) within promoters or enhancers of haematopoietic-
specific lineage genes and recruits CBFβ, which strengthens the DNA binding affinity of 
RUNX1 (Reilly, 2005). Other lineage-specific transcription factors are then recruited to the 
RUNX1/CBFβ complex, which drives transcription of myeloid lineage genes such as 
myeloperoxidase (MPO), interleukin 3 (IL3), colony stimulating factor 1 receptor (CSF1R) 
and granulocyte-macrophage colony stimulating factor (GM-CSF). 
In t(8;21) leukaemia, the RUNX1 protein becomes fused at the C-terminus to the co-
repressor protein ETO, otherwise known as RUNX1T1. The RUNX1-RUNX1T1 fusion 
protein still retains its ability to bind to RUNX1 DNA targets and its binding partner CBFβ, 
however the ETO protein functionally dominates (Licht, 2001). The ETO protein recruits a 
repressor complex comprised of mSin3A, N-Cor and histone deacetylase (HDAC), which 
blocks transcription of key myeloid differentiation genes (Licht, 2001). Inv(16) generates a 
fusion protein between the major contractile protein smooth muscle myosin heavy chain 11 
(MYH11) and CBFβ. The CBFβ-MYH11 fusion protein retains its ability to bind to RUNX1 
and contains an additional CBFβ binding site that increases its binding affinity for RUNX1. 
The MYH11 component interacts with the repressor proteins mSin3A, N-Cor and HDAC, 
leading to transcriptional repression of RUNX1-transcribed genes. The CBFβ-MYH11 
protein also actively retains RUNX1 either in the cytoplasm, in deposits on cytoskeletal 
filaments, or within the nucleus within rod-like complexes (Adya et al., 1998;Reilly, 2005). 
This further limits the amount of RUNX1 available for transcription of myeloid genes. In 
vitro studies have shown both fusion proteins promote self-renewal while causing a block in 
myeloid differentiation (Kuo et al., 2006;Elagib & Goldfarb, 2007). However, the fusion 
proteins alone are not capable of inducing AML in murine models and require additional co-
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operating mutations in signalling genes such as FLT3 or c-KIT to induce AML (Yuan et al., 




1.7.1 c-KIT structure and function 
The c-KIT proto-oncogene, also referred to as stem cell factor receptor (SCFR) or CD117, is 
a class III transmembrane receptor tyrosine kinase (RTK). The c-KIT gene is located on 
chromosome 4q11-q12 and is encoded by 21 exons. c-KIT is a 976 amino acid protein 
comprised of five immunoglobulin-like loops within the extracellular domain (ECD), a 
transmembrane domain (TMD), a juxtamembrane domain (JMD), two tyrosine kinase 
domains (TKD1 and TKD2) linked by a kinase insert domain (KID), and an activating loop 
domain (ALD) (Figure 1.2a). The first 3 immunoglobulin-like domains of the c-KIT receptor 
form a binding site for its ligand, stem cell factor (SCF) (Orfao et al., 2007). Binding of SCF 




 loops of the 
ECD and results in autophosphorylation of specific tyrosine residues in the cytoplasmic 
domain of the receptor. Four such residues are Y547, Y553, Y568, and Y570, which are 
critical for maintaining the auto-inhibitory structure of the JMD. When the receptor 
dimerises, these residues become phosphorylated (DiNitto et al., 2010). This causes a 
conformational change releasing the JMD from the kinase domain and switching of the ALD 
from a packed position to an extended form, allowing ATP and protein substrates into the 
catalytic site, as illustrated in Figure 1.2b. Phosphorylation of residue Y823 stabilises the 
ALD in the active conformation. Numerous docking proteins are capable of interacting with 
specific tyrosine phosphorylation sites within c-KIT, as shown in Table 1.6. c-KIT can 
therefore activate an array of signal transduction pathways including the Janus kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT), Phosphatidylinositol 3-
kinases/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and rat 
sarcoma/proto-oncogene c-RAF/extracellular signal-regulated kinases pathways 
(RAS/RAF/ERK). c-KIT mediates a number of functions including cell proliferation, 
differentiation, survival and migration (Malaise et al., 2009). c-KIT is also involved in 
cellular processes including haematopoiesis, melanogenesis and gametogenesis.  
Tyrosine 
residue 













Table 1.6 The docking sites in c-KIT that are phosphorylated upon receptor activation 






Figure 1.2 Schematic diagrams showing the functional domains of c-KIT in its inactive 
and active form. (a) c-KIT in its monomeric inactive form (b) c-KIT when the receptor 
dimerises in the presence of SCF causing structural reconfiguration leading to the activation 
of the receptor. 
 
Figure 1.3 A diagram highlighting the domains in which c-KIT mutations commonly 
occur in CBFL. Two hot spots are highlighted in red, one in the ECD and one in the TKD2. 
Point mutations and insertions/tandem duplications have been found in the TMD and JMDs 






1.7.2 c-KIT isoforms  
The mRNA of c-KIT can be alternatively spliced into two different isoforms. The two 
isoforms are characterised by the presence or absence of the Gly-Asn-Asn-Lys (GNNK) 
amino acid sequence found in the JMD. Both isoforms co-exist in different tissues such as 
the lung, BM, fetal liver, mast cells, brain, ovary and testis (Piao et al., 1994). However, the 
GNNK- transcript has been identified as the predominant isoform. Different cell signalling 
capabilities have been associated with the different isoforms. Ba/F3 cells transduced with 
constructs expressing either c-KIT GNNK- or c-KIT GNNK+ showed that cells expressing 
the GNNK- isoform activated PI3K/AKT more strongly, resulting in increased cell 
survival/proliferation in comparison to cells expressing the GNNK+ isoform (Pedersen et al., 
2009). In AML, GNNK- is the main transcript expressed and one study suggested that 
patients with AML expressing just the GNNK- transcript had a better 3 year OS and 
progression free survival (PFS) in comparison to patients expressing the GNNK+ and the 
GNNK- transcripts (Guerrini et al., 2007).  
1.7.3 c-KIT mutations in AML 
Somatic mutations in c-KIT have been identified in a host of diseases including 
gastrointestinal stromal tumours (GIST), melanoma, systemic mastocytosis, 
myeloproliferative diseases and leukaemias. In AML, c-KIT is highly expressed on 60-80% 
of myeloblasts and is mutated in approximately 5% of all AML (Beghini et al., 2004). c-KIT 
mutations are, however, more commonly found in CBFL. The largest study to date of 199 
adult patients with t(8;21) and 155 with inv(16) reported 28% of patients had a c-KIT 
mutation, with a greater frequency of mutations occurring in inv(16) in comparison to t(8;21) 
(35% versus 23%, p=0.02) (Allen et al., 2013).  In contrast, a study of 203 paediatric patients 
with CBFL reported a lower incidence of c-KIT mutations of 19% (Pollard et al., 2010). 
Other studies have reported that the incidence of c-KIT mutations in CBFL can range from 
13-46% (Care et al., 2003;Beghini et al., 2004). In CBFL, c-KIT mutations localise to 
mutational hotspots. Allen et al (2013) reported that 54% of c-KIT mutations occur in exon 
17 (ALD) as point mutations, 28% occur within exon 8 (ECD) in the form of inframe indels 
and 8% occur either as point mutations in exon 10 (TMD) or insertions/tandem duplications 
in exon 11 (JMD) (Figure 1.3). Table 1.7 lists some of the c-KIT mutations identified in 
patients with AML and the domains they target. Of note, point mutations in exon 17 
primarily reside at residues D816 and N822 and inframe indels occur between residues 417-




The structural impact of c-KIT mutations depends on their location. Mutations in the JMD 
are proposed to disrupt the auto-inhibitory structure of c-KIT, leading the receptor to 
spontaneously dimerise in the absence of SCF (Kitamura & Hirotab, 2004). Mutations in the 
ALD most likely stabilise the ALD in the extended configuration, therefore shifting the 
conformation equilibrium to the active state (Vendome et al., 2005;Gajiwala et al., 2009). 
Bioinformatic analysis of c-KIT-D816V X-ray structures has suggested that mutations at this 
residue can remodel the JMD by favouring removal of the JMD from the TKD, further 
triggering transition from an inactive to an active state (Laine et al., 2011). Based on this 
model the presence of mutations in the ALD may not require receptor dimerisation for 
activation.  
1.7.4 Impact of c-KIT mutations in AML models 
The role of numerous c-KIT mutations has been assessed in vitro in factor-dependent cell 
line models. Mutations in the ALD including N822K, D816V, D816F, D816H and D816Y 
lead to autophosphorylation of c-KIT, ligand-independent growth and activation of STAT5, 
STAT3, PI3K, AKT and ERK (Ning et al., 2001;Growney et al., 2005;Schittenhelm et al., 
2006;Wang et al., 2011). The D816V mutation is the most common c-KIT mutation and has 
therefore been extensively studied. The IL3-dependent lymphoid Ba/F3 cell line transfected 
with a construct expressing c-KIT-D816V showed constitutive activation of downstream 
proteins including ERK, AKT Gab2, Shc, SHP-2 and Cbl, which was not observed with cells 
expressing the WT receptor (Pedersen et al., 2009;Sun et al., 2009). Comparative analysis of 
WT and D816V c-KIT signalling revealed that, unlike the WT receptor, the c-KIT-D816V 
mutation did not require the Src kinase to phosphorylate c-KIT (Sun et al., 2009). The 
functional consequence of AML specific JMD mutations has not been investigated 
extensively. However, c-KIT mutations I571del14(ESVDPTQLPYDHKW) and L576P have 
been shown to constitutively activate c-KIT in murine IL3 dependent 32D and Ba/F3 cells 
respectively, with the former also showing ligand-independent growth (Antonescu et al., 
2007;Wang et al., 2011). JMD mutations identified in GIST and mastocytosis patients have 
also been reported to be activating in in vitro cell line models (Growney et al., 2005). 
Mutations in the ECD are particularly heterogeneous within AML (Table 1.7). Unlike the 
activating mutations in the ALD and JMD, the presence of an indel in exon 8 renders the 
receptor hypersensitive to SCF (Kohl et al., 2005). Exon 8 mutations also cause the receptor 
to spontaneously dimerise, leading to the removal of factor dependency in cell lines such as 






Exon Mutation Domain 
location 
Mutation reported in 
t(8;21) or inv(16) 
8 D419 deletion ECD t(8;21) 
8 T417del and D419del ECD t(8;21) 
8 ΔT417_D419 + insertion I ECD Both 
8 ΔT417_D419 + insertion V ECD inv(16) 
8 ΔT417_D419 + insertion W ECD inv(16) 
8 ΔT417_D419 + insertion IP ECD t(8;21) 
8 ΔT417_D419 + insertion NG ECD inv(16) 
8 ΔT417_D419 + insertion RG ECD inv(16) 
8 ΔD419_L421 + insertion VHV ECD inv(16) 
8 ΔY418 + insertion GFF ECD inv(16) 
9 502(AYFNF) repeat ECD t(8;21) 
10 I538V TMD t(8;21) 
10 V540L TMD t(8;21) 
10 V530I TMD Inv(16) 
11 L576P JMD t(8;21) 
11 Q575ins17 (EFCELPYDHKWEFPRNR) JMD t(8;21) 
11 I571del14(ESVDPTQLPYDHKW) JMD t(8;21) 
16 I748T KID t(8;21) 
17  D816Y  TKD-2 Both 
17  D816V TKD-2 Both 
17  D816H TKD-2 Both 
17 D816I TKD-2  inv(16) 
17 A814S TKD-2 t(8;21) 
17  N822K TKD-2 t(8;21) 
17 N822T TKD-2 t(8;21) 
17 N822Y TKD-2 t(8;21) 
17  V825I TKD-2 t(8;21) 
17 V825A TKD-2 t(8;21) 
17 L773S TKD-2 t(8;21) 
 




A comparison of the leukaemogenic potential of ECD and ALD c-KIT mutations has been 
assessed in vivo. Haematopoietic stem/progenitor cells were retrovirally co-transduced with 
constructs expressing the murine c-KIT-D814V (homolog to D816V in humans) or c-KIT-
T417IΔ418-419 in conjunction with RUNX1/RUNX1T1 and transplanted into mice. Mice 
co-expressing c-KIT-D814V and RUNX1/RUNX1T1 generated a transplantable aggressive 
AML phenotype in nine of twenty mice, a myeloproliferative phenotype in seven of twenty 
mice or a pre-B-cell leukaemia in four of twenty mice whereas, mice co-expressing c-KIT -
417IΔ418-419 and RUNX1/RUNX1T1 exclusively generated an AML phenotype in 
nineteen of thirty-seven mice (Nick et al., 2011). Of note, expression of just c-KIT-D814V 
or c-KIT-T417IΔ418-419 alone did not generate an AML phenotype but the mice did 
develop either a myeloproliferative disease (MPD), B-ALL or T-ALL. Mice receiving just 
RUNX1/RUNX1T1 rarely developed leukaemia. Other c-KIT mutations have also been 
examined in vivo, including the common ALD mutation N822K. A hybrid mouse/human c-
KIT-N822K receptor was capable of rendering murine 32D cells factor-independent. 
Transplantation of murine BM cells transduced with the hybrid c-KIT-N822K receptor and 
RUNX1/RUNX1T1 generated an AML phenotype in BALB/c mice (Wang et al., 2011). 
Expression of just the c-KIT N822K mutation generated an MPD phenotype, while no 
disease was observed in mice expressing just RUNX1/RUNX1T1.  
This data therefore supports the two hit hypothesis of leukaemogenesis proposed by Kelly 
and Gilliland (2002). This model suggests the cooperation of two types of mutations, a type I 
and a type II. Type I mutations promote cell proliferation and are often an activated RTK e.g. 
c-KIT, whereas type II mutations cause a block in myeloid differentiation and promote self-
renewal, e.g. RUNX1/RUNX1T1. Although the mouse models previously discussed support 
this, they do have a considerable disease latency suggesting other factors contribute to the 
pathogenesis and progression of AML. Whole genome or exome sequencing of samples 
from 200 de novo AML has revealed that, on average, 13 genes are mutated per patient (Ley, 
2013). Recurrent mutations are identified in NPM1, tumour-suppressor genes, DNA 
methylation-related genes, signalling genes, chromatin-modifying genes, myeloid 
transcription factor genes, cohesion complex genes and spliceosome-complex genes. The 
emerging interplay of mutations between these genes/subgroups illustrates that a ‘2-hit’ 




1.7.5 Prognostic impact of c-KIT mutations 
The presence of t(8;21) or inv(16) is usually associated with a favourable outcome in AML 
(Table 1.4). However, the presence of a c-KIT mutation in either subgroup has been 
associated with a significant increase in RR (Paschka et al., 2006;Cairoli et al., 2006;Allen et 
al., 2013).  
t(8;21)  
Several groups have reported that patients with AML co-expressing t(8;21) and a c-KIT 
mutation have a significantly poorer OS and relapse-free survival/event-free survival 
(RFS/EFS) when compared to patients with inv(16) and a c-KIT mutation (Boissel et al., 
2006;Cairoli et al., 2006;Park et al., 2011b;Allen et al., 2013). In particular, the presence of 
a c-KIT mutation in exon 17 has been associated with a significant poorer OS and EFS in 
t(8;21) patients (Park et al., 2011b). More recent data showed that t(8;21) patients with a 
mutant level >25% (KIT
high
) versus those with c-KIT-WT at 10 years from entry had a 
significant increase in RR (41% vs 25% respectively, p=0.05), with no significant impact on 
OS (45% versus 59% respectively, p=0.2)  (Allen et al., 2013). 
Inv(16) 
c-KIT mutations in exon 8 have been shown to occur more frequently in patients with 
inv(16) in comparison to those with t(8;21) and have subsequently been associated with a 
higher RR (Care et al., 2003). Mutations in exon 17 have not been associated with the same 
poor prognosis in patients with inv(16) (Park et al., 2011b). Patients with a mutant level 
>25% (KIT
high
) versus those WT for c-KIT have not been associated with a significant 
increase in RR or decrease in OS (Cumulative Incidence Relapse: 63% vs 51%, p=0.2, and 
OS 48% vs 59%, p=0.4, for c-KIT
high
 and c-KIT-WT respectively) (Allen et al., 2013). The 
discrepancy between different reports may be due to the differences in treatment and the 
relatively small samples sizes being examined. However, as proposed by Allen et al (2013) 
differences observed may be due to heterogeneity in mutant level.  
The treatment options for patients with CBFL and a c-KIT mutation is unclear. Some authors 
have suggested that there is insufficient data supporting the use of c-KIT mutational status as 
a method for directing therapy (Marcucci et al., 2011a). Others have suggested that patients 
with inv(16) or t(8;21) and a c-KIT mutation should be classified as intermediate risk and 
considered for either a matched sibling donor allogeneic haematological stem cell 
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transplantation (HSCT) or put forward for clinical trials using small molecule inhibitors 
(Park et al., 2011a;O'Donnell et al., 2012). Although HSCT has not been shown to improve 
outcome in t(8;21) leukaemia it does provide the most anti-leukaemic effect in comparison to 
autologous HSCT or consolidation therapy and therefore should be considered (Schlenk et 
al., 2008b).  
1.7.6 c-KIT inhibitors  
The use of c-KIT inhibitors to treat CBFL is in its infancy. A variety of selective and non- 
selective inhibitors have been designed and tested in AML cell lines and primary AML cells, 
such as SU5416, SU6668, sorafenib, sunitinib, EXEL-0862, imatinib, dasatinib and 
masitinib. However, direct translation into clinical studies has been limited. 
SU5416 and SU6668 
SU5416 and SU6668 are potent ATP competitive inhibitors of RTKs such as vascular 
endothelial growth factor receptor 1/2/3 (VEGFR-1/2/3), FLT3 and c-KIT. In vitro studies 
using SU5416 and SU6668 on a human myeloid cell line MO7E and primary AML cells 
showed that both compounds inhibited SCF-stimulated c-KIT-WT phosphorylation and were 
capable of inhibiting proliferation and inducing apoptosis (Smolich, 2001).  
Sorafenib and Sunitinib 
Sorafenib and Sunitinib are both ATP competitive drugs shown to inhibit a range of RTKs 
including c-KIT, FLT3, VEGFR and platelet-derived growth factor receptor (PDGFR), that 
are FDA-approved for the treatment of advanced renal cell carcinoma (RCC). The effect of 
both drugs has been examined on a panel of AML cell lines and showed that they both 
potently inhibit proliferation and induce apoptosis in a time-and-dose dependent manner (Hu 
et al., 2008). Sorafenib has also been shown to inhibit proliferation by ≥50% in six of nine 
primary AML cells and has been tested clinically in a cohort of 38 patients with AML, 
showing a short-term CR in only one patient (Crump et al., 2010). Sunitinib is currently used 
as a therapeutic agent to treat imatinib-resistant GIST. An analogue of Sunitinib called 
SU11657 has been assessed in paediatric primary AML cells which showed that samples 
with either a FLT3 or a c-KIT mutation were significantly more sensitive to SU11657 





EXEL-0862 is an inhibitor of VEGFR, fibroblast growth factor receptor (FGFR), PDGFR, 
FLT3 and c-KIT. The binding mechanism of EXEL-0862 is currently unknown. In the 
human mast cell leukaemia cell lines HMC1.1 and HMC1.2, which harbour V560G and 
V560G and D816V c-KIT mutations respectively, EXEL-0862 was capable of inhibiting c-
KIT phosphorylation in a dose-dependent manner, reducing cellular proliferation and 
inducing apoptosis (Pan et al., 2007). EXEL-0862 appeared to be more potent in the 
HMC1.2 cells, suggesting this compound could be more effective against malignancies that 
harbour a D816V activating mutation. 
Imatinib  
 
Imatinib, commercially known as Gleevec, is an ATP competitive inhibitor of BCR-ABL 
(fusion protein found in chronic myelogenous leukemia (CML)), PDGFR, and c-KIT. 
Imatinib is the first line treatment for CML. Imatinib binds to the inactive conformation of c-
KIT, locking it in this configuration. In vitro studies revealed that imatinib can bind and 
inhibit proliferation of cells expressing c-KIT mutations in the ECD, JMD and certain ALD 
mutations, e.g. N822K (Growney et al., 2005). However, mutations at residue D816 are 
resistant to imatinib (Growney et al., 2005;Shah et al., 2006). Studies examining the effects 
of imatinib on c-KIT in the Kasumi-1 cells, a human CBFL cell line expressing the c-KIT 
N822K mutation, and patient samples expressing the N822K mutation showed a decrease in 
c-KIT phosphorylation and induction of apoptosis in a time/dose-dependent manner (Wang, 
2005;Wang et al., 2011). Treatment of 18 patients with relapsed or refractory AML/MDS  
with a daily dose of 400mg of imatinib showed no partial or complete responses to imatinib 
(Cortes et al., 2003). These patients did express c-KIT however they were not screened for c-
KIT mutations. A phase II pilot study of 21 patients with refractory AML expressing c-KIT 
(c-KIT+) received 600mg/day of imatinib for 6 months showing a haematological response 
in 5 patients (Kindler, 2004). In support of this, a phase I study of 21 patients with relapsed 
c-KIT+ AML treated with cytarabine, daunorubicin and imatinib showed a partial or 
complete response in 57% of patients (Advani et al., 2010). A phase II study of patients with 
relapsed/refractory c-KIT+ AML used standard induction therapy in conjunction with 
escalating doses of imatinib (200-400mg/day) and showed a CR in twenty of thirty-one 
patients. Although initial results were promising, patients relapsed within a median of 6.8 
months. The current clinical trials with imatinib have not taken into consideration c-KIT 
mutational status, therefore the therapeutic benefit of imatinib for patients with c-KIT 




Dasatinib is an ATP-competitive BCR-ABL, SRC, c-KIT inhibitor. In a panel of cell lines 
with varying c-KIT mutations, dasatinib was capable of inhibiting c-KIT phosphorylation 
and decreasing cellular proliferation in cell lines with c-KIT-WT, ALD (including D816V) 
and JMD mutations (Schittenhelm et al., 2006;Shah et al., 2006;Guerrouahen et al., 2010). 
In a long term culture system, dasatinib potently inhibited proliferation of LSCs from 
primary AML cells with a c-KIT or BCR-ABL mutation while having a limited impact on 
healthy CD34+ cells (Han et al., 2010). A recent study combining dasatinib with 
daunorubicin or ara-C resulted in enhanced apoptosis and inhibition of proliferation 
compared to either drug alone in primary AML cells (Dos Santos et al., 2013). In vivo, a 
combination of daunorubicin or ara-C and dasatinib reduced the ability of murine AML stem 
cells to regenerate leukaemia in secondary recipient mice (Dos Santos et al., 2013). 
Dasatinib is beginning to be assessed within the clinic. A phase I dose escalation study in 
paediatric patients (1-21 years of age) with relapsed/refractory leukaemia has been 
completed and showed no clinical responses in any patients with AML (Zwaan et al., 2013). 
Of note, none of the patients included in the study had a c-KIT mutation. Investigations are 
now ongoing assessing the role of dasatinib as a monotherapy and in conjunction with 
standard chemotherapy in patients with CBFL (clinical trials NCT00850382 and 
NCT01876953).   
Masitinib  
Masitinib is an  ATP-competitive inhibitor against c-KIT and PDGFR α/β. Masitinib was 
capable of decreasing c-KIT phosphorylation and inhibiting cell growth in Ba/F3 cells 
expressing c-KIT-WT and c-KIT-JMD mutations but not those expressing c-KIT-D816V 
(Dubreuil et al., 2009). A nude mouse model injected with Ba/F3 cells expressing the murine 
c-KIT-Δ27 mutation (deletion of codons 547-555) treated with masitinib demonstrated 
inhibition of tumour growth and an increase in the median survival time in comparison to 
mice without treatment (Dubreuil et al., 2009). The impact of masitinib in AML has yet to be 




1.8 FLT3  
1.8.1 FLT3 structure and function  
FLT3, also known as CD135 or FLK2 (fetal liver tyrosine kinase 2) is a membrane bound 
class III tyrosine kinase receptor. The FLT3 gene is located on chromosome 13q12 and 
generates a 993 amino acid protein with a predicted molecular weight of 130-143kDa when 
unglycosylated. The structure of FLT3 is similar to other RTKs such as c-KIT and PDGFR. 
The receptor contains an ECD comprised of 5 immunoglobulin-like repeats, a TMD, a JMD, 
two tyrosine kinase domains (TKD1 and TKD2) linked by a kinase insert domain (KID) and 
an ALD (Figure 1.4a). Unstimulated FLT3-WT is unphosphorylated and in an inactive 
monomeric form. This is maintained by the JMD adopting a ‘wedged shape’ with the 
activating loop folded back between TKD1 and 2, blocking the ATP binding site and 
substrate loading (closed conformation) (Meshinchi & Appelbaum, 2009) (Figure 1.4a). 
Activation of the receptor is controlled by binding of the FLT3 ligand (FL) to the 3 distal 
immunoglobulin-like repeats. FL is a cytokine that functions to stimulate proliferation, 
survival and differentiation of haematopoietic progenitor cells (Wodnar-Filipowicz, 2003). 
Once FL is bound, the 2 immunoglobulin-like repeats closest to the receptor mediate 
dimerisation of two monomeric FLT3 units (Figure 1.4b). This leads to phosphorylation of 
Y589 and Y591 residues within the JMD, destabilising the autoinhibitory structure and 
releasing the ALD. The tyrosine residues within the activation loop are then available to be 
phosphorylated, freeing the ATP binding site and rendering the receptor active (open 
conformation) (Meshinchi & Appelbaum, 2009). ATP and other substrates can then bind to 
the receptor, resulting in phosphorylation and activation of downstream target proteins 
including PI3K, Ras GTPase, phospholipase C-γ, Shc, growth factor receptor-bound protein 
(Grb2) and Src family tyrosine kinases (Takahashi, 2011). These proteins can then 
subsequently activate AKT, mTOR, STAT5 and MAPK, which are implicated in a host of 







Figure 1.4 Schematic diagrams showing the functional domains of FLT3 in its active 
and inactive form. (a) FLT3 in its monomeric inactive form. (b) FLT3 when the receptor 





Figure 1.5 Diagrams of the two most frequent FLT3 mutations in AML. (a) FLT3-ITDs 







1.8.2 FLT3 mutations in AML 
FLT3 is highly expressed in 70-100% of AML cases and is frequently mutated in AML. 
FLT3 is mutated in approximately 30% of AML by either internal tandem duplications 
(ITDs) within the JMD or point mutations in the second tyrosine kinase domain (TKD).  
1.8.3 FLT3-ITD mutations 
FLT3-ITD mutations occur within exons 14-15 in approximately 25% of adult AML cases 
and vary in size (3 to >400 base pairs) and location (Nakao et al., 1996;Gilliland & Griffin, 
2002). The incidence of FLT3-ITDs is age-dependent ranging from 12-15% in 0.2-19.8 year 
olds versus 54% for AML patients 35-54 years of age (Kottaridis et al., 2001;Meshinchi et 
al., 2001;Meshinchi et al., 2006). Expression of FLT3-ITD mutations in murine 32D and 
Ba/F3 cells have demonstrated constitutive activation of FLT3 in the absence of ligand, 
constitutive activation of downstream target proteins (STAT5, AKT/PI3K and RAS/MAPK) 
and cytokine-independent growth (Mizuki et al., 2000;Hayakawa et al., 2000). Murine BM 
cells retrovirally transduced with FLT3-ITDs were capable of generating a MPD phenotype 
in a BM transplantation assay (Kelly et al., 2002). However, the presence of a FLT3-ITD 
alone was not sufficient to induce AML. The exact mechanism of auto-dimerisation resulting 
from a FLT3-ITD is unknown. Crystal structural analysis of the receptor suggests that the 
presence of ITD mutations may disrupt the auto-inhibitory conformation controlled by 
residues Y589 and Y591, thereby generating a more relaxed structure which more readily 
allows auto-dimerisation (Meshinchi et al., 2008).  
The presence of FLT3-ITD mutations is also associated with an increased production of 
reactive oxygen species (ROS), both in AML cell lines and primary AML cells. Increased 
levels of ROS, as a result of FLT3-ITD mutations, has been shown to cause genomic 
instability mediated by an increase in double strand breaks resulting in erroneous DNA 
repair (Sallmyr et al., 2008). These authors also showed that an increase in ROS levels by 
FLT3-ITD mutations appeared to be mediated by STAT5 signalling activating RAC1, a key 
GTPase protein required to activate NADPH oxidases.  
1.8.4 Clinical impact of FLT3-ITDs 
FLT3-ITDs are associated with a high white blood cell count, an elevated percentage of PB 
and BM blasts and a normal karyotype (Frohling et al., 2002). The CR rate in patients 
positive for a FLT3-ITD (FLT3-ITD+ AML) is not significantly reduced, but there are 
increased RR, decreased disease free survival (DFS) rates and poor OS rates resulting in it 
being identified in many studies as a poor prognosis marker (Kottaridis et al., 2001;Frohling 
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et al., 2002;Thiede et al., 2002). The mutant level has been reported to vary from 1-96% in 
FLT3-ITD+ AML (Gale et al., 2008). The allelic ratio of FLT3-WT to mutant receptor can 
impact on prognosis with a high ITD:WT allele ratio associated with a negative impact on 
RR and OS (Thiede et al., 2002;Gale et al., 2008). The variation in mutant level suggested 
that patients with a high mutant level (>50%) may have lost the WT allele, potentially by 
uniparental disomy (UPD), in a proportion of cells. An intermediate mutant level indicated a 
heterozygous mutation in the majority of cells or UPD of a mutant allele in up to 50% of the 
cells. A low mutant level (1-24%) implied that the acquisition of a FLT3-ITD mutation was a 
secondary event that occurred in a sub clone of cells. The impact of the size of the ITD on 
prognosis remains contradictory. Different groups have shown that both larger and shorter 
insertions can lead to an inferior prognosis, while others have reported no difference on 
outcome (Kusec et al., 2006;Ponziani et al., 2006;Meshinchi et al., 2008;Gale et al., 2008). 
More recently the actual site of the ITD has been examined. Kayser et al (2009) categorised 
ITDs into two classes, those occurring either within the JMD between amino acids 572 and 
609 (69.5% of the FLT3-ITDs examined) or 3’ of the JMD within the beta1-sheet of the 
TKD1 (30.5% of the FLT3-ITDs examined). Samples with insertion sites in the beta1-sheet 
TKD1 were associated with poorer a OS and an increased RR in comparison to patients with 
insertions sites outside of this region.      
1.8.5 FLT3-TKD mutations 
FLT3-TKD mutations occur in 5-10% of patients with AML (Frohling et al., 2007;Mead et 
al., 2007). Numerous FLT3 point mutations have been described primarily occurring in the 
ALD in exon 20, called FLT3-TKD mutations (Table 1.8). The most frequent FLT3-TKD, 
accounting for 50% of FLT3-TKD mutations, is the substitution of aspartic acid 835 for a 
tyrosine residue (D835Y) (Mead et al., 2007;Bacher et al., 2008). Residue D835 can also be 
deleted or substituted for numerous amino acids, as listed in Table 1.8. Mutations in the 
ALD do not just reside at D835, other residues have also been found to be mutated including 
G831, R834, I836, D839, N841 and Y842 (Kindler et al., 2005;Mead et al., 2007;Frohling et 
al., 2007;Smith et al., 2013). Rare mutations (1% of adult patients with AML) have also 
been found within the ECD, JMD and KID (Table 1.8) (Reindl et al., 2006;Frohling et al., 
2007;Smith et al., 2012). The crystal structure of FLT3 suggests that residues D835 and 
Y842 are critical for stabilising the inactive conformation of the ALD (Smith et al., 2012). 
Therefore, mutations at residues D835, Y842 or in close proximity to these residues are 
proposed to destabilise the inactive conformation, shifting the equilibrium to the active state 
and resulting in the ALD being maintained in the open (active) conformation.  
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In vitro studies assessing the functionality of FLT3-TKD mutations have demonstrated 
autophosphorylation of the receptor, activation of downstream signalling pathways 
(RAS/MAPK, STAT5 and PI3K/mTOR) and induction of ligand-independent growth in 
factor-dependent cell lines (Reindl et al., 2006;Rocnik et al., 2006;Frohling et al., 
2007;Smith et al., 2012). Mice receiving primary BM cells retrovirally transduced with 
FLT3-TKD mutations generated a lymphoid-proliferative disease, whereas mice receiving 
BM cells transduced with FLT3-ITD mutations develop a MPD (Grundler et al., 2005). This 
stark contrast in disease progression mediated by the two different mutations showed that 
different signalling pathways were involved. In support of this, FLT3-ITDs but not FLT3-
TKD mutations have been shown to activate downstream STAT5 proteins (CIS and PIM-2), 
and microarray analysis of cells from patients with FLT3-ITD+ AML or FLT3-TKD+ AML 
showed differential gene expression profiles (Choudhary et al., 2005;Neben et al., 2005).  In 
vitro studies have also shown that primary AML cells expressing FLT3-ITD mutations were 
significantly more sensitive to the FLT3 inhibitor lestaurtinib than cells expressing FLT3-
TKD mutations (Mead et al., 2008). The coincidence of a FLT3-ITD and a FLT3-TKD 
mutation occurs infrequently implying that in the absence of a selection pressure, such as the 
FLT3 inhibitor AC220, the presence of a double mutation may have no benefit. This 





Exon  Mutation  Domain  
5 T167A ECD 
5 V194M ECD 
9 Y364H ECD 
11 S451F ECD 
14 Y572C JMD 
14 V579A JMD 
14 V592A JMD 
14 V592G JMD 
14 F594L JMD 
14 E608K JMD 
16 N676K TKD1 
17 F691L TKD1 
18 M737I KID  
20 G831E ALD 
20 R834Q ALD  
20 D835Y ALD 
20 D835E ALD 
20 D835H ALD 
20 D835N ALD 
20 D835A ALD 
20 D835S ALD 
20 D835N ALD 
20 D835V ALD 
20 D835F ALD 
20 Δ835 ALD 
20 ΔD835delinsGPGP ALD 
20 ΔD835_I836delinsVIPT ALD 
20 Δ836 ALD 
20 D839G ALD 
20 N841I ALD 
20 N841K ALD 
20 N841Y ALD 
20 Y842C ALD 
 
Table 1.8 FLT3 mutations currently reported in AML. 
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1.8.6 Clinical impact of FLT3-TKD mutations 
As observed with FLT3-ITD+ AML, the presence of a FLT3-TKD mutation is associated 
with elevated PB and BM blast counts and a normal karyotype (Frohling et al., 2002;Bacher 
et al., 2008). Several groups have reported that the presence of a FLT3-TKD mutation 
correlates with an inferior OS and DFS (Thiede et al., 2002;Moreno et al., 2003;Yanada et 
al., 2005;Whitman et al., 2008). In contrast, FLT3-TKD mutations with a high mutant level 
median >25% have been reported to confer a more favourable OS and CIR in comparison to 
FLT3-WT (Mead et al., 2007). Bacher et al (2008) reported that FLT3-TKD mutations had 
no significant impact on EFS or OS. However, stratification of FLT3-TKD mutant positive 
patients based on NPM1, CEBPA and MLL-PTD mutation status revealed that a combination 
of a FLT3-TKD mutation with either an NPM1 or a CEBPA mutation further improved OS 
and EFS in comparison to just NPM1 and CEBPA mutated cases, while co expression of a 
FLT3-TKD mutation and MLL-PTD further reduced the poor prognosis already associated 
with MLL-PTD (Bacher et al., 2008). The differential prognostic impact observed between 
these reports is likely to have arisen due to sampling variability, small patient cohorts and 
differences in treatment regimes. Therefore, the impact of FLT3-TKD mutations on 
prognosis remains unclear. 
1.8.7 Clinical impact of FLT3-WT over expression  
Of interest, FLT3 is phosphorylated in approximately 60% of patients with AML, even in the 
absence of an activating mutation (Zheng et al., 2004). Other RTKs have been shown to 
dimerise in the absence of ligand-receptor interactions (Lemmon & Schlessinger, 2010). 
Therefore, as FLT3 is highly expressed in patients with AML, it has been suggested that this 
may contribute to spontaneous phosphorylation and activation of downstream signalling 
(Ozeki et al., 2004). Alternatively, FLT3 has been shown to be phosphorylated, in both AML 
cell lines and primary AML cells, by autocrine secretion of FL (Zheng et al., 2004). This 
suggests that although mutations often occur in FLT3 in AML, the WT receptor can also be 
activated, and that inhibitors that target the mutant and WT receptor may provide some 
clinical benefit.  
1.8.8 FLT3 inhibitors  
Inhibitors of FLT3 have been developed and examined extensively in pre-clinical models, 
with some now being tested within clinical trials. Some of the FLT3 inhibitors currently 
being assessed in clinical trials are reviewed in Table 1.9.  
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Rf = refractory AML, R= relapsed AML, U= unfit for standard chemotherapy, PR= partial remission, CRi=CR with incomplete haematologic recovery, CRc= 
CR+ CRp (CR with incomplete platelet recovery) + CRi.  
Table 1.9 Clinical trials using FLT3 inhibitors in patients with AML.  





with AML  
Disease 
status 
Clinical benefit  CR Reference 
Tandutinib Phase I 32/0/8 70.5 (22-90) Rf + R + U 2/5 evaluable FLT3-ITD patients had a reduction in PB/BM 
blasts. No significant anti-leukaemic effect observed in 
FLT3-WT patients.  
0 (DeAngelo et 
al., 2006) 
Tandutinib Phase II 0/0/23 Not available Rf + R 15 patients evaluable: 2 had stable disease ≥50 days and 6 
had a reduction in PB and BM blasts (1-3 month duration) 
0 (De Angelo et 
al., 2004) 
Sorafenib Phase I 
 
 






Rf + R 3/7 patients with FLT3-ITD achieved a CR compared to 1/3 





Sorafenib Phase II 36/2/13 53 (18-65) 
 
Rf + R 38 patients achieved a CR: 12/13 with a FLT3-ITD, 2/2 with 
a FLT3-TKD and 24/36 with FLT3-WT. Probability of 
survival at 12 months was 74%. FLT3-ITD patients 







Phase I 24/2/3 67 (19-82) Rf + R ≥200mg of sunitinib inhibited FLT3 phosphorylation in 50% 
of patients expressing the WT receptor and 100% in patients 
with mutant FLT3 




Phase I 10/2/2 72 (54-80) Rf + R + U 1 FLT3-TKD patient achieved a morphological remission, 1 
FLT3-TKD and 2 FLT3-ITD patients achieved PRs. 2/7 
patients without a FLT3 mutation also achieved a PR. All 
responses were of short duration (4-16 weeks). 




Phase I/II 0/1/16 61 (18-74) Rf + R 5 patients displayed a significant reduction in PB/BM blast 
counts (>50%), with one patient sustaining a CR with a 
decrease in BM blasts to <5%. Clinical responses 
corresponded to sustained inhibition of p-FLT3 and toxicities 
were mild 
6% (Smith et al., 
2004;Levis et 
al., 2006)  
Lestaurtinib Phase II 24/3/2 73 (67-82) U 3/5 FLT3 mutant patients achieved haematologic responses 
as demonstrated by a reduction in PB blasts. 5/22 patients 
with FLT3-WT also showed a decrease in BM blasts. The 8 
patients with clinical responses corresponded to sustained 
inhibition of p-FLT3. 




Lestaurtinib Phase II 
 
Control arm: 















There were no differences between patients treated with 
chemotherapy alone or in combination with lestaurtinib, 
either in OS or response rates. FLT3 blockade did correlate 




arm 26%  (P 
=0.35) 
(Levis et al., 
2011;Levis et 
al., 2012)  
Midostaurin Phase II 0/2/18 62 (29-78) Rf + R 14 patients achieved a 50% reduction in PB counts while 6 
patients saw a 50% reduced in BM blast count (2 to <5%) 
0 (Stone et al., 
2005) 
Midostaurin Phase Ib 27/4/9 50 (18-60) Rf + R Midostaurin and standard induction chemotherapy showed 
that patients with mutant FLT3 and FLT3-WT had equivalent 





(Stone et al., 
2009) 
Midostaurin Phase IIb 60/9/26 ≥18 Rf + R + U Only one patient (1%) experienced a PR 0 (Fischer et 
al., 2010) 
Ponatinib  Phase I 0/0/7 49 (30-72) Rf + R 2/7 patients with a FLT3-ITD achieved a CRi 0 (Smith et al., 
2013) 
KW-2449 Phase I  32/0/5 Not available  Rf + R 5 patients with a FLT3-ITD did have a >50% reduction in PB 
blasts.  
0 (Pratz et al., 
2009) 
AC220  Phase I 47/0/18  60 (23-86) Rf + R + U 9 FLT3-ITD patients responded (1 CR, 3CRi and 2 PR). 
9 FLT3-WT patients responded (1 CRi, 2 CRp, 6 PR).The 
median duration of response was 14 weeks (4-64+) 
12% (Cortes et al., 
2009) 







Rf + R 34% of FLT3-ITD- patients achieved a CRc with a median 
duration of 5 weeks. 44% of FLT3-ITD+ patients showed a 





(Levis et al., 
2012) 







Rf + R 44% of FLT3-ITD- patients achieved CRc with a median 
duration of 22.1 weeks. 39% of FLT3-ITD+ patients showed 





(Cortes et al., 
2012) 
Table 1.9 (continued)  
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The efficacy of FLT3 inhibitors in patients with AML has been disappointing (Table 1.9). 
This could be due to the kinetics of the individual compounds, such as the potency of the 
inhibitors to bind and maintain inhibition of FLT3, the biological half-life of the compounds 
and the dosing frequency. The disease features of AML may also impact on the response to 
FLT3 inhibitors, such as the allelic burden, the type and the site of mutation. There is some 
evidence to suggest that FLT3 may not be the driver mutation in all patients with AML. For 
example, relapse samples can lose their FLT3 mutation (Kottaridis et al., 2002). This 
suggests the FLT3 mutation may occur in a sub-clone population of cells. In contrast there is 
emerging evidence that FLT3-ITD mutations can be the driving genetic lesion (Ding et al., 
2012). Patients with FLT3-ITD+ AML treated with AC220 have been shown to acquire 
secondary mutations within the TKD that confer resistance to AC220 (Smith et al., 2013). 
Secondary mutations have primarily been detected in the activation loop at residue D835 
(D835Y/V/F) and the ‘gate keeper’ residue F691 (F691L). The ‘gate keeper’ residue is 
defined as a large hydrophobic residue found in the ATP binding cleft of protein kinases.  In 
vitro investigation of these secondary mutations has demonstrated cross resistance to 
sorafenib. This highlights that in these patients the leukaemic cells are dependent on FLT3 




1.9 AML and PI3K/ AKT, mTOR and MEK signalling  
The PI3K/AKT, mTOR and MEK signalling pathway are involved in a host of key 
regulatory roles including cell cycle progression, differentiation, survival and apoptosis. 
PI3K, AKT, mTOR and MEK have all been shown to be constitutively active in primary 
AML cells (Grandage et al., 2005). The function of these proteins in normal haematopoiesis 
is discussed below in conjunction with the proposed mechanism of dysregulation in AML, 
including current methods for inhibiting these activated pathways.  
1.9.1 PI3K /AKT 
PI3K exists in three classes, I-III, each with its own substrate specificity. The class IA PI3K 
is activated downstream of growth factors and is composed of a catalytic subunit of either 
p110α, p110β or p110δ in conjunction with one of the regulatory subunits p50, p55 or p85 
(Park et al., 2010). The PIK3CA gene, which encodes the p110α subunit, is frequently 
mutated in a range of cancers including breast, liver, gastric, brain and colon cancers 
(Karakas et al., 2006). Class I PI3Ks function by phosphorylating phosphatidylinositol 
bisphosphate (PIP2), which produces phosphatidylinositol trisphosphate (PIP3) (Figure 1.6). 
PIP3 recruits AKT and phosphoinositide-dependent protein kinase-1 and 2 (PDK1/PDK2) to 
the plasma membrane. AKT is phosphorylated by PDK1 within the ALD at residue T308, 
while PDK2 (otherwise known as mTORC2) phosphorylates residue S473 at the C-terminus; 
both are required to fully activate AKT (Park et al., 2010). AKT regulates a host of proteins 
such as Bcl-2-associated death promoter (BAD), IκB kinase α/β (IKKα/β), E3 ubiquitin-
protein ligase (MDM2), forkhead family of transcription factors (FOXO), cyclin D, 
mTORC1, endothelial nitric oxide (eNOS), Apoptosis signal-regulating kinase 1 (ASK1) and 
the cell cycle regulators p21/p27. PI3K activation is negatively regulated by phosphatases 
and a key protein is Phosphatase and tensin homolog (PTEN), which dephosphorylates PIP3 
to PIP2 and antagonises the PI3K/AKT/mTOR pathway (Figure 1.6) (Martelli et al., 2010).   
1.9.2 mTOR 
Mammalian target of Rapamycin (mTOR) is a member of the PI3K-related kinases. It occurs 
in two distinct complexes, mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2). 
mTORC1 is comprised of mTOR, DEP domain-containing mTOR-interacting protein 
(DEPTOR), regulatory-associated protein of mTOR (RAPTOR), PRAS40 and the mTOR 
subunit LST8 (Zoncu et al., 2011). This complex, as illustrated in Figure 1.6, is regulated by 
upstream proteins including AKT, the tumour suppressor tuberous sclerosis proteins 1 and 2 
(TSC1/TSC2), and the GTP-binding protein RHEB complex. AKT functions by 
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phosphorylating TSC2, which disrupts the binding of RHEB to the TSC1/TSC2 complex 
(Long et al., 2005). RHEB-GTP is then free to directly activate the mTORC1 complex. Once 
activated the mTORC1 complex functions to activate p70 S6K kinase and eukaryotic 
initiation factor 4E binding protein 1 (4E-BP1). Activation of p70 S6K leads to 
phosphorylation of 40S ribosomal protein S6, which drives translation of specific mRNAs 
(Martelli et al., 2009). Phosphorylation of 4E-BP1 by mTORC1 causes it to dissociate from 
the eukaryotic initiation factor 4E (elF4E), allowing it to recruit eIF4G and form part of the 
translation initiation complex (Martelli et al., 2009). The mTORC1 complex is essential for 
controlling biosynthesis of cell cycle progression proteins (cyclin D1, c-Myc, CDK2 and p27) 
and cell survival proteins (Mcl-1 and Bcl-x).  
The mTORC2 complex is comprised of mTOR, DEPTOR, rapamycin-insensitive companion 
of mTOR (RICTOR), LST8, mammalian stress-activated protein kinase-interaction protein 1 
(mSIN1), and protein observed with Rictor-1 (PROTOR). The mTORC2 complex 
phosphorylates AKT at residue S473, and activates the kinases glucocorticoid regulated 
kinase (SGK) and protein kinase C (PKC) (Figure 1.6). The full mechanism of mTORC2 
activation is still unclear, however the mTORC2 complex does regulate cell survival, 
cytoskeleton organisation and cell cycle progression.        
1.9.3 MEK   
The mitogen-activated protein kinase (MAPK) signal cascade is pivotal for cell proliferation, 
differentiation and survival. The MAPK family are serine/threonine kinases that fall into 3 
broad groups: extracellular signal-regulated kinases (ERKs), c-Jun NH2–terminal Kinases 
(JNK), and p38 members. ERKs are activated by the presence of growth factors/cytokines, 
while the JNK and p38 members are stimulated in response to radiation, oxidative stress, 
DNA damage and cytokines (Molina & Adjei, 2006). The MAPK pathway becomes 
activated when a RTK becomes stimulated. Two extensively characterised RTKs that 
activate MAPK are the epidermal growth factor receptor (EGFR) and the platelet-derived 
growth factor receptor (PDGFR). When ligand binds to EGFR, it activates the kinase domain 
allowing tyrosine autophosphorylation. This allows adaptor proteins such as growth factor 
receptor-bound protein 2 (Grb2) to bind to the receptor and recruit factors including guanine 
nucleotide exchange factors (GEFs) that mediate exchange of GDP for GTP, such as Son of 
sevenless (SOS), cell division cycle 25 phosphatase (CDC25) and Shc (Schlessinger, 2000). 
The GEFs, once at the plasma membrane, activate RAS by exchanging GDP for GTP. RAS-
GTP then stimulates its effector molecule the serine/threonine kinase RAF which in turn 
phosphorylates MAPK (MEK) and activates ERK1/2 (p42/p44) (Figure 1.6) (Molina & 
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Adjei, 2006). ERK1/2 regulates the transcription of cell cycle progression proteins including 













Figure 1.6 The protein signalling networks of PI3K/AKT, mTOR and MEK and their respective downstream targets.  Taken from Zoncu et al (2011). 
Permission to reproduce this has been granted by Dr. Roberto Zoncu.   
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1.9.4 PI3K/AKT/ mTOR and MEK activation in AML 
Constitutive activation of the PI3K/AKT, mTOR and MEK signalling pathways has been 
reported to be present in 50-80%, >90% and 75-80% of AML blast cells respectively (Xu et 
al., 2003;Grandage et al., 2005;Brandts et al., 2005;Ricciardi et al., 2005). Constitutive PI3K 
activation is associated with AKT phosphorylation at residues T308 and S473 and a 
significant increase in proliferation of primary leukaemic cells (Kubota et al., 2004). The 
presence of phosphorylated AKT has been identified as a poor prognostic marker in AML, 
corresponding to a shorter DFS and OS (Min et al., 2003;Kornblau et al., 2006). The 
PI3K/AKT pathway can control expression of the multidrug resistance protein 1 (MRP1), 
which can exclude chemotherapeutic agents from leukaemic cells (Tazzari et al., 2007). 
Therefore, constitutive PI3K/AKT activity is proposed to drive expression of MRP1 leading 
to chemoresistance. This could explain the poor prognosis of patients with AML associated 
with activated PI3K/AKT. However, Tamburini et al (2007) found that patients with 
activated PI3K/AKT had a more favourable outcome, with a lower RR and better OS. A 
more favourable outcome may be the result of constitutive PI3K activity driving the 
leukaemic cells into S phase of the cell cycle, making them more sensitive to DNA 
damaging chemotherapeutics. The discrepancies between these studies could arise from 
different culture conditions used to maintain primary AML cells, which could affect the level 
of PI3K/AKT activation. The prognostic implication of PI3K/AKT activation in AML 
remains unclear. The impact of mTOR dysregulation on prognosis in AML has not currently 
been assessed, however the presence of p-ERK has been associated with an independent 
poor prognosis (Kornblau et al., 2006).  
1.9.5 Mechanisms for PI3K/AKT/mTOR and MEK activation in AML  
The precise mechanisms of constitutive PI3K/AKT/mTOR and MEK activation in AML are 
unclear, but mutations in RTKs such as c-KIT and FLT3 or in K/N-RAS have all been 
shown to activate proteins within the PI3K/AKT/mTOR and MEK networks (Birkenkamp et 
al., 2004;Pedersen et al., 2009;Sun et al., 2009;Muranyi et al., 2009;Chen et al., 2010). 
Although RTK mutations can activate the PI3K/AKT/mTOR and MAPK signalling 
pathways, there is not always an association between a RTK mutation and constitutive 
PI3K/AKT/mTOR and MEK activation when examining primary AML cells in vitro (Iida et 
al., 1999, Martelli et al 2009). Other mechanisms of PI3K activation include over-expression 
of the PI3Kδ/β subunits, signalling through the insulin-like growth factor receptor (IGF-1R), 
autocrine/paracrine secretion of VEGF, interactions between β1 integrins (expressed on blast 
cells) and fibronectin (expressed on BM stromal cells) leading to up-regulation of integrin-
linked kinase 1 (ILK1), and high very late antigen (VLA)-4 expression (Sujobert et al., 
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2005;Billottet et al., 2006;Martelli et al., 2010). No activating mutations have been identified 
in the PI3K p110α or δ subunits or in the AKT1 (PH domain) in AML. PTEN, the negative 
regulator of PI3K, which is commonly deleted and mutated in acute lymphoblastic 
leukaemia (ALL), is infrequently deleted/mutated in AML (Liu et al., 2000).  
The activation of mTORC1 in AML blasts has been shown to be independent of PI3K/AKT 
and can be constitutively activated through the Src kinase Lyn, non-receptor kinase SYK and 
the ERK/MAPK pathway (Park et al., 2010;Carnevale et al., 2013). ERK activation can be 
mediated by genetic mutations of K/N-RAS, other cytoplasmic kinases or inhibition of 
specific phosphatases (Platanias, 2003). However, the presence of N-RAS mutations does 
not always correspond to ERK/MAPK activation in primary AML cells (Iida et al., 1999). In 
AML there are currently no known mutations in MAPK genes or mTOR, and neither 
chromosomal location is currently associated with recurrent genomic gains or losses. 
Therefore, numerous factors appear to contribute to the activation of the PI3K/AKT/mTOR 
and MEK pathways. This suggests that several intrinsic and extrinsic pathways may 
contribute to the activation of these target proteins or there may be other mutated or 
dysregulated G-proteins/signalling molecules in AML that are currently unknown.  
1.9.6 The use of PI3K/mTOR/AKT and MEK inhibitors in AML 
As PI3K/mTOR/AKT and MEK activation is found in a high proportion of patients with 
AML, numerous inhibitors have been developed to target these pathways listed in Table 1.10. 
PI3K Inhibitors 
The first characterised PI3K inhibitors were Wortmannin and LY294002, which are cell-
permeable and have a low molecular weight. Wortmannin is a potent irreversible inhibitor of 
class I, II and III PI3Ks (IC50=~5nM), binding to the p110 catalytic subunit 
(Vanhaesebroeck et al., 2001). LY294002 is a synthetic flavonoid-based compound that 
competitively binds to the ATP binding site of the PI3K p110 catalytic subunit. LY294002 
inhibits class I, II and III PI3Ks at an IC50 of ~1-20μM (Martelli et al., 2009). Although 
Wortmannin and LY294002 have been used in in vitro models of AML, their clinical use has 
been limited due to high toxicities and poor stability in aqueous solutions. 
One derivative of Wortmannin is pegylated-17-hydroxywortmannin (PWT-458). PWT-458 
has improved drug stability and water solubility and has demonstrated anti-tumour activity in 
xenograft models of glioma, renal cell carcinoma and non-small cell lung cancer in nude 
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mice (Yu et al., 2005). Other PI3K inhibitors have been examined in solid tumours, 
including an analog of Wortmannin, PX-866, which inhibits PI3Kα, γ, and δ (IC50 = 5.5, 9.0, 
and 2.7 nM, respectively), and inhibited tumour growth in xenograft tumour models (Garcia-
Echeverria, 2009). An optimised water-soluble pan-PI3K/mTOR LY294002 derivative, 
SF1126, demonstrated inhibition of all PI3K classes (IC50= 0.5–5.7μM) and has been 
examined in a phase I clinical trial in solid tumours (trial NCT00907205l) (Martelli et al., 
2009). However these inhibitors have not currently been evaluated in AML.  
IC87114, a selective inhibitor of the PI3K p110δ isoform, led to a reduction in proliferation, 
down-regulation of p-AKT/p-FOXO3a and synergistic cell killing of primary AML cells 
when combined with etoposide (Billottet et al., 2006). A dose escalation phase I clinical trial 
of IC87114 (CAL-101) in relapsed and refractory haematological malignancies including 
AML has been completed, but the results are yet to be published (trial NCT00710528). 
Recently, more potent PI3K inhibitors have been developed including ZSTK-474 and BEZ-
235. ZSTK-474 has shown potent inhibition of all class I isoforms of PI3K (~5-50nM) 
(Kong & Yamori, 2007). In vitro testing showed a reduction in proliferation in ALL cell 
lines and it is currently entering a phase I clinical trial in advanced solid malignancies to 
evaluate its safety profile (Levy et al., 2009). Although PI3K inhibitors can effectively 
decrease proliferation in in vitro AML models, they have not demonstrated effective cell 
killing.  
AKT inhibitors 
Several different AKT inhibitors have been designed and examined in AML. Perifosine, an 
orally available alkyl-phospholipid inhibitor, functions by preventing AKT localisation to the 
plasma membrane. Perifosine inhibits phosphorylation of AKT and ERK and induces 
apoptosis in primary AML cells and AML cell lines (Papa et al., 2008). CD34+ AML cells 
with constitutive AKT activity (AKT+) treated with perifosine reduced the clonogenicity of 
the cells while having a minimal impact on normal CD34+ cells. Perifosine has entered a 
phase I clinical trial in combination with UCN-01 (a PDK1 inhibitor) (trial NCT00301938) 
and a phase II trial in refractory and relapsed leukaemia (trial NCT00391560). The results of 
these trials have yet to be released. Triciribine, a synthetic reversible tricyclic nucleoside 
AKT1/2/3 inhibitor, is also being used in a phase I trial in adult patients with advanced 
haematological malignancies (trial NCT00642031).  
Akti-1/2, a reversible AKT1/AKT2 isoform-specific allosteric inhibitor, has been shown to 
reduce proliferation, decrease clonogenicity and induced apoptosis in primary AML cells 
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with high risk cytogenetics (Gallay et al., 2009). The limitation of this inhibitor is that the 
isoform(s) expressed in AML blasts is unknown. AZD5363, a orally available ATP 
competitive inhibitor of AKT1/2/3, has demonstrated potent anti-proliferative (<3µM) 
effects in several haematological cell lines (Davies et al., 2012). AZD5363 is currently 
entering a phase I clinical trial in advanced solid tumours (trial NCT01226316).  
mTOR inhibitors 
The mTOR pathway is activated in almost all AML cells and has become an attractive 
pathway to target with inhibitory molecules. Rapamycin and its derivates, including 
temsirolimus, everolimus and deforolimus, also referred to as rapalogs, do not bind directly 
to mTORC1 but bind to the immunophilin FK506 binding protein 12 (FKBP12). The 
rapamycin/FKBP12 complex can then bind to mTORC1 and inhibit downstream targets. 
Treatment of primary AML cells with rapamycin has demonstrated a potent reduction in 
mTOR target proteins, i.e. p-4EB-P1 and p-p70 S6K but only slightly decreased cell survival 
(Xu et al., 2003). In AML cell lines rapamycin has been shown to block transition from G0-
G1 of the cell cycle and impair the clonogenicity of primary AML cells while normal CD34+ 
HSCs were unaffected (Recher et al., 2005). Rapamycin has also been used in a preclinical 
study as a single agent, which showed a partial response in four of nine patients with 
refractory or relapsed AML (trial NCT00780104) (Recher et al., 2005). Everolimus has also 
been assessed in a phase I clinical trial in relapsed or refractory haematological diseases, 
including AML, and showed no-dose limiting toxicities, however there was no 
complete/partial responses in patients with AML (trial NCT00544999) (Yee et al., 2006). 
Other approaches have combined rapamycin with other cytotoxic agents. A combination of 
rapamycin and etoposide has demonstrated an enhanced cytotoxicity in primary AML cells 
and reduced the potential of these cells to engraft in NOD/SCID mice, suggesting specific 
killing of the LSC compartment (Recher et al., 2005). Various phase II clinical trials are 
currently ongoing combining rapamycin, everolimus or temsirolimus with different 
chemotherapeutic drugs such as cytarabine and daunorubicin (Table 1.10). In addition, the 
multi-drug target kinase inhibitors PKC412 and nilotinib are currently being assessed in 
conjunction with everolimus (trials NCT00819546 and NCT00762632).  
The modest efficacy of rapamycins in the clinic may be due to insufficient blockade of 
mTORC2. As a consequence, this has led to the development of second-generation ATP 
competitive inhibitors targeting mTORC1 and mTORC2. Targeting both mTORC1 and 
mTORC2 is proposed to reduce the positive feedback mechanism, described below, on 
PI3K/AKT and ERK/MAPK. Ku-0063794 and WYE-354 are two novel ATP competitive 
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inhibitors which target mTORC1 and mTORC2 directly. Ku-0063794 has demonstrated 
potent inhibition of mTORC1 and mTORC2 in vitro and in vivo, showing more efficient 
inhibition of p-4E-BP1 than rapalogs (Garcia-Echeverria, 2009). WYE-354 has shown 
potent down-regulation of mTORC1 substrates p-4E-BP1 and p-S6K (T389) and the 
mTORC2 substrate p-AKT S473 in different cancer cell lines (Yu et al., 2009). WYE-354 
also been shown to inhibit p-AKT S473 in nude mice bearing PC3MM2 tumours (prostate 
tumours). The use of WYE-354 has not yet been assessed in AML models. Current data 
suggests that second-generation inhibitors may have more clinical efficacy as they appear to 
more potently block protein translation and mTORC2 substrates in comparison to rapamycin 
and its rapalogs.  
1.9.7 Dual PI3K/mTOR inhibition  
The poor response to PI3K or mTOR inhibitors alone may be the result of complex 
compensatory feedback mechanisms. In AML cell lines everolimus can promote PI3K/AKT 
activation which up-regulates an autocrine IGF-1/IGF1-R activating loop (Tamburini et al., 
2008). One group has reported that inhibition of mTORC1 can lead to activation of 
ERK/MAPK signalling (Carracedo et al., 2008). mTORC1 can also be activated 
independently of PI3K. This therefore provides a rationale for blocking both PI3K/AKT and 
mTOR simultaneously to circumvent some of these compensatory feedback mechanisms. In 
support of this, combined inhibition of PI3K and mTOR with IC87114 and everolimus 
respectively has shown an additive reduction in proliferation in AML cells (Tamburini et al., 
2008). As a result, dual PI3K/mTOR inhibitors have been developed. PI-103, a PI3K/mTOR 
inhibitor, has demonstrated pro-apoptotic effects in primary AML cells, including those cells 






) (Park et al., 2008). Unfortunately, PI-
103 has not entered clinical trials due to its rapid metabolism in vivo. Novartis have 
subsequently developed an ATP competitive PI3K/mTOR inhibitor BEZ-235, which has 
shown inhibition of mTORC1, mTORC2 and PI3K in AML cell lines and primary AML 
cells (Chapuis et al., 2010). BEZ-235 can induce a significant level of apoptosis in primary 
AML progenitors while showing a minimal effect on normal CD34+ haematopoietic 
progenitors (Chapuis et al., 2010). The striking level of cell killing seen with BEZ-235 is 
thought to be attributable to potent inhibition of p-4E-BP1 resulting in a block in protein 
translation in conjunction with PI3K blockade. BEZ-235 has already been used in a dose 
escalation clinical trial in solid tumours (trial NCT00620594) and is currently being used in a 
phase I dose finding study in patients with relapsed or refractory AML (trial NCT01756118).  
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1.9.8  MEK inhibitors 
A number of different inhibitory molecules have been used to target the RAF/MEK/ERK 
pathway including U0126, PD184352 (both non competitive ATP inhibitors of MEK1/2) and 
PD98059 (a non-ATP competitive inhibitor of MEK1). All of these inhibitors have 
demonstrated potent inhibition of proliferation and varying degrees of apoptosis in AML cell 
lines and primary AML cells (Kerr et al., 2003;Lunghi et al., 2003;Milella et al., 
2007;Zhang et al., 2008). U0126 and PD98059 have not entered clinical trials due to poor 
pharmacokinetics and solubility. A phase II clinical trial of PD184352, otherwise known as 
CI-1040, in advanced non-small-cell lung, breast, colon and pancreatic tumours has been 
completed but showed no complete or partial responses (trial NCT00034827) (Rinehart et al., 
2004). 
Subsequently, second-generation MEK inhibitors are now being developed. AZD6244, an 
allosteric MEK1/2 inhibitor, has displayed cytostatic effects in AML cell lines but failed to 
induce apoptosis (Zhang et al., 2010). However, blocking MEK and MDM2 with AZD6244 
and Nutlin3a respectively could induce significant cell killing in AML cell lines (Zhang et 
al., 2010). AZD6244 is currently in several clinical trials for solid tumours. PD-0325901 is a 
non-ATP competitive MEK1/2 inhibitor which is more potent than its derivative PD184352. 
PD-0325901 has shown potent inhibition of cell growth in AML cell lines and primary AML 
cells (Ricciardi et al., 2012). Combined PD0325901 and temsirolimus treatment resulted in 
synergistic growth inhibition in OCI-AML3 and MOLM-13 AML cell lines (Ricciardi et al., 
2012). PD0325901 has entered phase I and II clinical trials in solid tumours, however 
patients suffered more severe side effects than with PD184352 and as a result its use has 
been discontinued (trials NCT00174369, NCT00147550). The use of MEK inhibitors as 
single agents in AML models has been disappointing. This suggests that MEK blockade is 
not sufficient alone to eradicate leukaemic cells.  
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Table 1.10 PI3K, AKT, mTOR, PI3K+mTOR and MEK inhibitors currently available illustrating their targets, the mechanisms of binding to their 
targets and current clinical status of each inhibitor. 
Inhibitor 
name  
Target  Method of binding Clinical status  
Akti-1/2 AKT1/AKT2 isoforms Allosteric Preclinical  
AZD5363 AKT1/2/3 ATP competitive NCT01226316 
AZD6244 MEK1/2 Allosteric Numerous clinical trials 
BEZ-235  Pan class I P13K and mTOR ATP competitive NCT00620594, NCT01756118 




PI3K P110 δ subunit  ATP competitive NCT00710528 
Ku-0063794 mTORC1 and mTORC2 ATP competitive Preclinical 
 
LY294002 PI3K p110 catalytic subunit ATP competitive  Preclinical  
PD-0325901 MEK1/2 Non-ATP competitive  NCT00174369, NCT00147550 
PD184352 MEK1/2 Non-ATP competitive  NCT00034827 
PD98059 MEK1 inhibitor Non-ATP competitive Preclinical  
Perifosine PH domain of AKT Non-ATP competitive NCT00301938, NCT00391560 
PI-103 Class I PI3K and mTOR ATP competitive Preclinical  
PWT-458 PI3K p110 catalytic subunit Not available  Preclinical  
PX866 PI3Kα, γ, and δ Irreversible  Preclinical  
Rapamycin Immunophilin, FK506 binding protein 12 Allosteric NCT00780104, NCT00634244 
SF1126 Pan PI3K/mTOR Not available  NCT00907205l 
Sorafenib RAF/ VEGFR1/2 /PDGFR and c-KIT kinases ATP competitive and Non-ATP 
competitive  
Numerous clinical trials 
Temsirolimus Immunophilin, FK506 binding protein 12 Allosteric NCT00084916 
Triciribine AKT1/2/3 Non-ATP/substrate competitive NCT00642031 
U0126 MEK1/2  Non-ATP competitive Preclinical 
Wortmannin PI3K p110 catalytic subunit Irreversible  Preclinical 
WYE-354 mTORC1 and mTORC2 ATP competitive Preclinical  
ZSTK-474 Pan-class I PI3K inhibitor  
 
ATP competitive  NCT01280487 
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1.9.9 Novel therapeutic approaches 
Overall there is an urgent requirement for new therapeutic options for treating non-APL 
AML. The use of small molecule inhibitors may be one such approach. A variety of small 
molecule inhibitors have been designed targeting an array of dysregulated proteins and 
signalling pathways, as discussed previously. However the majority, with the exception of 
AC220, have had disappointing clinical responses as single agents. This suggests that 
targeting just one genetic lesion or dysregulated signalling pathway is not enough to 
effectively eradicate leukemic blast cells in AML.  
1.10 Aims  
The following research aimed to: 
 Investigate which c-KIT isoforms, GNNK- or GNNK+ is most common in a cohort 
of unselected patient samples with AML. 
 Evaluate the impact of AML specific c-KIT mutations on receptor activation and 
downstream signalling in cells that express endogenous c-KIT mutations and a 
human cell line engineered to express c-KIT mutations in different domains. 
 Examine the response of cells that express endogenous c-KIT mutations, a human 
cell line engineered to express AML specific c-KIT mutations and primary AML 
samples with c-KIT mutations to small molecule inhibitors of c-KIT, PI3K/AKT and 
mTOR.  
 Investigate the functionality of a novel AML specific FLT3 mutation identified 





2. Materials and methods 
All reagents used, unless otherwise specified, are from VWR International Ltd, Lutterworth, 
UK. Some specific methods are given in the relevant result chapters.  
2.1 Cell culture  
2.1.1 Cell lines 
 




293T Embryonal kidney cell line Adherent Independent 
32Dcl3 Mouse Bone Marrow Suspension Dependent (IL3 - final 
concentration  2ng/mL) 
HMC1.2 Human Mast Cell leukaemia Suspension Independent 
Kasumi-1 Human acute myeloid 
leukaemia (AML FAB M2) 
t(8;21) 
Suspension Independent 
ME-1 Human acute myeloid 
leukaemia (AML FAB Me40) 
inv(16) 
Suspension Independent 
MOLM-13 Human acute myeloid 
leukaemia (AML FAB M5a) 
Suspension Independent 
MV4-11 Human acute monocytic 
leukaemia (AML FAB M5) 
Suspension Independent 
PL-21 Human acute promyelocytic 
leukaemia (AML FAB M3) 
Suspension Independent 
SKNO.1 Human acute myeloid 
leukaemia (AML FAB M2) 
t(8;21) 
Suspension Dependent (GM-CSF - final 
concentration  10ng/mL) 
UT-7 Human acute myeloid 
leukaemia (AML M7) 
Suspension Dependent (GM-CSF - final 
concentration  5 ng/mL) 
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2.1.2  Cell culture reagents  
 0.25% Trypsin-EDTA (PAA Laboratories Ltd, Somerset, UK) 
 CASY Ton (Diagnostics Corporation, Indianapolis) 
 Dimethyl sulfoxide (DMSO) (Sigma Aldrich, Poole, UK) 
 Dulbecco’s modified Eagle medium (DMEM) (PAA Laboratories Ltd, Somerset, 
UK) 
 Dulbecco’s Phosphate Buffered Solution (PBS) without calcium/magnesium (PAA 
Laboratories Ltd, Somerset, UK) 
 Ficoll-Paque™ gradient (Amersham Biosciences, Bucks, UK) 
 Foetal calf serum (FCS) heat-inactivated (PAA Laboratories, Pasching, Austria and 
BioSera, Boussens, France)     
 Penicillin/streptomycin 100X (PAA Laboratories Ltd, Somerset, UK) 
 Retronectin (TAKARA BIO INC, Saint-Germain-en-Laye, France) 
 RPMI Medium 1640 with L- glutamine (PAA Laboratories Ltd, Somerset, UK) 
 StemSpanTM H3000 (STEMSCELL Technologies SARL, Grenoble, France) 
 XtremeGene9 DNA transfection reagent (Roche Diagnostics Limited, West Sussex, 
UK) 
 
2.1.3 Cell culture plastics  
 24 well non-treated tissue culture plates (BD biosciences, Oxford)  
 6, 12, 24, 48 and 96 well tissue culture plates (PAA Laboratories Ltd, Somerset, UK) 




2.1.4 Small molecule inhibitors  
Inhibitor Targets Source Location 
ZSTK-474 PI3K Selleck Newmarket, Suffolk 
WYE-354 mTOR Axon MedChem Groningen, The 
Netherlands 
BEZ-235 PI3K + mTOR Axon MedChem Groningen, The 
Netherlands 
PD184352 MEK Merck Hertfordshire, UK 
AZD5363 AKT Astra Zeneca Cheshire, UK 





Imatinib BCR-ABL + c-KIT Axon MedChem Groningen, The 
Netherlands 
AC220 FLT3 Axon MedChem Groningen, The 
Netherlands 
Ponatinib Abl,PDGFRα,VEGFR2,FG
FR1 Src and FLT3 
Selleck Newmarket, Suffolk 
Masitinib PDGFRα/β and c-KIT Selleck Newmarket, Suffolk 
 
2.1.5 Recombinant Growth Factors  
 Murine IL3 (PeproTech, London, UK) 
 Human GM-CSF (PeproTech, London, UK) 
 Human SCF (PeproTech, London, UK) 
 Human FLT3 (PeproTech, London, UK) 
 Human TPO (PeproTech, London, UK) 
 Human IL3 (PeproTech, London, UK) 
 
2.1.6 Thawing of cells and cryo-preservation  
Primary AML cells and cell lines were quickly thawed in a water bath at 37⁰C and decanted 
into a 50mL universal. Pre-warmed RPMI containing 10% FCS and 1% penicillin and 
streptomycin (R1) or RPMI containing 20% FCS and 1% penicillin and streptomycin (R2) 
was added to cell lines and primary AML cells respectively in a dropwise fashion every 2-3 
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seconds up to 10mLs with gentle shaking. A further 10mLs of R1/R2 was then added to the 
cells and they were centrifuged at 450g for 5 minutes. Cell lines were re-suspended in R1 or 
R2 at a seeding density of 1x10
6 
cells/mL and incubated at 37⁰C in a humidified atmosphere 
containing 5% CO2. Primary AML cells were re-suspended at 2-5x10
5
 cells/mL in StemSpan 
medium (R3) containing 20ng/mL of human SCF, FLT3, TPO and IL3, in a relevant sized 
flask and incubated overnight at 37⁰C in a hypoxic atmosphere containing 5% CO2 and 5% 
O2. After 24 hours, viable primary AML cells were isolated by density centrifugation, as 
described in section 2.1.8 and re-suspended in R3 without growth factors. For cryo-
preservation, cell lines were frozen down at a cell density recommended by Deutsche 
SammLung von Mikroorganismen und Zellkulturen GmbH (DSMZ), approximately 
5x10
6
cells/mL, using a freezing mix of 70% RPMI, 20% FCS and 10% DMSO and stored in 
liquid nitrogen.  
2.1.7 Cell counting and cell viability using the Casy Counter system  
The Casy Counter system is an electric field multi-channel cell counting system that utilises 
the resistance measurement principle and pulse area analysis to determine cell number and 
cell viability. The Casy®Ton solution is a buffer specially designed for cell counting and 
aspiration through a pore of specific geometry at a constant flow rate. When measured, the 
cells displace a given volume of buffer which is equivalent to the volume of the cells. Cell 
viability is assessed on the integrity of the plasma membrane, as living cells have an intact 
cell membrane whereas dead or dying cells have ruptured or porous cell membranes. When 
cells with an intact cell membrane are exposed to a low voltage they can be described as 
electric insulators, whereas cells that are dead (ruptured or porous) allow the voltage to pass 
through the cells and are recorded by the size of their nucleus, therefore this allows live and 
dying cells to be distinguished based on size. Measurements are carried out by diluting the 
cell suspension 1:200 in Casy®Ton solution and analysing the diluted suspension on the 
Casy Counter. The results provide a diameter-linear size distribution, which indicates the 
volume, viability and concentration of the sample tested.  
2.1.8 Ficoll centrifugation  
A volume of 10mL Ficoll-Paque™ was layered underneath 5mL of R1/R2 in a 50mL falcon. 
Cells were washed with R1 and centrifuged at 450g for 5 minutes then re-suspended to 
approximately 1-5x10
6
cells/mL, layered on top of the R1/R2 layer and centrifuged at 352g 
for 25 minutes. Cells within the interface between the Ficoll-Paque™ and RPMI were 
aspirated, washed with 20mL of R1 and re-suspended to the desired concentration in either 
in R1/R2 or R3.  
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2.2 Retroviral production   
2.2.1 Reagents for retroviral production  
 X-tremeGENE 9 DNA Transfection Reagent (Roche Diagnostics Limited, West 
Sussex, UK) 
 
2.2.2 Transfection of 293T cells  
A total of 4.5x10
6
 293T cells were seeded on to a 10cm
2
 tissue culture dish in 10mL DMEM 
containing 10% FCS and 1% penicillin and streptomycin (R4). After 24 hours, the 293T 
cells were checked to see that they were approximately 50-60% confluent prior to 
transfection. For each plate, 36µL of X-tremeGENE 9 DNA Transfection Reagent (3µL/µg 
DNA to be transfected) was diluted in 1.2mL of serum-free RPMI and incubated at room 
temperature for 5 minutes. A total of 12µg of plasmid DNA was transfected per plate, 
(4.6785µg of the gag/pol expressing plasmid (PeqPam), 3.125µg of the envelop plasmid 
(RD114 or Ecotropic) and 4.6785µg of the respective Moloney murine leukaemia virus 
based (SFG) plasmids (kindly provided by Martin Pule)) and incubated at room temperature 
for 5 minutes. The DNA mix was then added, to the X-tremeGENE 9:RPMI mix and 
incubated at room temperature for 30 minutes. DNA:X-tremeGENE 9 mix was added 
dropwise to each respective plate and placed into the incubator. Viral supernatant was 
harvested after 48 hours and stored at 4°C. Fresh R4 (10mLs) was then added to each plate. 
After a further 24 hours the viral supernatant was harvested again and pooled with the 48 
hour supernatant. The viral supernatants were then aliquoted into cryotubes and either snap 




2.3 Immunoblotting  
2.3.1 Reagents for immunoblotting 
 Bovine Serum Albumin (BSA) fraction V (Sigma Aldrich, Poole, UK) 
 Complete, Mini Protease Inhibitor Cocktail Tablets (Roche Diagnostics Limited, 
West Sussex, UK)  
 DCTM protein assay (BIO- RAD Laboratories Ltd, Richmond, CA) 
 Enhance chemiluminescence kit (ECL Prime) (GE Amersham Life Sciences, Bucks, 
UK) 
 Full range Amersham Rainbow Marker (GE Healthcare Life Sciences, Bucks, UK) 
 Hybond-C-Extra nitrocellulose membrane (Amersham Life Sciences, Bucks, UK) 
 Hyperfilm™ high performance autoradiography film (GE Amersham Life Sciences, 
Bucks, UK) 
 Methanol (VWR International Ltd, Lutterworth, UK) 
 Non-fat dried milk (MARVEL) 
 NuPAGE® 4-12% Bis-Tris Gel 1.0 mm, 10/12/15 wells (Life Technologies Limited, 
Paisley, Scotland) 
 NuPAGE® Antioxidant (Life Technologies Limited, Paisley, Scotland) 
 NuPAGE® LDS Sample Buffer (4X) (Life Technologies Limited, Paisley, Scotland) 
 NuPAGE® Novex 7% Tris-Acetate Gel 1.0 mm, 12 Well (Life Technologies 
Limited, Paisley, Scotland) 
 NuPAGE® Sample Reducing Agent (10X) (Life Technologies Limited, Paisley, 
Scotland) 
 PhosSTOP phosphatase Inhibitor Cocktail Tablets (Roche Diagnostics Limited, 
West Sussex, UK) 
 Pierce ECL Western Blotting Substrate  (Thermo Scientific, UK) 
 Protein G-Sepharose 4 Fast Flow (Sigma-Aldrich Company Ltd,  Dorset, UK)  




2.3.2 Antibodies  
 Anti-phosphotyrosine 4G10 (Millipore, Temecula) 
 Bcl-2 (BD transduction, Oxford, UK) 
 Bcl-x (BD transduction, Oxford, UK) 
 BIM (Cell Signalling Technology, Hitchin, UK) 
 Flt-3/ Flk-2 (C20) (Santa Cruz biotechnology, Middlesex, UK)  
 GAPDH (Cell Signalling Technology, Hitchin, UK) 
 Mcl-1 (Santa Cruz biotechnology, Middlesex, UK) 
 Mouse IgG, HRP-linked (Cell Signalling Technology, Hitchin, UK) 
 Pan c-Kit (D13A2) XP (Cell Signalling Technology, Hitchin, UK) 
 PARP (Cell Signalling Technology, Hitchin, UK) 
 Phycoerythrin (PE) Mouse Anti-Human CD117 (BD Pharmingen™) 
 Phycoerythrin (PE) Mouse Anti-Human CD135 (BD Pharmingen™) 
 Phospho 4E-BP1 (Thr37/46) (Cell Signalling Technology, Hitchin, UK) 
 Phospho STAT5 (Tyr694) (Cell Signalling Technology, Hitchin, UK) 
 Phospho-AKT (Ser 473) (Cell Signalling Technology, Hitchin, UK) 
 Phospho-c-KIT (Tyr719) (Cell Signalling Technology, Hitchin, UK) 
 Phospho-FLT3 (Tyr589/591) (Cell Signalling Technology, Hitchin, UK) 
 Phospho-MAPK p42/44 (Thr 202/Tyr204) (Cell Signalling Technology, Hitchin, UK) 
 Phospho-S6 Ribosomal Protein (Ser235/236) (Cell Signalling Technology, Hitchin, 
UK) 
 P-p70-S6K (Thr389) (Cell Signalling Technology, Hitchin, UK) 
 Pro-caspase 3 (Cell Signalling Technology, Hitchin, UK) 
 Pro-caspase 9 (Cell Signalling Technology, Hitchin, UK) 





Lysis buffers:  
Protein lysis buffer (50mML HEPES pH 7.5, 100mM NaCl, 1% Triton X-100, 1mM EDTA, 
1mM EGTA, 20mM NaF, 1mM Na orthovanadate, 1mM Pefabloc, 10μg/mL each of 
aprotinin, pepstatin, and leupeptin). 
RIPA lysis buffer, 10X (0.5M Tris-HCl, pH 7.4, 1.5M NaCl, 2.5% deoxycholic acid, 10% 
NP-40, 10mM EDTA) diluted to 1X using Double Distilled Water (DDW) with 1 Complete 
Mini Protease Inhibitor Cocktail Tablet and 1 PhosSTOP Phosphatase Inhibitor Cocktail 
Tablet for each 10mLs.  
Running buffer: NuPAGE® MOPS SDS Running Buffer (20X) (Life Technologies 
Limited, Paisley, Scotland) diluted to 1X using DDW.  
Transfer Buffer: 10X stock (4.8mM Tris, 39mM Glycine, 0.038% SDS made to pH 9.1) 
diluted to 1X in 20% methanol.  
Tris Buffered Saline (TBS): 10X solution 0.5M TRIS, 3.76M NaCl diluted in 1.25L of 
DDW, made to pH7.5 
TBS-Tween-20 (TBST) Wash Buffer: 1L 10X TBS, 100mL 10% Tween-20 in PBS, made 
up to 10L with DDW.  
2.3.3 DCTM protein assay  
Working reagent A’ was prepared by adding 20µL of reagent S to each mL of reagent A 
needed. For each run a BSA standard curve of 10mg/mL, 7.5mg/mL, 5mg/mL, 2.5mg/mL, 
1mg/mL and 0.5mg/mL was used. For each standard or sample 5µL was pipetted into a 96 
well microtiter plate, 25µL of reagent A’ was added to each well then 200µL of reagent B. 
The protein lysate/reagent mix was incubated at room temperature for 15 minutes and the 
absorbance read at 750nm on the Varioskan® Flash microplate reader (Thermo Scientific). 
A standard curve was generated using the absorbance values from the known concentrations 
of BSA solution. Protein concentrations of the samples analysed were then determined using 
the equation of the straight line.    
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2.3.4 Western blotting   
Cells (5-10x10
6
) were harvested, washed with ice cold PBS and lysed in 50µL of protein 
lysis buffer or 1X RIPA lysis buffer supplemented with PhosSTOP phosphatases and 
Complete Mini Protease Inhibitor Cocktail Tablets (Modified RIPA) for 30 minutes on ice. 
Lysates were then centrifuged at 20,000g at 4°C for 10 minutes. The protein concentration in 
the supernatant was calculated using the DC
TM
 protein assay (section 2.3.3). NuPAGE® 
LDS Sample Buffer (4X) was prepared with a final concentration of 10% NuPAGE® 
Sample Reducing Agent. Based on the protein concentration 25-80µg of protein lysate was 
standardised in 16µL lysis buffer. To each sample 4µL of the prepared NuPAGE sample 
buffer was added and boiled for 10 minutes. The NuPAGE gels were prepared prior to use 
by removing the combs and protective strips and placed into the Invitrogen Novex Mini cell 
Electrophoresis apparatus. The gels were then immersed in 1X MOPS buffer, and 500µL of 
anti-oxidant was added to the central chamber. The protein was then loaded onto the gels, 
with 5-10 µL of the Full Range Amersham Rainbow Marker and run at 150V until sufficient 
protein size separation was achieved (judged by Rainbow Marker migration). The gels were 
removed and soaked in transfer buffer and transferred to a nitrocellulose membrane using the 
Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) at 25V for 30mins.  
Membranes were blocked in TBST with 4% MARVEL (MARVEL-TBST) or TBST with 
5% BSA (BSA-TBST) for 1 hour at room temperature. Membranes were then washed 3 
times in TBST. All membranes were incubated overnight at 4⁰C with primary antibody at 
dilutions specified by the manufacturer in BSA-TBST. The following day the primary 
antibody was removed and the membranes were washed 3 times for 5 minutes each in TBST. 
The relevant species-specific secondary antibody (conjugated to horseradish peroxidase) was 
diluted 1:15,000 in 3% MARVEL-TBST and incubated for 1 hour. Membranes were then 
washed 3 times in TBST for 5 minutes and proteins were detected using chemiluminescence 
with ECL prime or Pierce ECL Western Blotting Substrate according to the manufacturer’s 
instructions. The membranes were then exposed to Hyperfilm for ranging times, dependent 
on the band intensity. The film was then developed in an automated film developer (Konica 





2.4 Flow cytometry  
2.4.1 Reagents for flow cytometry  
 Annexin buffer (150mM NaCl, 10mM HEPES pH7.4 and 10mM CaCl2) 
 Annexin V-Fluorescein isothiocyanate (FITC) conjugate (Roche Diagnostics, 
Mannheim, Germany) 
 Flow-Check Fluorospheres (Beckman Coulter UK Ltd) 
 NormocinTM (50mg/mL) (InvivoGen, San Diego, USA) 
 PBS with 0.5% BSA (0.5% BSA/PBS) 
 Propidium iodide solution (PI) (diluted in filtered PBS at 2.5mg/mL) (Sigma 
Aldrich, UK) 
 
2.4.2  Annexin V / PI staining   
A total of 200µLs of cell suspension was added to 100µL of the following master mix: 20µL 
Flow-Check Fluorospheres, 100µL Annexin Buffer, 2.5µL PI solution and 0.25µL Annexin 
V-FITC conjugate and incubated for 15 minutes at room temperature. Samples were 
analysed on either the CyAn
TM
 ADP Analyzer (Beckman Coulter) or the BD FACSVerse
TM
 
(BD Biosciences) flow cytometer machines. To analyse cells bivariant dot plots of log side 
scatter (SS) versus linear forward scatter (FS) were generated. Beads were identified by their 
unique forward scatter and side scatter properties and an electronic gate applied to them. 
Two thousand bead events were assayed in each case. An electronic gate was applied to the 
cell populations and data from this gate was plotted on a second bivariant dot plot of PI 
versus Annexin V. Quadrants were applied identifying cells which were PI/Annexin V 
double negative (live cells), PI negative/Annexin V positive (early apoptotic cells) and 
PI/Annexin double positive (late apoptotic/dead cells).  
2.4.3 Flow cytometry examining BFP expression   
All constructs used expressed the enhanced Blue Fluorescent Protein (eBFP) as a marker and 
was used to determine the percentage of cells that had been transfected. Cells were re-
suspended to 1x10
6
/500µL in 0.5% BSA/PBS and analysed on the flow cytometer by gating 
the live cell population, based on their SS and FS. Data from this gate was then plotted on a 
second bivariant dot plot of BFP versus SS. The native cell line was used as a negative 
control to set the level of BFP expression to approximately 1%, hence anything above this 
threshold was considered positive. 
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2.4.4 Staining of cells with PE-conjugated antibodies 
Cells were re-suspended to 1x10
6
/100µL in 0.5% BSA/PBS. Following the manufacturers’ 
guidelines, the relevant amount of PE-conjugated antibody was added. The cell suspension 
was incubated for 1 hour on ice, then 400µL of 0.5% BSA/PBS was added. The live cell 
population was gated based on the cells SS and FS and from this gate the data was plotted 
onto a second bivariant dot plot of BFP versus PE. The appropriate native cell line was used 
as a negative control to set the level of BFP/PE expression to approximately 1%, and 
anything above this 1% threshold was considered positive.  
2.4.5 Cell sorting 
Cells were re-suspended to 1-10x10
6
/mL in R1 or R2 containing 100µg/mL of Normocin
TM
 
and placed into sterile 5mL polystyrene round-bottom tubes and kept on ice. Cells were 
sorted based on BFP expression using a MoFlo
TM
 XDP machine (Beckman Coulter UK Ltd). 
Following sorting cells were washed in 1mL of PBS and re-suspended in 300 - 1000µL of 
R1 or R2 containing 100µg/mL of Normocin
TM
 and incubated at 37⁰C in a humidified 
atmosphere containing 5% CO2. 
2.5  Molecular Biology 
2.5.1 Molecular biology reagents  
 Agar (Sigma-Aldrich Company Ltd, Dorset, UK)  
 Agarose (Bioline, London, UK) 
 Ampicillin (Invitrogen, Paisley, UK) 
 Bioline buffer and magnesium chloride (Bioline, London, UK) 
 BIOTAQ™  DNA polymerase (Bioline, London, UK) 
 CEQ™ DNA Size Standard Kit – 400/600 (Beckman Coulter UK Ltd, 
Buckinghamshire, UK) 
 CEQ™ Separation Buffer (Beckman Coulter UK Ltd, Buckinghamshire, UK) 
 Chloroform (VWR International Ltd, Lutterworth, UK) 
 dNTPs (Bioline, London, UK) 
 Ethanol 100% (VWR International Ltd, Lutterworth, UK) 
 Ethidium Bromide (1mg/ml) (Invitrogen, Paisley, UK) 
 Human c-KIT cDNA clone SC120061 (OriGene Technologies, Inc. Rockville, USA) 
 Hyperladder I and IV (Bioline, London, UK) 
 LB tablets (Sigma-Aldrich Company Ltd, Dorset, UK) 
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 One Shot® Stbl3™ Chemically Competent E. Coli (Life Technologies Limited, 
Paisley, Scotland) 
 Optimase buffer and magnesium sulphate (Transgenomic Ltd, Glasgow, UK) 
 OptimaseTM DNA polymerase (Transgenomic Ltd, Glasgow, UK) 
 PeqGOLD MicroSpin Cycle-Pure Kit (Peqlab, Sarisbury Green)  
 Phusion® High-Fidelity DNA Polymerase (New England BioLabs, Hitchin, 
Hertfordshire) 
 Plasmid DNA purification NucleoBond® Xtra Midi Kit (MACHEREY-NAGEL 
Düren, Germany) 
 Primers (Integrated DNA Technologies, Belgium) 
 QIAGEN plasmid mini kit (Crawley, West Sussex, UK) 
 QIAGEN QIAquick gel extraction kit (Crawley, West Sussex, UK) 
 QIAGEN QIAquick PCR purification KIT (Crawley, West Sussex, UK) 
 QIAGEN RNeasy Mini Kit (Crawley, West Sussex, UK) 
 Quick BluntingTM Kit (New England BioLabs, Hitchin, Hertfordshire 
 Restriction enzymes and the corresponding buffers (New England BioLabs, Hitchin, 
Hertfordshire) 
 Sample loading solution (SLS) (Beckman Coulter UK Ltd, Buckinghamshire,UK) 
 Sterile molecular water (Sigma Aldrich Company Ltd, Dorset, UK)  
 Super Optimal Broth (S.O.C) (Invitrogen Life Technologies, Paisley, UK) 
 SuperScript® III First-Strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, Paisley, UK) 
 T4 DNA ligase (New England BioLabs, Hitchin, Hertfordshire) 
Buffers 
1x Tris/Borate/EDTA (TBE) solution: 89mM Tris base, 90mM boric acid and 2mM EDTA 
in 1L of ddH2O 
5x Loading buffer: 30% glycerol and 0.025% bromophenol blue in 1x TBE 
Dodecyltrimethylammonium bromide (DTAB) solution: 260mM DTAB, 1.5M NaCl,  
100mM Trizma and 50mM EDTA made up to 1L DDW. 
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2.5.2  DNA extraction  
Cells were pelleted and suspended in PBS (100µL per 1 x 10
6
). To this, twice the volume of 
DTAB solution was added, mixed and incubated for 5 minutes at 68°C. Samples were stored 
at -20°C until required. Samples were thawed at 37°C and an equal volume of chloroform 
added, mixed thoroughly by inversion. Samples were centrifuged at 2465g for 15 minutes at 
room temperature. The upper aqueous layer containing the DNA was removed and to this an 
equal volume of 100% ethanol was added. This was mixed gently to precipitate out the DNA 
then centrifuged for 5 minutes at 2465g. The supernatant was removed and the pellet was 
transferred to a 1.5mL eppendorf. The pellet was washed in 70% ethanol and centrifuged at 
20,000g for 5 minutes. The ethanol was removed and the pellet was allowed to air dry. The 
pellet was then re-suspended in sterile water (100µL for 10-15 x10
6 
cells lysed) and stored at 
4°C. 
2.5.3 RNA extraction  
RNA was isolated from 1x10
6
 cells following the RNeasy Mini Kit (QIAGEN) 
manufacturer’s instructions.  
2.5.4 Generation of cDNA  
cDNA was made according to the SuperScript® III First-Strand Synthesis System 
(Invitrogen Life Technologies) for RT-PCR  manufacturer’s protocol. 
2.5.5  Polymerase Chain Reaction (PCR) 
PCR was used to amplify regions of interest in genomic DNA or cDNA, with repeated 
thermal cycling consisting of denaturation followed by annealing of specific forward and 





or Phusion® DNA polymerases were used 
according to the manufacturer’s instructions. Master mixes were made for each PCR reaction 
prior to the addition of the DNA template to ensure reproducibility. A negative control of 
double-distilled water (DDW), in place of the DNA template, was also included within each 
PCR reaction to ensure there was no contaminating DNA template within the master mix. 
Denaturation was carried out at 95⁰C for 30 seconds. The primer annealing temperature was 
calculated based on the composition of the primers and was incubated for 30 seconds. The 
extension temperature was 72⁰C and the time of the extension step was calculated based on 
the number of base pairs in the PCR product. The general rule for calculating the extension 
time was 1 minute per kilobase of DNA. These steps were repeated and modified according 
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to the individual requirement of each PCR and will be specified in more detail within the 
relevant chapters. The final step was an extension step for 5-15 minutes at 72⁰C to ensure 
complete amplification of each DNA amplicon. The standard reaction mix for a 20µL PCR 
using BIOTAQ
TM
 DNA polymerase contained 0.5U of BIOTAQ
TM 
DNA polymerase, 1X 
NH4 reaction buffer, 1mM MgCl2, 200µM dNTP mix, 0.5µM of forward/reverse primers. 
The standard reaction mix for a 20µL PCR using Optimase
TM 





polymerase, 1X Optimase buffer, 200µM dNTP mix, 0.5µM of 




 DNA polymerase 
were cycled 35 times as described above.  
The standard reaction mix for a 20µL PCR reaction using Phusion® DNA polymerase 
contained 0.2U of Phusion® DNA polymerase, 1X Phusion HF buffer, 200µM dNTPs, 
0.5µM of forward/reverse primers. The cycling conditions were an initial 2 minute 
denaturation step at 98⁰C, followed by 35 cycles of denaturation at 98⁰C for 42 seconds, 
annealing of primers for 42 seconds and extension at 72⁰C for the relevant amount of time 
followed by a final extension step between 5-15 minutes. All PCR reactions used 10-100ng 
of DNA template.  
2.5.6 Principle of overlapping extension PCR 
Overlapping extension PCR can be used to replace, delete or insert nucleotides into a desired 
fragment of DNA. This PCR based technique requires the design of primers containing the 
altered sequence to both the sense and antisense strands of DNA template sequence. The 
length of the horizontal segment of the primers is determined by the number of nucleotides 
required to reach the desired melting temperature. The primers were extended at the 3 prime 
ends to contain sufficient DNA sequence of the opposite fragment so that the melting 
temperature of the overlapping sequence is as required. An example is illustrated in Figure 
2.1. An initial PCR was required to amplify fragment (x) using primer pair (1) and (3) and 
fragment (y) with primer pair (2) and (4). A master mix of: 1x HiFid buffer, 200µM dNTPs, 
1 unit Phusion® DNA polymerase, 1µM or forward (1,2) and reverse primer (3,4) 30ng 
template DNA made up to 50µL with water and cycled according to the conditions described 
in section 2.5.5.  PCR products were visualised on a 1% agarose gel and gel extracted and 
purified with a QIAGEN QIAquick gel extraction kit. A second PCR was then used to 
anneal PCR product (x) and PCR product (y) together and amplify across the whole of 
fragment (xy). Annealing of the PCR products was mediated by the overhangs incorporated 
into the primers (2) and (3). A master mix of: 1x HiFid buffer, 200µM dNTPs, 1 unit 







Fragment (y)  Fragment (x)  
(4)  
 (1)  
(4)  
(a)  PCR amplification of 
fragments x and y and purification   
(b) Melting and annealing of fragments x 
and y providing template for 2nd PCR 
amplification    
Fragment (x)  
Fragment (y)  
Fragment (x) 
Fragment (y) 
Fragment xy  
Sense  
Antisense  
each cleaned PCR product (x) and (y) made up to 175µL with water and divided between 3 
PCR tubes. The cycling conditions were the same as previously described (section 2.5.5). 
From the second PCR reaction 12µL was ran on a 1% agarose gel to confirm that fragment 
(x) and (y) had annealed and amplified. The remaining PCR product was then cleaned up 





























2.5.7 Fragment size separation using the Capillary Electrophoretic Genetic Analysis 
System (CEQ)
TM
 8000  
Size differences within PCR products were quantified using PCR incorporating a 
fluorescently labelled reverse primer. Approximately 50ng of DNA was amplified using the 
BIOTAQ
TM
 DNA polymerase PCR conditions as described in section 2.5.5 but using 
0.25µM of forward/reverse primers and 25-28 PCR cycles. CEQ™ DNA Size Standard Kit 
400 or 600 (3.5µL) was added to 1mL of SLS. Each PCR product (2µL) was added to 38µL 
of SLS + CEQ™ DNA Size Standard mix. The PCR product/SLS mix was then loaded onto 
the sample plate and one drop of mineral oil was layered on top of each well. Separation 
buffer was also loaded on to the separation buffer plate. The samples were analysed by 
fragment separation on a CEQ 8000 Genetic Analysis System (Beckman Coulter). Following 
size separation of the PCR products, the area under each peak was determined by the 
instruments software algorithm. The relative proportion of each peak was determined by 
calculating the area under each peak as a percentage of the total alleles. 
2.5.8 Agarose gel electrophoresis 
PCR products or digested DNA products were visualised on 1-2% agarose gels. To make the 
gels, the required amount of agarose was added to 1X TBE. This was microwaved to 
dissolve the agarose. When cooled, ethidium bromide was added to the gel (final 
concentration 0.1µg/mL). This was then poured into a mould and allowed to set for 30 
minutes. To run samples, the gels were submerged in 1X TBE containing 0.1µg/mL 
ethidium bromide. The desired amount of PCR product or digested DNA was added to the 
relevant amount of loading dye and loaded into a well within the gel. With each gel 4µL or 
either Hyperladder I or IV was also loaded to confirm the size of the DNA products. Samples 
were electrophoresed at 75mA for 30-45 minutes. DNA products were visualised under a 
UV transilluminator and a polaroid image was taken.   
2.5.9 Agar plates and LB broth  
LB broth was made with 25 LB tablets in 1L of DDW and autoclaved. Agar plates were 
made with 8 LB tablets and 7.5g of Agarose, made up to 500mL with DDW and autoclaved. 
When both the LB broth and Agar were cool to touch, ampicillin was added to a final 
concentration of 100µg/mL. Agar plates were poured in the presence of a bunsen burner and 
allowed to set before storing at 4⁰C.   
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2.5.10 Restriction enzyme digests 
Amplified DNA or plasmid constructs were digested overnight using restriction enzymes, 
according to the manufacturer’s instructions. 
2.5.11 Sequencing 
PCR products for sequencing were generated following the BIOTAQ
TM
 PCR conditions 
(section 2.5.5). PCR products were cleaned up using the PeqGOLD MicroSpin Cycle-Pure 
Kit and diluted to a concentration of 1ng/µL per 100bp. For plasmid constructs, 100ng/µL 
samples were prepared. Samples were sent for sequencing by the Scientific Support Services 
(SSS) at UCL cancer institute.  
2.5.12 Cloning  
PCR products were generated from template DNA using the high-fidelity proof-reading 
Phusion® DNA polymerase and were visualised on a 1% agarose gel and purified using a 
QIAGEN QIAquick gel extraction kit. Extracted PCR products and the retroviral plasmid 
vector (SFG) were digested with restriction enzymes and purified using a QIAGEN 
QIAquick PCR purification kit. Ligation reactions were carried out using either T4 DNA 
Ligase or Quick T4 DNA Ligase. For the T4 DNA Ligase reaction 3µL of digested PCR 
product (10-30ng/µL) was ligated to 1µL of digested vector (50-100ng/µL) using 1X T4 
DNA Ligase Buffer and 400 NEB units of T4 DNA Ligase and incubated at 16⁰C overnight. 
Ligation reactions using the Quick T4 DNA Ligase were carried out with the same ratio of 
digested insert:vector but using 1X Quick Ligation Buffer, 2000 units of Quick T4 DNA 
Ligase in a total volume of 20µL, incubated at 25⁰C for 5 minutes and stored at 16⁰C. The 
ligated vector (1µL) was transformed into One Shot® Stbl3™ Chemically Competent E. 
Coli by heat shock at 42⁰C for 45 seconds and incubated on ice for 2 minutes. To the cells 
250µl of SOC medium was added per vial and the cells were incubated in a shaking 
incubator to recover for 1 hour at 37⁰C. The transformed E. Coli cells were diluted 1:4 in 
S.O.C medium, with 100µL plated onto pre-warmed agar plates containing 100µg/mL of 
ampicillin. Plates were incubated overnight at 37⁰C.  Uptake of vector provided ampicillin 
resistance allowing for bacterial colonies to form. Several colonies from each plate were 
selected and expanded in 4mL LB containing 100µg/mL Ampicillin (starter culture) at 37⁰C 
in a shaking incubator. DNA was extracted from 3mL of the expanded colonies using a 
QIAGEN plasmid mini kit as described by the manufacturer’s instructions. Following 
isolation of the DNA from the individual clones, restriction enzyme digests were carried out 
to confirm the presence of the correct insert size and run on a 1% agarose gel. If the insert 
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was present at the correct size, then the remaining 1mL of starter culture was added in to 
250mL LB with 100µg/mL ampicillin and incubated overnight at 37⁰C in a shaking 
incubator. DNA was isolated from the bulked up cultures using a Plasmid DNA purification 
NucleoBond® Xtra Midi Kit following the manufacturer’s instructions. To confirm that the 
insert was still present at the expected size in the midi prep, a restriction enzyme digest was 
carried out and the products were run on a 1% agarose gel. If the insert corresponded to the 





































3.  Chapter 3: Functional consequence of c-KIT mutations in the 
UT-7 AML cell line  
3.1 Introduction  
CBFL is defined by the presence of t(8;21)(q22;q22) or inv(16)(p13;q22) which generate the 
fusion proteins RUNX1-RUNX1T1 and CBFβ-MYH11 respectively. Both t(8;21) and 
inv(16) are associated with a favourable clinical outcome, however, 40-50% of patients with 
these translocations eventually relapse (Grimwade et al., 2010). c-KIT is expressed on 60-
80% of myeloblast cells and is mutated in 28% of CBFL (Beghini et al., 2004;Allen et al., 
2013). In CBFL, c-KIT mutations are found as indels in exon 8 (extracellular domain - ECD), 
point mutations in exon 10 (transmembrane domain - TMD), insertions/tandem duplications 
in exon 11 (juxtamembrane domain - JMD) or point mutations in exon 17 (activating loop 
domain - ALD). The presence of c-KIT mutations is associated with an increased RR in 
CBFL (Paschka et al., 2006;Cairoli et al., 2006;Allen et al., 2013). As a result, c-KIT has 
become an attractive therapeutic target for this subset of patients. Dasatinib, an inhibitor of 
wild-type and mutant c-KIT isoforms has been shown to inhibit c-KIT phosphorylation and 
induce apoptosis in human AML cells harbouring c-KIT-WT, c-KIT-V560G or c-KIT-
D816V and in murine Ba/F3 cells expressing  c-KIT-D816V, c-KIT-D816F or c-KIT-D816Y 
(Schittenhelm et al., 2006;Guerrouahen et al., 2010). Most studies have focused on 
evaluating the response of cells expressing c-KIT mutations in individual domains i.e. ALD 
to small molecule inhibitors. Therefore, there has been no direct comparison evaluating the 
response of a human AML cell line expressing c-KIT mutations occurring in different 
domains to c-KIT inhibitors.  
This chapter aimed to evaluate whether there are differences in proliferation and cell 
signalling between the c-KIT ∆417-419>Y, L576P, D816V and N822K mutations in the 
factor-dependent UT-7 megakaryoblastic leukaemia cell line. UT-7 cells expressing c-KIT-
∆417-419>Y, c-KIT-L576P, c-KIT-D816V and c-KIT N822K and were treated with c-KIT 
inhibitors to investigate if the mutation location impacted on the response to inhibitory 





3.2 Methods  
3.2.1 Cell lines 
UT-7, a human GM-CSF dependent megakaryocytic AML cell line, was cultured in R2 
media supplemented with 5ng/mL GM-CSF. 293T cells were cultured in R4. All cell lines 
were incubated in 5% CO2 at 37°C.  
3.2.2 Screening of pCMV6-XL5-c-KIT (NM_000222 OriGene) 
The pCMV6-XL-c-KIT construct, containing the c-KIT cDNA sequence, was purchased 
from OriGene. The entire coding sequence of c-KIT was sequenced directly from the 
plasmid using the primers listed in Table 3.1. 
 
Exon Primer Sequence 
5 c-KIT 5D 5’-TGGCATAACACATGAACACTCCAG-3’ 
7 c-KIT-7U 5’-CATTCCTAGTGTCCAATTCTGA-3’ 
9 c-KIT 9D 5’-GCCCAGATGAGTTTAGTGTCTGC-3’ 
19 c-KIT 19D 5’-CTTAGAATCGACCGGCATTCCAG-3’ 
17 c-KIT 17/F3 5’-GCCAGAAATATCCTCCTTACTCATG-3’ 
 
 D= Exonic reverse primer, U = Exonic forward primer and R=Reverse primer 
Table 3.1 Primers used to sequence the coding region of c-KIT from the pCMV6-XL5-







3.2.3 Quantification of the c-KIT GNNK+ isoform transcript in samples from AML 
patients   
cDNA was available from the tissue bank held in the department from the MRC AML-15 
trial. 70 unselected patients were screened for the presence of the c-KIT GNNK+ isoform 
transcript. PCR products were generated using the forward primer c-KIT 8F and a 
fluorescently labelled reverse primer, c-KIT 10R*, as listed in Table 3.2, at an annealing 
temperature of 63°C. DNA was amplified with the BIOTAQ
TM 
DNA polymerase following 
the manufacturer’s instructions, as described in chapter 2 section 2.5.5. cDNA was amplified 
for 28 cycles producing a 258bp product for the c-KIT GNNK- transcript and a 270bp 
product for the GNNK+ transcript. The relative level of c-KIT GNNK +/- isoform transcripts 
was assessed by fragment separation using the CEQ 8000 Genetic Analysis System 
(Beckman Coulter) as described in chapter 2 section 2.5.7. The level of the two isoforms was 
determined by calculating the area under each peak as a percentage of the total alleles. 
3.2.4 Screening of samples from AML patients for the presence of c-KIT CAG repeat 
cDNA was amplified using c-KIT 3F and c-KIT 5R, as listed in Table 3.2, at an annealing 
temperature of 64°C using the BIOTAQ
TM 
DNA polymerase as described in chapter 2 
section 2.5.5. cDNA was amplified for 35 cycles producing a 341bp product which was 
sequenced using c-KIT 3F.  
F=Forward primer, R=Reverse primer and *= fluorescently labelled primer. 
Table 3.2 PCR primers used to identify the presence or absence of the GNNK isoform 
and the additional CAG repeat.  
 





















3.2.5 Preparation of c-KIT-WT construct lacking the GNNK+ insert and CAG repeat 
In order to remove the GNNK+ insert and the CAG repeat from the c-KIT-WT sequence 
overlapping extension PCR was used, illustrated in Figure 3.1. The pCMV6-XL5-c-KIT 
construct served as a DNA template and c-KIT was amplified using Phusion® DNA 
polymerase as described in chapter 2 sections 2.5.5 and 2.5.6. Three initial PCR reactions 
were carried out using the following primer pairs MP11224:F-fuse:.SalI.kozak and 
MP11225-R (794bp product), MP11226-F and MP11227-R (811bp product) and MP11228-
F and MP11229-R-fuse:.MluI (1421 bp product) as listed in Table 3.3. Fragment 1 (794bp) 
contained 5’ overhangs for the SFG vector and removed the CAG repeat, fragment 2 (811bp) 
removed the CAG repeat and the GNNK+ insert with sufficient overhangs for both 
fragments 1 and 3 and fragment 3 (1421bp) removed the GNNK+ insert and contained 3’ 
overhangs for the SFG vector. PCR products were visualised on a 1% agarose gel to check 
they were the expected size, and purified using a QIAquick PCR purification kit. Fragments 
1, 2 and 3 were annealed and amplified across using primers MP11224:F-fuse:.Sal.kozak and 
MP11229 R-fuse:.MluI producing a 2973bp PCR product  (Figure 3.1).  
3.2.6 Cloning of corrected c-KIT-WT into SFG-xm.eGFP.I2.eBFP2 vector 
The SFG-xm.eGFP.I2.eBFP2 retroviral plasmid sequentially expresses eGFP, an internal 
ribosome entry site (IRES) and eBFP (8404bp), and was a kind gift from Martin Pule 
(haematology department, UCL). This cassette is flanked by two long tandem repeats 
(LTRs). The SFG vector has a SalI restriction site at the 5’ end of the GFP sequence and a 
MluI site at the 3’end of the IRES sequence as illustrated in Figure 3.2. The PCR primers 
used to clone c-KIT from the pCMV6-XL5-c-KIT plasmid were designed with SalI and MluI 
restriction sites at the 5’ and 3’ of c-KIT respectively allowing it to be cloned directly into 
the SFG-xm.eGFP.I2.eBFP2 vector. This allowed direct replacement of GFP for c-KIT 
which produced SFG-xm.c-KIT.eBFP (subsequently referred to as SFG-c-KIT) constructs 
that use BFP as a selectable marker. A total of 0.5µg of corrected c-KIT-WT PCR product 
(2961bp) lacking the GNNK insert and CAG repeat and 1µg of SFG-xm.eGFP.I2.eBFP2 
were each digested using MluI and SalI in a 100µL reaction at 37°C for 4 hours according to 
the manufacturer’s instructions. Digested vector products were visualised on a 1% agarose 
gel and the desired band (7684bp) was cut out and purified using a QIAquick Gel Extraction 
Kit (QIAGEN). The digested c-KIT-WT PCR product was cleaned up using a QIAGEN PCR 
purification kit. The digested SFG-xm.eBFP2 vector and c-KIT-WT PCR product were 
ligated together as described in chapter 2 section 2.5.12 to create SFG-c-KIT-WT (Figure 
3.2). Mini preps and midi preps of bacterial cultures were screened for c-KIT using a MluI 
and SalI digest. If c-KIT was present two bands were observed when run on a 1% agarose 
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gel, one at 7684bp corresponding to the vector backbone and a fragment at 2961bp 
corresponding to c-KIT.  The coding region of c-KIT was sequenced using the primers listed 
in Table 3.1 to confirm that the GGTAACAACAAA insert and CAG repeat had been 
removed.    
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Figure 3.1 Amplification of c-KIT removing the GGTAACAACAAA insert and CAG 
repeat. c-KIT was amplified from the pCMV6-XL5-c-KIT construct with three PCR 
reactions using primer pairs MP11224:F-fuse:.SalI.kozak and MP11225-R, MP11226-F and 
MP11227-R  and MP11228-F  and MP11229-R-fuse.MluI. Fragments (1), (2) and (3) were 
gel extracted, annealed and amplified across using primers MP11224:F-fuse:.SalI.kozak and 
MP11229-R-fuse.MluI. The c-KIT-WT PCR product and SFGs.xm.eGFP.I2.eBFP vector 











































Figure 3.2 Schematic of the cloning strategy used to introduce c-KIT-WT into the SFG 
vector. SFG-xm.eGFP.I2.eBFP and c-KIT-WT PCR product were digested with MluI and 
SalI. The SFGs-xm.eBFP fragment was ligated to the digested c-KIT-WT PCR product to 
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SalI and MluI digested c-KIT-WT PCR product  
Digested SFGs-xm.eBFP2 
Ligation of digested 
SFGs-xm.eBFP to 















































Green = SalI restriction site, Blue = kozak sequence, underlined = MluI restriction site  
Table 3.3 c-KIT primers used to remove the GGTAACAACAAA insert and CAG 
repeat. 
 
3.2.7 Generation of c-KIT mutant constructs 
The c-KIT mutations ∆417-419>Y, L576P, D816V, and N822K were introduced with 
mismatch primers using splicing by overlap extension PCR as described in chapter 2 section 
2.5.6. c-KIT was amplified from the SFG-c-KIT-WT construct using Phusion® DNA 
polymerase as described in chapter 2 sections 2.5.5 and 2.5.6. For each mutant two PCR 
amplicons were prepared using primers given in Table 3.4. One amplicon used the 
MP11224:F fuse:.SalI.kozak primer (1) and the mutant-specific reverse primer (3); the other 
amplicon used the mutant-specific forward primer (2) and MP11229 R-fuse:.MluI reverse 
primer (4) (Figure 3.3). The PCR products were visualised on a 1% agarose gel, cut out and 
extracted using the QIAquick Gel Extraction Kit. The two PCR products for each of the 
desired c-KIT mutations were annealed together and amplified across using primers 
MP11224:F fuse:.SalI.kozak (1) and MP11229 R-fuse:.MluI (4) (Figure 3.3). PCR products 
were run on a 1% agarose gel, gel extracted and digested with MluI and SalI in a 100µL 
reaction at 37°C for 4 hours according to the manufacturer’s instructions. Each of the 
respective c-KIT mutant PCR products were then ligated together with digested SFG.xm-
eBFP vector and cloned as described in chapter 2 section 2.5.12. MluI and SalI digests were 
used to screen mini preps and midi preps from bacterial cultures for the presence of c-KIT as 
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previously described. For each mutant construct, the entire coding sequence of c-KIT was 
sequenced using the primers listed in Table 3.1. 










17 c-KIT D816V-R 5’­TCATTCTTGATGACTCTGGCTAGAC­3’ 




17 c-KIT N822K-R 5’­ACCACATACTTAGAATCATTCTTGATG-3’ 













Green = SalI restriction site, Blue = kozak sequence, underlined = MluI restriction site, Red 
= mutated codons.  
Table 3.4 c-KIT primers used to introduce the ∆417-419>Y, L576P, D816V and N822K 
mutations. 
 
3.2.8 Generation of SFG-EMPTY vector  
In order to generate an SFG-EMPTY vector control the ends of the MluI and SalI digested 
SFG-xm.eBFP2 vector were blunted using the Quick Blunting
TM
 KIT according to the 
manufacturer’s guidelines, and the vector was then re-ligated using T4 DNA ligase as 
described in chapter 2 section 2.5.12. The ligated SFG-EMPTY vector was cloned as 
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Figure 3.3 Schematic of the cloning strategy used to introduce c-KIT mutations into the 
SFG vector. c-KIT mutations were introduced by amplifying from the SFG-c-KIT-WT 
construct using mismatched primers. Two initial PCR reactions were carried out using 
MP11224:F-fuse:.SalI.kozak (1) and c-KIT mutant reverse primer (3) and c-KIT mutant 
forward (2) and MP11229-R-fuse.MluI (4). Products were gel extracted, annealed and 
amplified across using primers MP11224:F-fuse:.SalI.kozak (1) and MP11229-R-fuse.MluI 
(4). The amplified c-KIT-mutant PCR products were digested with SalI and MluI and ligated 















3.2.9 Retroviral production 
Retroviral supernatant for each of the c-KIT constructs was made as described in chapter 2 
section 2.2.2 using the RD114 envelope. Viral supernatants were directly stored at -80°C.  
3.2.10 Transduction of UT-7 cells with SFG-c-KIT constructs 
Non tissue culture treated 24 well plates were coated with 1µg/cm
2
 of RetroNectin® per well 
overnight at 4°C. Retroviral supernatants were thawed on ice and 250µL was used to coat 
each RetroNectin® coated well for 30 minutes at room temperature. The viral supernatant 
was then removed from each well and discarded. UT-7 cells were re-suspended at 6x10
5
 
cells/mL in R2 with 5ng/mL GM-CSF and 500µL plated onto the RetroNectin® bound virus. 
The remaining viral supernatant (1.75mL) was gently overlaid on top of the UT-7 cells. The 
plate was centrifuged for 10 minutes at 1000g and incubated at 37°C in 5% CO2 for 24 hours. 
The cells were then centrifuged, and re-suspended in fresh R2 with 5ng/mL GM-CSF and 
incubated at 37⁰C in a humidified atmosphere containing 5% CO2. After 48 hours, cells were 
examined for BFP positivity by flow cytometry (see chapter 2 section 2.4.3) and then 
subsequently sorted based on BFP expression (see chapter 2 section 2.4.5).  
3.2.11 Examination of CD117 expression 
A total of 1x10
6 
transduced and sorted cells were re-suspended in PBS/0.5% BSA and 
incubated with anti-CD117 PE conjugated antibody as described in chapter 2 section 2.4.4 
and analysed on the flow cytometer.  
3.2.12 Proliferation assay 
UT-7 cells were washed 3 times in PBS, re-suspended at 5x10
4
cells/mL in R2 and 100µL 
plated, in triplicate, into a 96 well plate in the presence or absence of 5ng/mL GM-CSF, with 
or without increasing concentrations of human SCF (5-50ng/mL). Cell proliferation was 
assessed every 24 hours using alamarBlue® following the manufacturer’s guidelines. 
Measurements were corrected for background using absorbance values from wells 
containing media only.  
3.2.13 Cytotoxicity assay  
UT-7 cells at 5x10
5
cells/mL were treated with increasing concentrations of dasatinib 
(0.1nM-1µM) or masitinib (0.1nM-10µM) for 72 hours in the presence of 100ng/mL SCF. 
Annexin V/PI staining was assessed as described in chapter 2 section 2.4.2. The live cell 
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fraction (Annexin and PI negative) and the absolute number of live cells were quantified by 
flow cytometry, and results expressed as a percentage of the control cells.   
3.2.14 Data analysis  
To examine if drug interactions were antagonistic, additive or synergistic at cell killing, the 
data was analysed using CalcuSyn software. This uses the Chou-Talalay method, which is 
based on the median-effect equation (Chou & Talalay, 1983;Chou & Talalay, 1984). The CI 









3.3 Results  
3.3.1 Sequencing of the pCMV6-XL5-c-KIT (OriGene) construct 
Sequencing of the OriGene pCMV6-XL5-c-KIT construct revealed that the c-KIT cDNA 
sequence contained a GGTAACAACAAA insert at the end of exon 9 which would result in 
expression of the c-KIT GNNK+ isoform (Figure 3.4a). The GGTAACAACAAA insert is 
not novel and has previously been reported as an alternative splice variant (Crosier et al., 
1993). The plasmid construct also had an additional CAG repeat at the end of exon 4 which 
would result in an additional glutamine (Q) that OriGene reported to be a naturally occurring 
polymorphism (SC120061) (Figure 3.4b). An unselected cohort of samples from AML 
patients were therefore assessed for the presence of these transcripts to identify which 
isoforms were predominant. 
 
 
  Figure 3.4 Sequencing chromatograms of c-KIT from the pCMV6-XL5-c-KIT construct 
showing the presence of the GNNK insert and CAG repeat. (a) Boxed sequence shows 
the presence of the GGTAACAACAAA repeat at the end of exon 9 sequenced in the 
forward direction. (b) Boxed sequence shows the presence of a CAG repeat at the end of 
exon 4, sequenced in the reverse direction.  
 
3.3.2 Detection of c-KIT GNNK +/- isoforms in samples from patients with AML 
The incidence of c-KIT GNNK+/- isoforms and their relative levels were quantified using 
cDNA from 70 samples with AML using PCR amplification with a fluorescently labelled 
primer and subsequent fragment size separation on the CEQ 8000 Genetic Analysis System. 
A sample with AML which expressed both the GNNK+ and GNNK- isoforms was identified 
and included in each fragment analysis run as a positive control to establish the variability 
within a single sample between repeats. The median GNNK- expression for the positive 
control was 96% (range 95-98%) and the median GNNK+ isoform expression was 4% 
(b) 
Expected WT: TTTAAA- - - - - - - - - - - - - - - GAGCAA 
Construct :       TTTAAAGGTAACAACAAAGAGCAA 
 
Expected WT: TTTAGT-  -  - CTGACTGTT 




(range 2-5%). Two peaks at 258 and 270bp were identified for 44 (63%) of the samples 
corresponding to expression of both the c-KIT GNNK- and GNNK+ transcripts respectively 
(Figure 3.5a). In 26 samples (37%) only a single peak was detected at 258bp indicative of 
expression of only the GNNK- isoform (Figure 3.5b). In the 44 cases where the GNNK+ 
isoform was detected the median GNNK+ isoform expression was 5.5% ranging from 1-13% 
and the median GNNK- isoform expression was 94.5% ranging from 87-99%. The GNNK- 
isoform was identified as the predominant transcript within this AML cohort and therefore 




Figure 3.5 Chromatograms showing size separation of the GNNK- and GNNK+ 
isoforms. (a) A sample with AML in which two peaks at 258bp and 270bp were detected 
corresponding to expression of both the GNNK- and GNNK+ isoforms respectively. (b) A 
sample with AML in which only a single peak at 258bp was detected indicative of only the 
GNNK- transcript being expressed. 
 
 
3.3.3 Sequencing of samples with AML for the additional CAG (Q) repeat  
In order to determine the level of the CAG repeat isoform, exon 4 of c-KIT was sequenced 
from four samples with AML. A representative example is shown in Figure 3.6 indicating 
that the additional CAG isoform is a low level transcript. Therefore all constructs used in 










Figure 3.6 Sequencing chromatogram illustrating the additional CAG repeat isoform in 
a sample with AML. The red arrow indicates the presence of a low level transcript with the 
additional CAG repeat.  
 
3.3.4  Transduction of UT-7 cells with SFG-c-KIT and SFG-EMPTY constructs 
To investigate the impact of different c-KIT mutations on cell signalling, cell growth and 
response to small molecule inhibitors, UT-7 cells were transduced with constructs expressing 
SFG-c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-419>Y, SFG-c-KIT-L576P, SFG-c-KIT-
D816V and SFG-c-KIT-N822K. These mutations were selected as they are representative 
examples that occur across c-KIT in AML. UT-7 cells were selected as they are a factor 
dependent AML cell line and had no detectable mutations in exons 8, 10+11 and 17 of c-KIT 
and no mutations in exons 14-15 (FLT3-ITD) or exon 20 (FLT3-TKD) of FLT3 (data not 
shown). UT-7 cells were successfully transduced with the various SFG-c-KIT and SFG-
EMPTY constructs with transduction efficiencies ranging from 27-95% as assessed by BFP 
expression using flow cytometry. Cells were subsequently sorted based on BFP on the 
assumption that BFP expression is equivalent to c-KIT expression. Following cell sorting, 
BFP and CD117 (c-KIT) expression were simultaneously examined in each transduced cell 
line. As expected UT-7 native cells were negative for BFP (Figure 3.7a). UT-7 cells 
transduced with constructs expressing c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-419>Y, SFG-
c-KIT-L576P, SFG-c-KIT-D816V and SFG-c-KIT-N822K were all ≥ 97% BFP positive 
(Figure 3.7a).  The UT-7 c-KIT-D816V cells were 97% BFP positive, however they were 
dimmer in comparison to the other generated cell lines. UT-7 native cells expressed very low 
levels of CD117 (5%) which was equivalent to UT-7 SFG-EMPTY cells (Figure 3.7b). UT-7 
cells expressing c-KIT-WT were the only cells to have approximately equivalent BFP and 
CD117 expression (median MFI: 3.3 and 3.7 respectively) (Figure 3.7 a,b). In contrast 
CD117 expression was considerably lower in UT-7 cells expressing c-KIT Δ417-419>Y, c-
KIT-L576P, c-KIT-D816V and c-KIT-N822K (median MFI: 1.0, 0.4, 0.5 and 0.7 
Expected WT sequence :                GAAAAGAGAAAACAGTCAG - - - ACTAAACTACAGGAGAAAT   




respectively) (Figure 3.7b). Lower CD117 staining in the c-KIT mutant-expressing cells 
could be due to a lower expression of the 145kDa fully glycosylated mature membrane-
bound c-KIT. Mutations in the ALD (D816V) and in the JMD have been reported to be 
retained in the endoplasmic reticulum and Golgi apparatus, reducing the amount of mature c-
KIT receptor reaching the cell surface (Xiang et al., 2007;Tabone-Eglinger et al., 2008). 
This may explain why UT-7 cells transduced with c-KIT-L576P or c-KIT-D816V had 
particularly low surface CD117 expression (median MFI: 0.4 and 0.5 respectively) (Figure 
3.7b). Western blotting confirmed that all UT-7 cells transduced with constructs expressing 
c-KIT-WT or mutant c-KIT over-expressed c-KIT in comparison to the UT-7 native or SFG-
EMPTY transduced cells (Figure 3.8). UT-7 c-KIT-D816V cells had lower levels of c-KIT 
expression in comparison to the other c-KIT expressing cells, which is consistent with being 
dimmer for BFP. UT-7 cells expressing mutant c-KIT did not show a predominance of the 










Figure 3.7 Examination of (a) BFP and (b) CD117 expression within UT-7 transduced 
cells. 
1
refers to the gated area, 
2 







Figure 3.8 Western blotting of transduced UT-7 cells examining total c-KIT expression. 
GAPDH was used as a loading control.  
Ref. 
colour 
Cell line BFP 
(%1) 




CD117  Median 
(MFI2) 
 UT-7 Native 1.1 0.0 5.1 0.2 
 UT-7 c-KIT-WT 100.0 3.3 88.5 3.7 
 UT-7 c-KIT-D816V 97.0 1.3 30.5 0.5 
 UT-7 c-KIT-N822K 99.0 1.5 42.8 0.7 
 UT-7 c-KIT-L576P 99.0 1.7 20.6 0.4 
 UT-7 c-KIT-Δ417-419>Y 99.0 4.5 56.1 1 




3.3.5  Impact of c-KIT mutations on proliferation  
The impact on proliferation of c-KIT-Δ417-419>Y, c-KIT-L576P, c-KIT-D816V and c-KIT-
N822K mutants was assessed in transduced UT-7 cells compared with cells expressing c-
KIT-WT or SFG-EMPTY (Figure 3.9 a-f). There were equivalent proliferation rates in all 
cells in the presence of 5ng/mL of GM-CSF and this was not increased by the addition of 
5ng/mL or 50ng/mL SCF.  UT-7 SFG-EMPTY cells did not proliferate in the absence of 
GM-CSF and subsequently died after 4-5 days. A low level of SCF (5ng/mL) did not 
increase proliferation whereas 50ng/mL SCF was sufficient to maintain a low level of 
proliferation   (Figure 3.9a). UT-7 c-KIT-WT cells died in the absence of GM-CSF by day 4-
5 and 5ng/mL SCF did not stimulate proliferation. In contrast, 50ng/mL promoted cell 
proliferation which was comparable to the levels observed in the presence of GM-CSF 
(Figure 3.9b). c-KIT-Δ417-419>Y expressing cells showed factor-independent growth, 
which was not significantly increased in the presence of SCF (Figure 3.9c). UT-7 c-KIT-
D816V did not die in the absence of GM-CSF but maintained a low level of proliferation 
which was equivalent in the presence of only 5ng/mL of SCF (Figure 3.9d). Of note, UT-7 c-
KIT-WT and c-KIT-D816V cells washed in PBS and starved of GM-CSF for four weeks 
showed that UT-7 c-KIT-D816V cells could proliferate in the absence of cytokines whereas 
c-KIT-WT cells died after one week (data not shown). This suggests that c-KIT-D816V can 
confer factor-independent growth and that 5 days was insufficient time to observe this. 
Addition of 50ng/mL SCF did increase proliferation rates of c-KIT-D816V expressing cells 
to an equivalent level to that observed in the presence of GM-CSF. For c-KIT-L576P and c-
KIT-N822K expressing cells 5ng/ml SCF was not sufficient to promote proliferation (Figure 
3.9 e,f). The presence of 50ng/mL SCF did stimulate cell proliferation in both cell lines, 
however this did not reach the levels observed in the presence of GM-CSF, and was only 
slightly greater than the level of proliferation seen treatment in the UT-7 SFG-EMPTY cells 
treated with 50ng/mL SCF. Overall, c-KIT-Δ417-419>Y and c-KIT-D816V were the only 
























Figure 3.9 The impact of c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-419>Y, c-KIT-D816V, c-KIT-L576P and c-KIT-N822K on proliferation in UT-7 
cells. Each cell line were incubated with ± GM-CSF (5ng/mL) in the presence of increasing concentrations of SCF and treated with alamarBlue®. Data shown 






3.3.6 Impact of c-KIT mutations on downstream signalling  
To assess differences in c-KIT activation and downstream signalling each cell line was 
washed with PBS and cultured for eight hours in the presence or absence of 50ng/mL SCF 
(Figure 3.10). UT-7 native and SFG-EMPTY cells showed no activation of c-KIT or 
downstream targets in the absence of SCF but stimulation with SCF caused low level 
phosphorylation of STAT5, MAPK and S6 and up regulation of PIM-1. In the absence of 
SCF, c-KIT-WT expressing cells showed no activation of c-KIT or downstream targets, but 
stimulation with SCF caused phosphorylation of c-KIT and activation of STAT5, AKT, 
MAPK and S6, and up regulation of PIM-1. As the WT receptor is over-expressed in these 
cells the activation of downstream target proteins was greater than observed in UT-7 native 
or UT-7 SFG-EMPTY cells.  
In the absence of any growth factor, UT-7 c-KIT-Δ417-419>Y showed strong 
autophosphorylation of c-KIT which corresponded to constitutive activation of downstream 
target proteins (STAT5, MAPK, PIM-1 and S6) as indicated by  the levels of p-STAT5, p-
MAPK and p-S6. Of interest, AKT was not activated in these cells and MAPK, although 
constitutively active was only expressed at a low level. The addition of SCF did not further 
activate downstream signalling in these cells. In the absence of SCF UT-7 c-KIT-D816V 
cells showed autophosphorylation of c-KIT however this was weaker than UT-7 c-KIT-
Δ417-419>Y cells. Autophosphorylation of c-KIT constitutively activated STAT5, PIM-1 
and S6, with a very low level activation of MAPK. Stimulation of c-KIT-D816V expressing 
cells with SCF further increased activation of these downstream proteins and in addition 
stimulated low level phosphorylation of AKT. In contrast c-KIT-L576P or c-KIT-N822K 
expressing cells did not show constitutive c-KIT autophosphorylation nor activation of the 
majority of downstream target proteins. However, stimulation with SCF did cause 
phosphorylation of c-KIT, STAT5, AKT, MAPK and S6 and up regulation of PIM-1. There 
was no difference in activation in downstream signalling in the presence of SCF between 
UT-7 c-KIT-WT or c-KIT-c-KIT-L576P cells. However, c-KIT-N822K expressing cells did 
more strongly activate AKT and up regulate PIM-1 in the presence of SCF compared to c-
KIT-WT expressing cells. Of note, there was residual S6 phosphorylation in the absence of 
SCF in these mutant c-KIT transduced cells but not in c-KIT-WT expressing cells suggesting 




Figure 3.10 UT-7 cells transduced with c-KIT-WT and mutant constructs treated with 
or without 50ng/mL SCF for 8 hours. Cell lysates were analysed by western blotting 
using the indicated antibodies. GAPDH was used as a loading control.  
3.3.7 Effect of dasatinib treatment on UT-7 cells expressing c-KIT 
UT-7 cells transduced with SFG-EMPTY or c-KIT constructs were treated with dasatinib, 
a known c-KIT and SRC kinase inhibitor, for 72 hours in the presence of 100ng/mL SCF, 
to evaluate if the different c-KIT mutants had different responses to the inhibitor. UT-7 c-
KIT-WT, SFG-EMPTY and c-KIT-L576P  expressing cells treated with dasatinib showed 
no difference in growth inhibition (IC50s  19nM ± 5.8, 15.7nM ± 7.3, 23.1nM ± 3.9 c-KIT-
WT, SFG-EMPTY and c-KIT-L576P respectively; WT vs EMPTY P = 0.73, unpaired t-
test ; WT vs L576P P = 0.58, unpaired t-test) or cell killing (IC50s 29.4nM ± 5.3, 20.6nM 
± 6.2, 29nM ± 2.3 c-KIT-WT, c-KIT-L576P and SFG-EMPTY respectively; WT vs 
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EMPTY P = 0.32, unpaired t-test ; WT vs L576P P = 0.94, unpaired t-test) (Figure 3.11 a,b) 
reflected in Table 3.5. UT-7 c-KIT-Δ417-419>Y cells treated with dasatinib showed no 
difference in growth inhibition in comparison to UT-7 c-KIT-WT expressing cells (IC50 
27.4nM ± 5.4, c-KIT-Δ417-419>Y; WT vs Δ417-419>Y P = 0.58, unpaired t-test) however 
there was a suggestion that these cells were more resistant to cell killing (IC50 53.8nM ± 
11.3, c-KIT-Δ417-419>Y; WT vs Δ417-419>Y P = 0.1, unpaired t-test). UT-7 c-KIT-
D816V cells were significantly more resistant to dasatinib-mediated growth inhibition 
(IC50 181.2nM ± 39.8, c-KIT-D816V; WT vs D816V P = 0.007, unpaired t-test) and cell 
killing (IC50 316nM ± 50.6, c-KIT-D816V; WT vs D816V P = 0.001, unpaired t-test) in 
comparison to c-KIT-WT expressing cells. UT-7 c-KIT-N822K cells were also more 
resistant to dasatinib-mediated growth inhibition (IC50 41.4nM ± 3.3, c-KIT-N822K; WT 
vs N822K P = 0.02, unpaired t-test) and cell killing (IC50 77.3nM ± 13.5, c-KIT-N822K; 
WT vs N822K P = 0.02, unpaired t-test) in comparison to UT-7 c-KIT-WT cells. 
To demonstrate that the differences in growth inhibition and cell killing were mediated by 
reduced activation of c-KIT and its downstream target proteins, cell signalling was 
examined. c-KIT-transduced and SFG-EMPTY cells were washed with PBS and exposed 
to 0.1, 1, 10, 100, 1000nM dasatinib  in the presence of 50ng/mL SCF for 24 hours. In UT-
7 c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-419>Y and c-KIT-L576P cells, a concentration 
of 100nM dasatinib was sufficient to completely inhibit phosphorylation of c-KIT and 
activation of downstream target proteins (Figure 3.12). A concentration of 100nM dasatinib 
was also capable of decreasing the pro-survival protein Mcl-1 in these transduced cells. In 
UT-7 c-KIT-D816V cells 100nM dasatinib did not completely decrease the 
phosphorylation of c-KIT or activation of downstream target proteins whereas a 
concentration of 1000nM dasatinib was sufficient to potently decrease phosphorylation of 
c-KIT, AKT, MAPK and S6. Mcl-1 was only decreased at 1000nM dasatinib in UT-7 c-
KIT D816V cells. c-KIT-N822K expressing cells were slightly more resistant  to dasatinib 
at a concentration of 100nM  in comparison to c-KIT-WT expressing cells as indicated by 
residual c-KIT, AKT and S6 phosphorylation. c-KIT-N822K expressing cells were more 







Figure 3.11 Response of transduced UT-7 cells to dasatinib in the presence of 100ng/mL 
SCF after 72 hours. (a) Total number of live cells. (b) Percentage of cells in the live cell 







Table 3.5 Live cell number and live cell fraction IC50 values from UT-7 transduced 




Cell line Live cell number 
IC50 (nM) 
Live cell fraction 
IC50 (nM) 
UT-7 c-KIT-WT 19 ± 5.8 29.4 ± 5.3 
UT-7 c-KIT-D816V 181.2 ± 39.8 316 ± 50.6 
UT-7 c-KIT-N822K 41.4 ± 3.3 77.3 ± 13.5 
UT-7 c-KIT-L576P 23.1 ± 3.9 29 ± 2.3 
UT-7 c-KIT-Δ417-419>Y 27.4 ± 5.4 53.8 ± 11.3 















Figure 3.12 Western blots of UT-7 transduced cells treated with 0.1-1000nM of dasatinib, in the presence of 50ng/mL SCF for 24 hours. The boxed 




3.3.8 Response of UT-7 cells expressing c-KIT to dasatinib and BEZ-235   
c-KIT-D816V and c-KIT-N822K mutations have previously been reported to activate 
PI3K/AKT and mTOR (Ning et al., 2001;Growney et al., 2005;Schittenhelm et al., 
2006;Wang et al., 2011). In Figure 3.10 UT-7 cells expressing mutant c-KIT showed 
constitutive activation of mTOR, as indicated by phosphorylation of S6, but there was no 
detectable phosphorylation of AKT. It was therefore hypothesised that a combination of 
dasatinib and BEZ-235, the dual PI3K/mTOR inhibitor, may overcome the resistance to 
dasatinib observed and sensitise the cells to a greater level of cell killing. Each cell line was 
washed with PBS and treated with 12.5, 25, 50 and 100nM dasatinib in combination with 
0.125, 0.25 and 0.5µM BEZ-235 in the presence of 100ng/mL SCF for 72 hours. c-KIT-WT, 
c-KIT-∆417-419>Y and c-KIT-L576P expressing cells treated with dasatinib showed 
equivalent growth inhibition and cell killing (Figure 3.13 a,b,g,h,i,j). c-KIT D816V and c-
KIT-N822K expressing cells were more resistant to dasatinib-mediated growth inhibition 
and cell killing in comparison to UT-7 c-KIT-WT cells, the former being most resistant 
(Figure 3.13 c,d,e,f) All of the transduced UT-7 cells treated with BEZ-235 showed an 
equivalent dose dependent decrease in cell proliferation and cell killing. A combination of 
dasatinib and BEZ-235 only slightly increased growth inhibition and cell killing, compared 
to dasatinib alone in c-KIT-WT, c-KIT-∆417-419>Y and c-KIT-L576P expressing cells. A 
combination of dasatinib and BEZ-235 was capable of overcoming some of the resistance 
observed with dasatinib alone in UT-7 c-KIT-D816V and c-KIT-N822K cells, by sensitizing 
the cells to a greater level of growth inhibition and cell killing in comparison to either drug 
alone (Figure 3.13 c-f).  
CalcuSyn was used to assess if the interactions between dasatinib and BEZ-235 was 
synergistic in each UT-7 c-KIT transduced cell line at inducing cell killing. Dasatinib and 
BEZ-235 showed a weak additive or slight synergistic effect in UT-7 cells harbouring c-
KIT-WT and c-KIT-L576P at an ED50, ED75 or ED90 (Table 3.6). UT-7 cells expressing c-
KIT-∆417-419>Y and N822K were more sensitive to this drug combination as indicated by 
CI values at an ED90 of 0.61 and 0.59 respectively. Dasatinib and BEZ-235 showed the 
strongest synergistic effect in UT-7 c-KIT-D816V cells as indicated by CI values at an ED50, 
ED75 and ED90 of 0.54, 0.406 and 0.31 respectively. This data suggests that targeted 
blockade of c-KIT and PI3K/mTOR could specifically enhance cell killing in cells 




3.3.9 Impact of dasatinib and BEZ-235 on c-KIT and downstream signalling in c-
KIT transduced UT-7 cells 
Western blotting was used to examine the impact of dasatinib and BEZ-235 on downstream 
signalling in UT-7 transduced cells. Each cell line was washed with PBS and incubated with 
no inhibitor, 100nM dasatinib, 0.5µM BEZ-235 or a combination of both inhibitors for 24 
hours in the presence of 50ng/mL SCF.  Dasatinib alone reduced phosphorylation of c-KIT, 
STAT5 and MAPK in all UT-7 transduced cells however there was residual mTOR 
signalling, as indicated by p-4E-BP1, in all cell lines and p-S6 in UT-7 c-KIT-D816V and c-
KIT-N822K cells (Figure 3.14). UT-7 c-KIT-D816V cells also had residual AKT signalling, 
as indicated by p-AKT. BEZ-235 alone reduced phosphorylation of PI3K/mTOR targets, as 
indicated by p-AKT and p-4E-BP1, in all cell lines but had little or no impact on p-c-KIT, p-
STAT5, p-MAPK or p-S6. In the presence of dasatinib and BEZ-235 residual mTOR 
signalling was eliminated as demonstrated by a reduction in p-4E-BP1 in all transduced cells 
and a potent decrease in p-S6 in UT-7 c-KIT-D816V and c-KIT-N822K cells. Dasatinib and 
BEZ-235 also reduced residual AKT signalling in c-KIT-D816V expressing cells. Inhibition 
of residual mTOR and AKT signalling may have contributed to the decrease in cell 
proliferation and increase in apoptosis observed in Figure 3.13.  In general the pro-survival 
protein Mcl-1 decreased in the presence of both dasatinib and BEZ-235 which corresponded 
with an increase in the pro-apoptotic protein BIM in all UT-7 transduced cells. The effect of 
dasatinib and BEZ-235, compared to either drug alone, was most prominent in c-KIT-
D816V expressing cells which may explain why this drug combination showed the strongest 




















Figure 3.13 Response of transduced UT-7 cells to combinations of dasatinib and BEZ-
235 in the presence of 100ng/mL SCF after 72 hours. (a,c,e,g,i) Total number of live cells. 
(b,d,f,h,j) Percentage of cells in the live cell fraction. Data shown is the mean ± SEM of three 
or four individual experiments. 
 
  CI Values at:  
Drug Combination Cell line  ED50 ED75 ED90 
Dasatinib + BEZ-235 (1:5)  c-KIT-WT 0.76 0.76 0.76 
Dasatinib + BEZ-235 (1:5)  c-KIT-D816V 0.54 0.406 0.31 
Dasatinib + BEZ-235 (1:5) c-KIT-N822K 0.76 0.676 0.59 
Dasatinib + BEZ-235 (1:5) c-KIT-L576P 0.94 0.876 0.81 
Dasatinib + BEZ-235 (1:5) c-KIT-Δ417-419>Y 0.78 0.69 0.61 
CI = Combination Index value, ED = Effective dose   
Table 3.6 CI values for the cell killing data of transduced UT-7 cells treated with 














Figure 3.14 Effect of dasatinib and BEZ-235 on c-KIT and downstream signalling in UT-7 transduced cells. Cells were treated with each inhibitor for 




3.3.10 Effect of masitinib treatment on UT-7 cells expressing c-KIT 
To examine if the differential response to dasatinib observed in the UT-7 c-KIT-expressing 
cells is limited to this inhibitor, the various cell lines were treated with another ATP 
competitive inhibitor, masitinib. Each cell line was washed with PBS and treated with 0.1, 1, 
10, 100, 1000, 10,000nM masitinib, in the presence of 100ng/mL SCF for 72 hours. 
Treatment of UT-7 c-KIT-WT, SFG-EMPTY, c-KIT-∆417-419>Y and c-KIT-L576P 
expressing cells with masitinib showed no significant difference in growth inhibition (IC50s 
443nM ± 80, 258nM ± 27, 181nM ± 62, 236nM ± 27  c-KIT-WT, SFG-EMPTY, c-KIT-
∆417-419>Y and c-KIT-L576P respectively; WT vs SFG-EMPTY P = 0.09, unpaired t-test ; 
WT vs c-KIT-∆417-419>Y P = 0.06, unpaired t-test ; WT vs c-KIT-L576P P = 0.07, 
unpaired t-test) or cell killing (IC50s 689nM ± 165, 358nM ± 11, 351nM ± 66, 236nM ± 17  
c-KIT-WT, SFG-EMPTY, c-KIT-∆417-419>Y and c-KIT-L576P respectively; WT vs SFG-
EMPTY P = 0.12, unpaired t-test ; WT vs c-KIT-∆417-419>Y P = 0.13, unpaired t-test ; WT 
vs c-KIT-L576P P = 0.12, unpaired t-test) (Figure 3.15 a,b), IC50s listed in Table 3.7. Of 
note, UT-7 c-KIT-WT expressing cells were less responsive to masitinib in comparison to 
SFG-EMPTY, c-KIT-∆417-419>Y and c-KIT-L576P expressing cells. UT-7 c-KIT-D816V 
cells were significantly more resistant to dasatinib-mediated growth inhibition (IC50 
5307nM ± 2378, c-KIT-D816V; WT vs D816V P = 0.02, unpaired t-test) and cell killing 
(IC50 12388nM ± 3005, c-KIT-D816V; WT vs D816V P = 0.02, unpaired t-test) in 
comparison to UT-7 c-KIT-WT expressing cells. c-KIT-N822K expressing cells were also 
significantly more resistant than UT-7 c-KIT-WT cells to masitinib-mediated growth 
inhibition (IC50  2104nM ± 295, c-KIT-N822K; WT vs N822K P = 0.01 , unpaired t-test)  
and cell killing (IC50 3084nM ± 227, c-KIT-N822K; WT vs N822K P = 0.001, unpaired t-
test). This suggests that mutations in the ALD may prevent masitinib from binding 
effectively to c-KIT. Comparing the IC50s listed in Table 3.5 and Table 3.7 for each UT-7 
transduced cell line treated with either dasatinib or masitinib shows that dasatinib was more 










Figure 3.15 Response of transduced UT-7 cells to masitinib in the presence of 
100ng/mL SCF after 72 hours. (a) Total number of live cells. (b) Percentage of cells in the 







Table 3.7 Live cell number and live cell fraction IC50 values from UT-7 transduced 
cells treated with masitinib.  
 
 
Cell line Live cell number 
IC50 (nM) 
Live cell fraction 
IC50 (nM) 
UT-7 c-KIT-WT 443 ± 80 689 ± 165 
UT-7 c-KIT-D816V 5307 ± 2378 >10,000 
UT-7 c-KIT-N822K 2104 ± 295 3084 ± 227 
UT-7 c-KIT-L576P 236 ± 27 364 ± 17 
UT-7 c-KIT-Δ417-419>Y 181 ± 62 351 ± 66 




3.4 Discussion  
In order to investigate the functional consequence of c-KIT mutants, a construct containing 
the c-KIT coding sequence was purchased from OriGene. Sequencing of this construct 
revealed the presence of the GGTAACAACAAA (GNNK+) insert and CAG (Q) repeat. The 
GNNK+ isoform has previously been described as an alternative splice variant (Crosier et al., 
1993) while the additional CAG repeat at the end of exon 4 is reported by OriGene to be a 
naturally occurring polymorphism (SC120061). It was important to establish which of these 
c-KIT isoforms was the primary transcript as the c-KIT GNNK- protein has been shown to 
have stronger activation of PI3K/AKT than the c-KIT GNNK+ isoform, resulting in 
increased cell survival/proliferation in comparison to cells expressing the c-KIT GNNK+ 
protein (Pedersen et al., 2009).  Samples with AML were therefore evaluated for the 
presence or absence of the GNNK transcript. Expression of both the c-KIT GNNK- and 
GNNK+ isoforms were detected in 63% of the samples with a median GNNK+ isoform 
expression in of 5.5% (range 1-13%). This showed that the GNNK- isoform was the primary 
transcript in the samples with AML examined, consistent with a previous report (Guerrini et 
al., 2007). As the GNNK+ isoform was identified as a low level transcript four samples with 
AML were sequenced directly to examine the level of the additional CAG (Q) repeat isoform. 
The additional CAG repeat was a minor transcript in all four samples. The functional 
consequence of this additional CAG repeat is currently unknown. As a result c-KIT was 
cloned by overlapping extension PCR from the pCMV6-XL-c-KIT construct removing the 
GNNK+ insert and the CAG repeat at the end of exon 4.   
Plasmid constructs were generated expressing c-KIT-WT, SFG-EMPTY, c-KIT-Δ417-
419>Y, c-KIT-L576P, c-KIT-D816V and c-KIT-N822K and transduced into UT-7 cells to 
investigate the functional consequence of different c-KIT mutations. These mutations were 
selected as they are representative examples of mutations that occur across the receptor in 
AML. The c-KIT-Δ417-419>Y mutation is representative of an ECD mutation as residues 
417-419 are most commonly deleted in CBFL, the c-KIT-L576P mutation is an  example of a 
JMD mutation that is also frequently found in melanoma and the c-KIT-D816V and c-KIT 
N822K mutations are the most common point mutations in the ALD (Care et al., 
2003;Goemans et al., 2005;Wang, 2005;Paschka et al., 2006;Shimada et al., 2007). 
Mutations in the ECD have been shown to render c-KIT hyper-sensitive to SCF, stimulate 
autophosphorylation of the receptor and induce factor independent growth in murine Ba/F3 
and FDC-P1 cell lines (Kohl et al., 2005;Growney et al., 2005;Nick et al., 2011).  The c-
KIT-Δ417-419>Y mutation has not been assessed in an in vitro system. The c-KIT-L576P 
mutation has been stably expressed in Ba/F3 cells which showed autophosphorylation of c-
116 
 
KIT however the impact on growth has not been examined (Antonescu et al., 2007;Wang et 
al., 2011).  Mutations in the ALD including c-KIT-D816V and N822K have also been shown 
to cause autophosphorylation of c-KIT, ligand-independent growth and activation of STAT5, 
STAT3, PI3K, AKT and ERK in murine and human factor dependent cell line models (Ning 
et al., 2001;Growney et al., 2005;Schittenhelm et al., 2006;Wang et al., 2011).  
UT-7 c-KIT-Δ417-419>Y, c-KIT-L576P, c-KIT-D816V and c-KIT-N822K cells expressed 4, 
9, 7 and 5 times respectively lower cell surface c-KIT in comparison to c-KIT-WT 
expressing cells. Total c-KIT protein level was assessed by western blotting which showed 
equivalent expression between c-KIT-WT, c-KIT-L576P and c-KIT-N822K expressing cells. 
In contrast UT-7 c-KIT-D816V cells had slightly lower total c-KIT levels in comparison to 
c-KIT-WT cells whereas c-KIT-Δ417-419>Y expressing cells had twice as much total c-KIT 
protein. This suggests that the mutant receptors may be retained in the endoplasmic 
reticulum and/or Golgi apparatus in the transduced cells, which has been reported in other 
studies using c-KIT transduced cell line models (Xiang et al., 2007;Tabone-Eglinger et al., 
2008). Alternatively, it has been shown that c-KIT-D816V can constitutively phosphorylate 
Cbl leading to ubiquitin degradation of the receptor (Sun et al., 2009). This may have 
contributed to a lower expression of c-KIT in the mutant c-KIT expressing cells; in particular 
it may explain why surface expression and total c-KIT was lower in c-KIT-D816V 
expressing cells.  
Initial experiments investigated the impact of the different c-KIT mutations on proliferation. 
Expression of c-KIT-L576P or c-KIT-N822K did not confer factor independent growth, and 
there was low/no detectable autophosphorylation of c-KIT and activation of downstream 
proteins. Previous reports have shown that expression of c-KIT-L576P or c-KIT-N822K in 
Ba/F3 cells led to constitutive activation of c-KIT and factor independent growth (Growney 
et al., 2005;Antonescu et al., 2007). Discrepancies may relate to other studies selecting their 
transduced cells for antibiotic resistance prior to use whereas this study sorted transduced 
cells based on BFP expression. Alternatively it could be due to the different properties of the 
cell line models used. Only UT-7 cells expressing c-KIT-Δ417-419>Y and c-KIT-D816V 
exhibited factor independent growth; greater in UT-7 c-KIT-Δ417-419>Y cells than UT-7 c-
KIT-D816V cells. UT-7 c-KIT Δ417-419>Y cells showed a higher level of c-KIT 
autophosphorylation and activation of STAT5, S6 and up regulation of PIM-1 in comparison 
to UT-7 c-KIT-D816V expressing cells which may explain why UT-7 c-KIT Δ417-419>Y 
cells had a greater growth advantage. Similar mutations in the ECD and the D816V mutation 
have previously been reported to constitutively active c-KIT and confer factor independent 
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growth in cell line models (Kohl et al., 2005;Growney et al., 2005;Pedersen et al., 2009;Sun 
et al., 2009;Nick et al., 2011).  
Investigation of cell signalling in UT-7 cells expressing mutant c-KIT revealed that c-KIT-
Δ417-419>Y only weakly activated p-MAPK and p-AKT, even in the presence of SCF, 
whereas c-KIT-WT, c-KIT-L576P, c-KIT-D816V and c-KIT-N822K  expressing cells 
treated with SCF increased phosphorylation of both these proteins. This suggests that 
mutations in the ECD may activate different cell signalling molecules compared to mutations 
in the ALD or JMD. This is supported by mouse model data showing co-expression of c-KIT 
T417IΔ418-419 and RUNX1/RUNX1T1 exclusively generated an AML phenotype whereas 
mice co-expressing c-KIT-D814V and RUNX1/RUNX1T1 variably developed AML, a 
myeloproliferative disease or a pre-B-cell leukaemia (Nick et al., 2011). 
As the UT-7 transduced cells had various transforming capabilities it was of interest to 
assess the response of each cell line to dasatinib and masitinib, c-KIT inhibitors. In the data 
shown here, c-KIT-WT, c-KIT-Δ417-419>Y and c-KIT-L576P expressing cells were all 
approximately equivalent in their sensitivity to dasatinib-mediated growth inhibition, cell 
killing and reduction in phosphorylation of c-KIT. UT-7 c-KIT-D816V cells were more 
resistant to growth inhibition, cell killing and reducing phosphorylation of c-KIT and 
downstream target proteins. For example UT-7 c-KIT-D816V cells were ten times more 
resistant to dasatinib-mediated cell killing compared to UT-7 c-KIT-WT cells.  The UT-7 c-
KIT-N822K cells were more resistant to dasatinib than UT-7 c-KIT-WT cells, however this 
was less pronounced than UT-7 c-KIT-D816V cells. The reason for these differences may 
relate to conformational changes conferred by the different mutations. When c-KIT is in its 
inactive form it adopts an autoinhibited conformation whereby the ALD folds back into the 
ATP-binding cleft, blocking the loading of substrates (Mol et al., 2004). In this conformation, 
the Asp810-Phe811-Gly812 (DFG) motif, found at the amino-terminal end of the ALD, is 
flipped away from the active site (DFG OUT). When SCF binds to c-KIT it causes the 
receptor to dimerise. This results in phosphorylation of key residues in the cytoplasmic 
domain (Y547, Y553, Y568, and Y570), causing a conformational change which releases the 
JMD from the kinase domain (DiNitto et al., 2010). This releases the ALD from a ‘packed’ 
position to an ‘extended’ form whereby the DFG motif adopts an ‘IN’ position, allowing 
ATP and substrates to bind to the catalytic site. Modelling of the binding mechanism of 
dasatinib to c-KIT indicated that it is a type I inhibitor showing preferential binding to the 
catalytic site of the receptor in its active conformation (Shah et al., 2006).  Modelling of 
dasatinib binding to the c-KIT-D816V mutation suggested that mutations at this residue 
should not significantly alter binding to c-KIT (Shah et al., 2006). Data presented here 
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demonstrates that mutations in the ALD may cause secondary changes in the ATP-binding 
cleft reducing the affinity of dasatinib for the mutant receptors.  
To try and overcome some of the resistance to dasatinib observed in the c-KIT-D816V 
expressing cells, each cell line was treated with a combination of dasatinib and varying 
concentrations of BEZ-235, a dual PI3K/mTOR inhibitor. BEZ-235 was selected as c-KIT 
mutations are known to activate PI3K/AKT and mTOR (Ning et al., 2001;Growney et al., 
2005;Schittenhelm et al., 2006;Wang et al., 2011). In UT-7 c-KIT-D816V expressing cells 
dasatinib did reduce phosphorylation of c-KIT in a dose dependent manner, however there 
was still strong activation of PI3K/AKT and mTOR targets including AKT and S6 (Figure 
3.12). Therefore, it was proposed that targeted blockade of c-KIT and PI3K/mTOR may 
sensitise c-KIT-D816V expressing cells to a greater level of cell killing. UT-7 c-KIT-D816V 
expressing cells treated with dasatinib and BEZ-235 showed the strongest synergistic effect 
on cell killing which was most likely mediated by a reduction in residual AKT and mTOR 
signalling compared with either inhibitor alone.  Dasatinib and BEZ-235 showed a moderate 
additive or synergistic effect on cell killing in UT-7 c-KIT-WT, c-KIT-Δ417-419>Y, c-KIT-
L576P and c-KIT-N822K cells which may be due to an enhanced reduction in the pro-
survival protein Mcl-1 and an increase in BIM, not observed with either drug alone. This 
indicated that a combination of dasatinib and BEZ-235 had beneficial effects in all of the c-
KIT transduced cells.     
Finally, each c-KIT transduced cell line was treated with masitinib to examine if the dose 
responses observed to dasatinib were restricted to this drug. Masitinib was selected as this is 
also a type I inhibitor that can target the WT receptor and certain c-KIT mutations.   
Masitinib was not as potent at inhibiting cell growth and inducing cell killing as dasatinib 
which is indicated when the IC50 values are compared for each cell line treated with each 
drug (Table 3.5 and Table 3.7). SFG-EMPTY, c-KIT-Δ417-419>Y and c-KIT-L576P 
expressing cells were most sensitive to masitinib. The c-KIT-Δ417-419>Y and c-KIT-L576P 
mutations may be more sensitive to masitinib because these mutations are thought to 
stabilise the ALD in a more active conformation, thereby increasing the binding affinity for 
masitinib. c-KIT-WT expressing cells were approximately 2 fold more resistant to growth 
inhibition and cell killing in comparison to SFG-EMPTY, c-KIT-Δ417-419>Y and c-KIT-
L576P cells. The differences in response of c-KIT-WT and SFG-EMPTY expressing cells to 
masitinib may be due to differences in drug receptor occupancy. UT-7 c-KIT-WT cells 
express a higher level of c-KIT compared to SFG-EMPTY expressing cells which suggests a 
greater concentration of masitinib would be required to saturate the receptors and mediate a 
response. In contrast, UT-7 c-KIT-D816V and c-KIT-N822K cells were considerably more 
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resistant to masitinib-mediated growth inhibition and cell killing in comparison to c-KIT-WT, 
SFG-EMPTY, c-KIT-Δ417-419>Y and c-KIT-L576P cells. Recent bioinformatic analysis of 
c-KIT-D816V X-ray structures has suggested that mutations at this residue not only modify 
the ALD but can also remodel the JMD by favouring removal of the JMD from the TKD, 
and this is proposed to further activate the receptor (Laine et al., 2011).  This supports the 
notion that mutations in the ALD may cause secondary structural changes that could prevent 
effective binding of inhibitors such as dasatinib and masitinib to the active site of c-KIT.  
This may pose implications not only for the treatment of AML but also for other diseases 
including systemic mastocytosis (SM). The presence of the c-KIT-D816V mutation has been 
reported to occur in 93% of patients with SM and has become an attractive therapeutic target 
for this disease (Garcia-Montero, 2006). However, clinical trials using dasatinib to treat SM 
have yielded disappointing results (Purtill et al., 2008;Verstovsek et al., 2008). This could be 
due to dasatinib being less effective at inhibiting c-KIT in the presence of the D816V 
mutation. 
In summary this chapter aimed to evaluate if all c-KIT mutations should be considered the 
same. To address this UT-7 cells were transduced with c-KIT-Δ417-419>Y, c-KIT-L576P, 
c-KIT-D816V and c-KIT-N822K as representative examples of mutations that occur in AML. 
This is the first direct comparison of c-KIT mutations occurring in different domains 
expressed in a human AML cell line. There were intrinsic differences in signal strengths 
between the mutants examined, only c-KIT-Δ417-419>Y and c-KIT-D816V expressing cells 
constitutively activated c-KIT in the absence of SCF and conferred ligand-independent 
growth. There were also differences in the level of factor independent growth and 
downstream signalling between these two mutants.  Each c-KIT mutant expressing cell line 
was treated with RTK inhibitors including dasatinib and masitinib. UT-7 cells expressing c-
KIT mutations in the ALD were more resistant to dasatinib or masitinib-mediated cell killing 
in comparison to cells expressing c-KIT mutations in the ECD and JMD. The resistance to 
dasatinib observed in UT-7 cells expressing c-KIT-D816V or c-KIT-N822K could be 
overcome by co-blockade of c-KIT and PI3K/mTOR. This data suggests that all c-KIT 
mutations cannot be considered the same and that screening for mutations in c-KIT may be 
imperative as the domain they occur in can affect the sensitivity to c-KIT inhibitors. The 
impact of c-KIT inhibitors in CBFL patients is currently ongoing in several clinical trials 
(trials NCT00850382 and NCT02013648).      
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4.  Chapter 4: Identification and functional analysis of a novel FLT3 
activating mutation in CBFL 
4.1 Introduction  
FLT3-TKD mutations occur in 5-10% of patients with AML (Frohling et al., 2007;Mead et 
al., 2007). Mutations within the TKD constitutively activate FLT3, promoting ligand-
independent growth and activation of downstream target proteins such as AKT and MAPK 
(Reindl et al., 2006;Rocnik et al., 2006;Frohling et al., 2007). The clinical implications of 
FLT3-ITD mutations on prognosis in AML have been assessed in large patient cohorts 
showing an adverse impact on outcome, but the impact FLT3-TKD mutations have on 
outcome is unclear (Mead et al., 2007;Whitman et al., 2008). Although the prognostic 
significance of FLT3-TKD mutations is debatable, patients with FLT3-TKD mutations have 
shown clinical responses to FLT3 inhibitors (Fiedler et al., 2005). Of note, patients without a 
FLT3-ITD or a TKD mutation have also shown clinical responses to FLT3 inhibitors, which 
may highlight the presence of unknown activating mutations outside of the currently 
screened domains. In accordance with this, point mutations, although rare (1% of adult 
patients with AML) have been found outside the TKD in regions including the ECD, JMD 
and KID and are listed in Table 1.8 (Reindl et al., 2006;Frohling et al., 2007;Smith et al., 
2012). 
Frohling et al (2007) highlighted the importance of distinguishing which of these mutations 
are so-called ‘driver’ or ‘passenger’ mutations. ‘Driver’ mutations which constitutively 
activate FLT3 and confer a proliferative advantage are proposed to respond to targeted 
inhibition. Although ‘passenger’ mutations do not activate FLT3 or confer a proliferative 
advantage, they may have an alternative role. The identification of new ‘driver’ FLT3 
mutations is therefore important as they may be sensitive to RTK inhibitors. This suggests 
that as diagnostic screening improves, patients with AML and these less frequent FLT3 
mutations could be eligible for clinical trials using FLT3 inhibitors. This chapter reports 
studies investigating a novel FLT3 mutation T820N identified in the ME-1 cell line. The 
functional properties of FLT3-T820N were examined by expression in the factor-dependent 
32D cell line. 
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4.2 Methods  
4.2.1 Cell lines 
MV4-11, MOLM-13, MV4-11, PL-21 and HMC1.2 AML cell lines were cultured in R1 or 
R2 media. 32D clone 3 (32Dcl3) IL3 dependent immature myeloid cell line was cultured in 
R1 plus 2ng/mL of murine IL3 (mIL3). 293T cells were cultured in R4. All cell lines were 
incubated in a humidified environment at 37°C in 5% CO2.  
4.2.2 Identification of FLT3 T820N mutation  
PCR was used to amplify exons 14-15 (328bp product) and 20 (278bp) of FLT3 and exons 8 
(206bp), 10-11 (454bp) and 17 (201bp) of c-KIT using 30ng of ME-1 gDNA. gDNA was 
amplified for 35 cycles with primers and the corresponding annealing temperatures listed in 
(Table 4.1). PCR products were obtained using the BIOTAQ
TM
 DNA polymerase or 
Optimase
TM
 following the manufacturer’s instructions and visualised on a 2% agarose gel as 
described in chapter 2 section 2.5.5. PCR products were sequenced using the appropriate 
primers.  
F= forward primer and R= reverse primer 
Table 4.1 PCR primers used to screen for common FLT3 and c-KIT mutations. 









































4.2.3 RNA extraction and cDNA amplification from ME-1 cells 
RNA was isolated from 1x10
6 
ME-1 cells were using the RNeasy mini Kit (QIAGEN) 
according to the manufacturer’s instructions. cDNA was subsequently made following the 
SuperScript® III First-Strand Synthesis System (Invitrogen Life Technologies) 
manufacturer’s protocol.  
4.2.4 PCR of FLT3 WT and T820N from ME-1 cDNA 
Full length FLT3 WT and T820N cDNA were amplified from the transcriptional start site to 
the stop codon using 30ng of cDNA from ME-1 cells illustrated in Figure 4.1.  DNA was 
amplified with primer pair SFG-FLT3-For and FLT3-reverse (2982bp product) listed in 
Table 4.2 using Phusion® DNA polymerase (New England BioLabs) following the cycling 
conditions described in chapter 2 sections 2.5.5 and 2.5.6 (Figure 4.1a).   FLT3 could not be 
cloned into the SFG vector using the SalI restriction site as it is also found within the FLT3 
sequence. To circumvent this FLT3 was cloned into the SFG vector using the restriction sites 
AgeI and MluI. A portion of the SFG vector containing the AgeI restriction site was 
amplified using primer pair MP1835 and SFG-FLT3-Inv/Rev (376bp) as this sequence is 
essential for transgene expression (Table 4.2 and Figure 4.1b). To anneal the SFG PCR 
product to the FLT3 PCR product overlapping primer extension PCR was performed using 
MP1835 and FLT3-reverse primers (3367bp) (Table 4.2) as illustrated in Figure 4.1c. PCR 
products were visualised and purified as described in chapter 2 section 2.5.6 and 2.5.12. All 












Blue = kozak sequence, under lined = MluI restriction site and red = mutated codon D835 



















































Figure 4.1. Amplification of FLT3 and subsequent cloning into the SFG vector backbone. (a) Amplification of FLT3-WT and FLT3-T820N from cDNA 
taken from the ME-1 cells. (b) Amplification of 376bp of the SFG vector containing the AgeI restriction site. (c) Overlapping by extension PCR of FLT3-WT 
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4.2.5 Cloning of FLT3 WT and T820N cDNA into the SFG-xm.eGFP.I2.eBFP2 
retroviral vector 
Approximately 0.5µg SFG-FLT3-WT and SFG-FLT3-T820N PCR products and 1µg of 
SFG-xm.eGFP.I2.eBFP2 vector were sequentially digested with MluI and AgeI in a 100µL 
reaction for 4 hours at 37°C following the manufacturer’s guidelines illustrated in Figure 4.2 
a,b. Digested plasmid vector was visualised on a 1% agarose gel and the desired band 
(7472bp) was cut out and purified as described in chapter 2 section 2.5.12. The digested 
SFG-xm.eBFP2 vector was ligated with the cut SFG-FLT3-WT or SFG-FLT3-T820N PCR 
products and cloned as described in chapter 2 section 2.5.12 (Figure 4.2c). Mini preps and 
midi preps were screened for the presence of FLT3 using an EcoR1 digest. If FLT3 was 
present two fragments were visualised when run on a 1% agarose gel one at 7183bp and 
another at 3500bp. Clones with FLT3 were sequenced directly using primers listed in Table 
4.3. 
4.2.6 Removal of the D7G polymorphism in the SFG-FLT3-WT construct 
After the SFG-FLT3-WT and SFG-FLT3-T820N constructs were sequenced a 20A>G 
nucleotide change, which would result in a D7G SNP, was identified in the SFG-FLT3-WT 
construct. To maintain the same background and examine the effect of just the T820N 
mutation, the D7G SNP was removed by correcting the SFG-FLT3-WT sequence with the 
SFG-FLT3-T820N sequence which did not have the SNP. The SFG-FLT3-WT and SFG-
FLT3-T820N constructs were digested with AgeI-HF and MfeI for 3 hours at 37°C. Digested 
fragments were visualised on a 1% gel and the SFG-FLT3-WT backbone product (8805bp) 
and the SFG-FLT3-T820N 1861bp (with no D7G SNP) product were gel extracted, 
illustrated in Figure 4.3a. These two fragments were then ligated together, cloned into the 
SFG-xm.eBFP2 vector and sequenced as described in chapter 2 section 2.5.11 (Figure 4.3b).  
U = exonic forward primer, D = exonic reverse primer, F = forward primer and underlined = 
MluI restriction site  



























Figure 4.2 Cloning FLT3-WT and FLT3-T820N into the SFG vector. (a) Sequential digest of SFGs-xm.eGFP.I2.eBFP with AgeI and MluI restriction 
enzymes. (b) Sequential digest of SFG-FLT3-WT and SFG-FLT3-T820N PCR products with AgeI and MluI restriction enzymes. (c) Ligation and cloning of 
SFG-FLT3-WT and SFG-FLT3-T820N into the SFG-xm.eBFP2 vector. Blue cross denotes T820N mutation.  
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Figure 4.3 Removal of D7G SNP from the SFG-FLT3-WT construct. (a) SFG-FLT3-WT and SFG-FLT3-T820N plasmid constructs were both digested 
with AgeI and MfeI restriction enzymes. (b) Ligation of 1861bp fragment from the SFG-FLT3-T820N construct, without the D7G SNP, to the 8805bp 
fragment from the SFG-FLT3-WT, WT at residue T820. Blue star denotes T820N mutation and green star denotes D7G SNP.
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4.2.7 Generation of SFG-FLT3-D835Y construct 
FLT3 D835Y is the most common FLT3-TKD in AML and therefore was used as a positive 
control. The FLT3-D835Y mutation was introduced by amplifying FLT3 from the SFG-
FLT3-WT construct using splicing by overlap extension PCR as described in chapter 2 
section 2.5.6. Two initial PCR reactions were carried out the first using primers MP1835 and 
FLT3-D835Y Reverse-Inverse (2894bp) and the second using FLT3-D835Y Forward and 
FLT3 Reverse (517bp) (Figure 4.4). A total of 30ng of the SFG-FLT3-WT construct was 
used as a DNA template and amplified for 35 cycles using the Phusion® DNA polymerase 
following the cycling conditions described in chapter 2 sections 2.5.5 and 2.5.6. Products of 
the correct size were gel extracted and purified.  MP1835 and FLT3-Reverse primers were 
used to anneal and amplifying across the 2894bp and 517bp FLT3-D835Y PCR products 
(Figure 4.4). The PCR reaction used 105-280ng of each purified PCR product and was 
carried out as specified in chapter 2 section 2.5.6. The amplified SFG-FLT3-D835Y PCR 
product (3367bp) was sequentially digested with AgeI and MluI and gel extracted. The cut 
SFG-FLT3-D835Y PCR product was ligated into the SFG-xm.BFP construct and cloned as 
described in chapter 2 section 2.5.12. The entire coding sequence of FLT3 was sequenced. 
4.2.8 Retroviral production.  
Retroviral supernatant for each of the FLT3 constructs was made as described in chapter 2 
section 2.2.2 using an Ecotropic envelope. Viral supernatant was snap frozen in an 
ethanol/dry ice bath and stored at -80°C.  
4.2.9 Transduction of 32D cells  
Non tissue culture treated 24 well plates were coated with 1µg/cm
2
 of RetroNectin® per well 
overnight at 4⁰C. Retroviral supernatants were thawed on ice and 250µL was used to coat 
each RetroNectin® coated well for 30 minutes at room temperature. The viral supernatant 
was then removed from each well and discarded. 32D cells were re-suspended at 6x10
5
 
cells/mL in R1 with 2ng/mL mIL3 and 500µL plated onto the RetroNectin® bound virus. 
The remaining viral supernatant (1.75mL) was gently overlaid on top of the 32D cells. The 
plate was centrifuged for 10 minutes at 1000g and incubated at 37°C in 5% CO2 for 24 hours. 
The cells were then harvested, re-suspended in fresh R1 with 2ng/mL mIL3 and incubated at 
37⁰C in a humidified atmosphere containing 5% CO2. After 48 hours, cells were examined 
for BFP positivity by flow cytometry (see chapter 2 section 2.4.3) and then subsequently 
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Figure 4.4 Cloning of FLT3-D835Y into the SFG vector. The FLT3-D835Y mutation was 
introduced by amplifying FLT3 from the SFG-FLT3-WT construct using splicing by overlap 
extension PCR. Two initial PCR reactions were carried out using primers MP1835 and 
FLT3-D835Y Reverse-Inverse and FLT3-D835Y Forward and FLT3-Reverse. Fragments (1) 
and (2) were gel extracted, annealed and amplified across using primers MP1835 and FLT3-
Reverse. The amplified SFG-FLT3-D835Y PCR product was sequentially digested with 
AgeI and MluI and ligated into the SFG-xm.BFP construct. Red crosses represent the FLT3-















4.2.10 Examination of CD135 expression 
A total of 1x10
6 
transduced and sorted cells were re-suspended in PBS/0.5% BSA and 
incubated with anti-CD135 PE conjugated antibody as described in chapter 2 section 2.4.4 
and analysed by flow cytometry.   
4.2.11 Proliferation assay 
32D cells were washed 3 times in PBS, re-suspended at 2.5x10
4
cells/mL in R1 and 100µL 
plated, in triplicate, into a 96 well plate in the presence or absence of mIL3 (2ng/mL), with 
or without increasing concentrations of human FL (1.56-6.25ng/mL). Cell proliferation was 
assessed every 24 hours using alamarBlue® following the manufacturer’s guidelines. 
Measurements were corrected for background using absorbance values from wells 
containing media only.  
4.2.12 Cytotoxicity assay  
MV4-11, MOLM-13, MV4-11, PL-21 and HMC1.2 cells at 4x10
5
cells/mL were treated with 
the indicated amounts of AC220 for 72 hours (see Figures 4.6). 32D cells at 4x10
5
cells/mL 
were treated with increasing concentrations of AC220 (range 0.1-100nM) or Ponatinib 
(range 3.125-200nM) for 48 hours with various cytokine combinations. Annexin/PI staining 
was assessed as described in chapter 2 section 2.4.2. The live cell fraction (Annexin and PI 
negative) and the absolute number of live cells were quantified by flow cytometry, and 
results expressed as a percentage of the control cells.   
4.2.13 Detection of Reactive Oxygen Species (ROS) 
A total of 10x10
6
 cells from each transduced cell line were washed three times in 20mL of 
PBS. For each cell line 5x10
6
 cells/mL were re-suspended in 5mL of R1 either with or 
without FL (10ng/mL) and returned to the incubator for 8 hours. After 8 hours cells were 
centrifuged at 448g for 5 minutes and re-suspended in 0.5% BSA/PBS at 1x10
6
 cells/mL. A 
total of 1x10
6
 cells/mL was aliquoted into individual 5mL polystyrene round-bottom tubes 
and centrifuged. Cells were then pre-loaded with CM-H2DCFDA by adding to each tube 
500µL of a master mix containing 495µL of  Hank’s Balanced Salt solution (HBSS) and 5µL 
of CM-H2DCFDA and incubated at 37°C for 30 minutes in the dark. To each tube 1mL of 
0.5% BSA/PBS was added and centrifuged at 448g for 5 minutes. Working stocks of 
hydrogen peroxide (H2O2) 0.25mM, 0.5mM, 1mM and 5mM were made fresh for each 
biological repeat. Cells were re-suspended in 500µL of 0.25mM, 0.5mM, 1mM, 5mM of 
H2O2 or 500µL HBSS for untreated cells and incubated for 15 minutes at 37°C 5% CO2 in 
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the dark. Cells were washed with 1mL of 0.5% BSA/PBS and centrifuged at 448g for 5 
minutes. Cells were re-suspended in 500µL 0.5% BSA/PBS and kept on ice until analysed 
on the flow cytometer. Live cells were gated based on their forward and side scatter 
properties. Cells within this gate were plotted onto a separate histogram with log CM-
H2DCFDA on the X axis and counts on the Y axis. The mean fluorescence intensity (MFI) 
was recorded for each point.   
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4.3 Results  
4.3.1 Screening of ME-1 cells for c-KIT and FLT3 mutations 
The ME-1 cell line is derived from a patient carrying inv(16) and therefore may be a useful 
model for studying signalling in CBFL. ME-1 cells were screened for mutations in known 
hotspots in c-KIT and FLT3. For each PCR reaction two controls were used - a negative 
control, the HL60 cell line, and a no DNA template control. There were no mutations in 
exons 8, 10+11 and 17 of c-KIT and they did not have a FLT3-ITD mutation (WT fragment 
size is 328bp) (Figure 4.5a). Sequencing of the FLT3-TKD region (278bp) revealed a 
heterozygous C>A DNA nucleotide substitution that would result in a missense Thr820Asn 





Figure 4.5 Analysis of FLT3-ITD and FLT3-TKD PCR products from HL60 and ME-1 
cells highlighting the identification of the FLT3 T820N mutation in ME-1 cells. (a) 
FLT3-ITD and FLT3-TKD PCR products amplified from HL60 and ME-1 cells and run on a 
agarose gel. (b) A sequence chromatogram from the ME-1 FLT3-TKD PCR product 






4.3.2 Response of ME-1 cells to the FLT3 inhibitor AC220 
ME-1 cells expressing FLT3-T820N, MV4-11, MOLM-13 and PL-21 cells, all carrying a 
FLT3-ITD, and FLT3-WT HMC1.2 cells were all treated with increasing concentrations of 
AC220 for 72 hours. MV4-11 and MOLM-13 cells were very sensitive to AC220 as 
demonstrated by potent growth inhibition (IC50s: 1.4 and 2.6nM respectively) and cell 
killing (IC50s: 4.5 and 8nM respectively) (Figures 4.6 a,b). PL-21 cells showed a clear 
decrease in the live cell number and the live cell fraction between 1.25µM and 10µM AC220 
(Figures 4.6 c,d). In contrast, AC220 had minimal effect on growth inhibition or cell killing 






Figures 4.6 Growth inhibition and cell killing of MV4-11, MOLM-13, PL-21, HMC1.2 
and ME-1 cells treated with AC220 for 72 hours. (a,c) Total number of live cells. (c,d) 














Figure 4.7 Effect of AC220 on signalling downstream of FLT3 in the HMC1.2, MV4-11, 
MOLM-13, PL-21 and ME-1 cells.  (a) Western blotting of HMC1.2, MV4-11, MOLM-13 
and PL-21 cells treated in the presence or absence of AC220 for 4 hours. (b) IP of FLT3 and 
western blotting from ME-1 cells treated in the presence or absence of AC220 for 4 hours. 
GAPDH was used as a loading control. 
 
Western blotting was used to assess the effect of AC220 on signalling downstream of FLT3 
in MV4-11, MOLM-13, PL-21, ME-1 and HMC1.2 cells. A concentration of 100nM of 
AC220 was used as this potently inhibited cell growth and induced cell killing in MV4-11 
and MOLM-13 cells. AC220 did not reduce phosphorylation of AKT, MAPK or S6 in the 
ME-1, HMC1.2 or PL-21 cells (Figure 4.7 a,b). In contrast, although MV4-11 and MOLM-
13 cells express low levels of phosphorylated AKT and MAPK there was a reduction in p-
AKT and p-MAPK which is mediated by inhibition of FLT3 autophosphorylation (see 
chapter 5 section 5.3.12). Immunoprecipitation of FLT3 showed that ME-1 cells do not 
express active FLT3, as indicated by no detectable p-FLT3, which could explain the lack of 
response to AC220 (Figure 4.7b). This data suggests that FLT3-T820N is not constitutively 
active in ME-1 cells.  
4.3.3 Transduction of 32D cells with SFG-FLT3 and SFG-EMPTY constructs  
To investigate the function of the FLT3-T820N mutation further, 32D cells were transduced 
with SFG-FLT3-T820N and for comparison SFG-FLT3-WT, SFG-FLT3-D835Y and SFG-
EMPTY constructs. 32D cells were successfully transduced with the various SFG-FLT3 and 
SFG-EMPTY constructs with transduction efficiencies ranging from 10-70% as assessed by 
BFP expression via flow cytometry. Cells were subsequently sorted based on BFP on the 
assumption that expression of BFP indicates expression of FLT3. Following sorting BFP and 




native cells were negative for BFP and CD135 expression whereas 32D cells transduced with 
FLT3-WT, FLT3-T820N, FLT3-D835Y and SFG-EMPTY vector were all 95-99% BFP 
positive (Figure 4.8a). Although 32D FLT3-D835Y cells were 95% BFP positive, they were 
dimmer in comparison to the other generated cell lines. For 32D cells expressing FLT3-WT 
or FLT3-T820N, the median MFI for BFP was 11.1 and 14.8 respectively which was roughly 
equivalent to the median MFI for CD135 11.5 and 13.1 respectively (Figure 4.8). In contrast 
CD135 expression was considerably lower in 32D FLT3-D835Y cells (median MFI: 0.8) 
(Figure 4.8 a,b). The lower CD135 staining within these cells may be due to a lower 
expression of the 160KDa fully glycosylated (membrane bound) FLT3 as a previous study 
has reported that FLT3-D835Y is retained within the endoplasmic reticulum, preventing it 
from reaching the cell surface (Choudhary et al., 2005). Western blotting confirmed a 
predominance of the 130KDa unglycosylated isoform in 32D FLT3-D835Y cells (Figure 
4.9). There was equivalent total FLT3 expression between 32D FLT3-WT and FLT3-T820N 
cells (Figure 4.9). Total FLT3 expression was considerably less in 32D FLT3-D835Y cells in 
comparison to FLT3-WT and FLT3-T820N expressing cells which is consistent with a 
dimmer BFP level.  
4.3.4 Impact of FLT3-T820N on proliferation  
The impact on proliferation of the FLT3-T820N mutation was examined in transduced 32D 
cells in comparison to 32D cells expressing FLT3-WT, FLT3-D835Y and SFG-EMPTY 
cells. 32D SFG-EMPTY cells did not proliferate in the absence of mIL3 and subsequently 
died after 3/4 days; they were unresponsive to FL (Figure 4.10a). FLT3-T820N expressing 
cells showed factor-independent growth which was significantly greater, from day 3 
onwards, when compared to 32D SFG-EMPTY (P <0.001, Two-way analysis of variance 
(ANOVA) with Bonferroni’s multiple comparisons post-test) and FLT3-WT expressing cells 
(P <0.01, Two-way ANOVA with Bonferroni’s multiple comparisons post-test) (Figure 
4.10b). 32D FLT3-D835Y cells also showed factor-independent growth but this was not 
increased further by the addition of FL (Figure 4.10c). The level of factor-independent 
growth was not statistically different on days 1-5 between cells expressing FLT3-D835Y and 
FLT3-T820N (P >0.05, Two-way ANOVA with Bonferroni’s multiple comparisons post-
test) however it was when comparing 32D FLT3-D835Y cells to SFG-EMPTY and FLT3-
WT expressing cells from day 4 onwards (D835Y vs EMPTY P <0.0001; D835Y vs WT P 
<0.01, Two-way ANOVA with Bonferroni’s multiple comparisons post-tests). In the absence 
of any growth factor, 32D FLT3-WT cells did not die but maintained a very low level of 
proliferation which was considerably lower than observed for 32D FLT3-T820N or FLT3-
D835Y cells (Figure 4.10d).  There was no statistical difference in proliferation rate between 
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FLT3-WT and SFG-EMPTY expressing cells in the absence of any growth factors between 
days 1-5 (P >0.05, Two-way ANOVA with Bonferroni’s multiple comparisons post-test). 
The addition of FL did increase the proliferation rates, however they did not reach the levels 
achieved in cells expressing FLT3-T820N. Both the FLT3-D835Y and FLT3-T820N 
expressing cells showed ligand-independent growth which was greater than FLT3-WT 






Figure 4.8 Examination of (a) BFP and (b) CD135 expression within 32D transduced 
cells. 
1
refers to the gated area, 
2
 refers to the entire cell population. 
 
 
Figure 4.9 Western blotting of transduced 32D cells examining total FLT3 expression. 
GAPDH was used as a loading control. 
Ref. 
colour 
Cell line BFP 
(%1) 






 32D Native 1.0 0.4 1.1 0.3 
 32D FLT3-WT 98.7 11.1 98.5 11.5 
 32D FLT3-T820N 97.8 14.8 98.1 13.1 
 32D FLT3-D835Y 95.3 4.2 41.0 0.8 




Figure 4.10 The impact of FLT3-T820N on proliferation in 32D cells in comparison to FLT3-WT, FLT3-D835Y and SFG-EMPTY expressing cells. 
Each cell line were incubated with ± IL3 (2ng/mL) in the presence of increasing concentrations of FL and treated with alamarBlue
®
. Data shown is the mean ± 
SEM of three individual experiments. 
(a) (c) 
(b)






   
Figure 4.11 Examining FLT3 signalling in 32D FLT3-T820N, FLT3-WT, FLT3-D835Y 
and SFG-EMPTY cells ± 3.125ng/mL FL for 4 hours. GAPDH was used as a loading 
control  
4.3.5 Impact of FLT3-T820N on downstream signalling 
32D FLT3-T820N cells demonstrated factor-independent growth, therefore the FLT3-
transduced and SFG-EMPTY cells were washed with PBS and cultured for four hours in the 
presence or absence of FL to evaluate differences in FLT3 downstream signalling. 
Autophosphorylation of FLT3 was used as a measure of FLT3 activity as indicated by 
phosphorylation of residues Tyr589/591. In the absence of any growth factor, 32D FLT3-
T820N cells showed autophosphorylation of FLT3 and constitutive activation of downstream 
target proteins (STAT5, AKT and PIM-1) as indicated by p-STAT5 and p-AKT (Figure 
4.11). Stimulation of 32D FLT3-T820N cells with FL further phosphorylated FLT3, 
however there was no corresponding up regulation of downstream target proteins. Although 
32D FLT3-D835Y cells had no detectable p-FLT3, they did show constitutive activation of 
STAT5, AKT, PIM-1 and MAPK. The addition of FL did not further activate downstream 
signalling. In contrast, 32D FLT3-WT cells starved of FL showed low/absent constitutive 
activation of FLT3, STAT5, AKT and PIM-1 in comparison to FLT3-WT cells stimulated 
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with FL (Figure 4.11). Stimulation of 32D FLT3-WT cells with FL increased 
phosphorylation of FLT3 resulting in activation of downstream target proteins. This suggests 
that constitutive activation of FLT3, STAT5, AKT and PIM-1 may contribute to the factor-
independent growth observed in 32D FLT3-T820N cells. Interestingly, 32D FLT3-WT cells 
had detectable p-FLT3 in the absence of FL. This suggests that the WT receptor can 
autophosphorylate, providing a rationale as to why FLT3-WT expressing cells did not die 
following continued growth factor starvation. 32D SFG-EMPTY cells treated with or 
without FL showed no detectable activation of FLT3, STAT5, AKT, PIM-1 or MAPK.  
4.3.6 Effect of AC220 treatment on 32D FLT3-expressing cells  
32D EMPTY, FLT3 WT, FLT3-T820N and FLT3-D835Y cells were treated with increasing 
concentrations of AC220 in the presence of mIL3 alone (2ng/mL), FL alone (10ng/mL) or in 
the presence of both cytokines for 48 hours examining growth inhibition and cell killing. In 
the absence of mIL3, 32D EMPTY cells died after 48 hours. In the presence of FL and mIL3 
or mIL3 alone 32D EMPTY cells were relatively resistant to AC220-mediated growth 
inhibition and cell killing (≤100nM) (Figure 4.12 a,b). 32D SFG-EMPTY cells did respond 
to 1000nM of AC220 as indicated by growth inhibition and cell killing, however as these 
cells do not express FLT3 the effects observed were most likely off-target effects. 
32D FLT3-T820N, FLT3-D835Y and FLT3-WT cells stimulated with FL and mIL3, mIL3 
alone or FL alone and treated with AC220 had similar dose responses in terms of growth 
inhibition and cell killing (Figure 4.12 c-h). The presence of FL and mIL3 or mIL3 alone did 
protect 32D FLT3 expressing cells to a certain extent from AC220 mediated growth 
inhibition and cell killing, however they were considerably more sensitive to AC220 when 











Figure 4.12 32D SFG-EMPTY, FLT3-WT, FLT3-T820N and FLT3-D835Y cells treated 
with AC220 in the presence or absence of 2ng/mL mIL3 with or without 10ng/mL FL 
for 48 hours. (a,c,e,g) Total number of live cells. (b,d,f,h) Percentage of cells in the live cell 







AC220 treatment in the presence of FL  
Data in Figure 4.12 did not show any striking differences between the FLT3 transduced cells 
in response to AC220 therefore each cell line was treated with a narrower dose range of 
AC220, between 6.25nM and 100nM, in the presence of FL (Figure 4.13). 32D FLT3-
T820N cells were significantly more sensitive to AC220-mediated growth inhibition (IC50 = 
17.6nM ± 2.3) compared to 32D FLT3-D835Y cells (IC50 = 52.2nM ± 11.1, P = 0.01, 
unpaired t-test) but not compared to 32D FLT3-WT cells (IC50 = 24.5nM ± 4.7, P = 0.25, 
unpaired t-test). 32D FLT3-T820N cells were significantly more sensitive to AC220-
mediated cell killing compared to both 32D FLT3-D835Y and FLT3-WT cells (IC50s 26 ± 
2.5, 61.1nM ± 11.8, 39.9nM ± 4.6, FLT3-T820N, FLT3-D835Y and FLT3-WT respectively; 
T820N vs D835Y P = 0.008, unpaired t-test ; T820N vs WT P = 0.03, unpaired t-test). To 
demonstrate that the difference in growth inhibition and cell killing were mediated by 
differences in sensitivity to FLT3 blockade, the level of phosphorylation of FLT3 target 
proteins was assessed. FLT3-transduced cells were washed with PBS and exposed to 6.25, 
12.5, 25, 50 and 100nM AC220 in the presence of 10ng/mL FL for 24 hours. In 32D FLT3-
T820N cells, concentrations ≥25nM of AC220 potently reduced phosphorylation of FLT3, 
STAT5 and AKT whereas concentrations ≥50nM were required to completely block p-FLT3 
and downstream signalling in 32D FLT3-WT cells (Figure 4.14). A concentration ≥50nM of 
AC220 reduced phosphorylation of AKT in FLT3-D835Y cells whereas 100nM of AC220 
was required to slightly reduce phosphorylation of FLT3 and STAT5. 
AC220 treatment in the absence of FL 
Similar results were obtained in the absence of FL (Figure 4.15). 32D FLT3-T820N cells 
were significantly more sensitive to AC220 mediated growth inhibition (IC50 = 7.9nM ± 
0.9) in comparison to 32D FLT3-D835Y cells (D835Y: IC50 = 38.7nM, P = 0.04 unpaired t-
test) but not 32D FLT3-WT cells (WT: IC50 = 14.3nM ± 2.6, T820N vs WT P = 0.08, 
unpaired t-test). AC220 induced significantly more cell killing in 32D FLT3-T820N cells in 
comparison to 32D FLT3-D835Y cells (IC50 = 42.1nM ± 2.8, P = 0.0004, unpaired t-test) 
but not 32D FLT3-WT cells (IC50 = 20 ± 5.8, P = 0.18, unpaired t-test) (Figure 4.15). FLT3-
transduced cells were washed with PBS and exposed to concentrations between 6.25 and 
100nM AC220 in the absence of FL for 24 hours. In the absence of FL, a concentration 
≥25nM AC220 most potently reduced p-FLT3, p-STAT5 and p-AKT in 32D FLT3-T820N 
cells, whereas both 32D FLT3-WT and FLT3-D835Y expressing cells were more resistant 
requiring 100nM of AC220 to reduce phosphorylation of FLT3 and downstream target 





Figure 4.13 Response of 32D FLT3 WT, FLT3-T820N and FLT3-D835Y cells to a 
narrower dose range of AC220 in the presence of 10ng/mL FL after 48 hours. (a) Total 
number of live cells. (b) Percentage of cells in the live cell fraction. Data shown is the mean 
± SEM of WT n=6, T820N n=5 & D853Y n=4 independent repeats. 
 
Figure 4.14 Western blots of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y 
expressing cells treated with 6.25-100nM of AC220, in the presence of 10ng/mL FL for 







Figure 4.15 Response of 32D FLT3 WT, FLT3-T820N and FLT3-D835Y cells to a 
narrower dose range of AC220 in the absence of FL after 48 hours. (a) Total number of 
live cells. (b) Percentage of cells in the live cell fraction.  Data shown is the mean ± SEM of 
three individual experiments. 
 
 
Figure 4.16 Western blots of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y 
expressing cells treated with 6.25-100nM of AC220, in the absence of FL for 48 hours. 






4.3.7 Response of FLT3-expressing cells to ponatinib 
To examine if the differential response to AC220 observed in 32D FLT3-expressing cells is 
limited to this inhibitor, the various cell lines were treated with another type II FLT3 
inhibitor, ponatinib. Treatment of 32D EMPTY cells with increasing concentrations of 
ponatinib in the presence of mIL3 did not inhibit cell growth or induce cell killing (Figure 
4.17 a,b). Ponatinib, in the presence of FL, inhibited cell growth at equivalent levels in 32D 
FLT3-T820N (IC50 = 20.6nM ± 2.3) and FLT3-WT cells (IC50 = 18.7nM ± 4, P=0.69, 
unpaired t-test) whereas FLT3-T820N cells were significantly more sensitive to growth 
inhibition than FLT3-D835Y cells (IC50 = 68.2nM ± 9, P = 0.002, unpaired t-test) (Figure 
4.17a). There was no differential response to ponatinib-mediated cell killing between 32D 
FLT3-T820N (IC50 = 25.6nM ± 3) and FLT3-WT cells (IC50 = 26.6nM ± 2.8, P = 0.8, 
unpaired t-test) whereas FLT3-T820N cells were significantly more sensitive to cell killing 
when compared to 32D FLT3-D835Y (IC50 = 88nM ± 12.2, P = 0.002, unpaired t-test) 
(Figure 4.17b). In the absence of FL, there was no differential response to ponatinib-
mediated growth inhibition between 32D FLT3-T820N (IC50 = 28.3nM ± 1) and FLT3-WT 
cells (IC50 = 38.4nM ± 8, P= 0.25, unpaired t-test) (Figure 4.17c). There was, however a 
trend for FLT3-T820N cells to be more sensitive to ponatinib-mediated cell killing than 32D 
FLT3-WT cells (T820N: IC50 = 28.3nM ± 1 and WT: IC50 = 63.8nM ± 9, P = 0.07, 
unpaired t-test) (Figure 4.17d). 32D FLT3-D835Y cells were more resistant to ponatinib 
when compared to 32D FLT3-T820N and FLT3-WT cells requiring concentrations ≥100nM 
to inhibit cell growth or induce cell killing (Figure 4.17c,d).  
4.3.8 Level of Reactive Oxygen Species (ROS) in FLT3-expressing cells  
The level of ROS was investigated in each cell line to ascertain whether this may contribute 
to the proliferative advantage observed in 32D FLT3-T820N cells. Each cell line was 
washed and treated with or without 10ng/mL FL for 8 hours. Each cell line was then 
incubated with the fluorescent probe CM-H2DCFDA and treated with H2O2 (Figure 4.18). 
Oxidation of CM-H2DCFDA produces a fluorescent adduct that becomes trapped within the 
cell, therefore providing a quantitative measure of ROS that can be assessed by flow 
cytometry. The basal level of ROS was not significantly different between the variant cells 
lines, whether in the presence or absence of FL (P >0.05, Two-way ANOVA with 
Bonferroni’s multiple comparison post-test) (Figure 4.18). The level of ROS was also 
measured in the presence of increasing concentrations of H2O2, with or without FL, in each 
variant cell line. The level of ROS did not significantly alter between the variant cell lines at 
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any H2O2 concentration, whether in the presence or absence of FL (P >0.05, Two-way 




   
  Figure 4.17 Response of 32D FLT3-WT, FLT3-T820N and FLT3-D835Y expressing 
cells to ponatinib in the presence or absence of 10ng/mL FL after 48 hours. 32D SFG-
EMPTY cells were treated with ponatinib in the presence of 2ng/mL mIL3. Data shown is 
the mean of FLT3-WT, FLT3-T820N, FLT3-D835Y n=4 & SFG-EMPTY n=3 independent 






Figure 4.18 Examining the level of ROS in 32D FLT3-WT, FLT3-T820N, FLT3-D835Y 
and SFG-EMPTY cells pre-incubated with or without 10ng/mL FL for 8 hours and 























4.4 Discussion  
Various different FLT3 point mutations have been identified and the functional consequence 
of these mutations examined in vitro. This is the first report of the FLT3-T820N mutation 
being identified in the ME-1 cell line and the functional consequence investigated. In AML 
the majority of activating point mutations in FLT3 occur in the ALD at residues D835 or 
N841. The FLT3-T820N mutation falls outside the ALD and lies just after the catalytic loop 
domain. This indicated that the FLT3-T820N mutation was not a ‘classical’ FLT3 mutation 
and therefore warranted further investigation. Initially ME-1 cells were treated with AC220 
to identify whether the mutation conferred resistance or increased sensitivity to growth 
inhibition or cell killing. These cells were completely resistant to AC220-mediated growth 
inhibition, cell killing or reducing phosphorylation of FLT3 target proteins. 
Immunoprecipitation of FLT3 from the ME-1 cell line revealed an absence of active FLT3. 
One explanation for this could be that the FLT3-T820N mutation has become redundant, 
suggesting that with multiple in vitro passages this mutation has been superseded by 
acquisition of a more potent driver mutation. Additional driver mutations were not 
indentified in mutational hotspots of c-KIT or FLT3 as initially investigated (Figure 4.5). 
AC220 is a type II inhibitor that binds to the inactive conformation of FLT3. ME-1 cells do 
not have active FLT3 signalling hence AC220 treatment did not impact on downstream 
signalling, cell killing or inhibition of growth. The reason why FLT3 is not 
autophosphorylated in ME-1 cells is not clear. It could be that a phosphatase has been up 
regulated in these cells resulting in FLT3 being constantly dephosphorlyated. Further 
investigation would be required to address this. HMC1.2 cells did not express detectable 
FLT3, explaining why they did not respond to AC220. There was also no detectable FLT3 in 
PL-21 cells which suggested the growth inhibition and cell killing observed between 
1.25µM-10µM AC220 was most likely the result of off-target effects. In contrast, MV4-11 
and MOLM-13 cells were sensitive to AC220-mediated growth inhibition and cell killing, 
demonstrating that AC220 is a potent inhibitor of activating FLT3 mutations (addressed 
further in Chapter 5).  
In order to investigate the functional consequence of the FLT3-T820N mutation 32D cells 
were transduced with constructs containing FLT3-WT, FLT3-T820N, FLT3-D835Y and 
SFG-EMPTY. Initial experiments examined the impact of the FLT3-T820N mutation on 
proliferation compared to cells expressing FLT3-WT, FLT3-D835Y and SFG-EMPTY. In 
the absence of mIL3, 32D EMPTY cells did not proliferate and died after 3/4 days (Figure 
4.10). 32D FLT3-D835Y expressing cells conferred factor-independent growth, which is 
consistent with previous reports (Abu-Duhier et al., 2001;Spiekermann et al., 2003). 32D 
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FLT3-T820N expressing cells were capable of factor-independent growth which was 
equivalent to 32D FLT3-D835Y cells, suggesting that FLT3-T820N is a gain of function 
mutation. FLT3 was autophosphorylated by the T820N mutation in the absence of any 
growth factor, resulting in strong activation of STAT5, PIM-1 and AKT which corresponds 
with other known activating FLT3 mutations (Figure 4.10) (Reindl et al., 2006;Rocnik et al., 
2006;Frohling et al., 2007;Smith et al., 2012). 32D FLT3-WT cells were capable of 
surviving without cytokines but only had a very low level of proliferation (Figure 4.10d). 
Reports have suggested that over-expression of the WT receptor may induce spontaneous 
phosphorylation of FLT3 and activate downstream signalling (Ozeki et al., 2004). This is 
supported in Figure 4.11 which shows that 32D FLT3-WT expressing cells could 
autophosphorylate FLT3, although at low levels, when starved of FL which may explain why 
the 32D FLT3-WT cells did not die following cytokine removal.  
As the FLT3-T820N mutation resulted in autophosphorylation of FLT3 conferring a 
proliferative advantage, it was of interest to examine the response of these cells to AC220. 
32D SFG-EMPTY cells in the presence of mIL3 were resistant to AC220-mediated growth 
inhibition and cell killing at concentrations ≤100nM AC220. In contrast, mIL3 could not 
protect 32D FLT3-expressing cells from AC220-mediated growth inhibition or cell killing at 
100nM concentration (Figure 4.12). As the FLT3-expressing cells did not die in the absence 
of mIL3 it suggests that these cells are less dependent on signalling via the IL3 receptor for 
cell survival, and that the IL3 receptor may be redundant and/or down-regulated in these 
cells. Another explanation could be that over-expression of FLT3 may swamp the 
endoplasmic reticulum machinery preventing as much IL3 receptor from being produced and 
expressed on the cell surface of these cells. Further experiments would be needed to explore 
this.   
32D FLT3-T820N cells were more sensitive to AC220-mediated cell killing, inhibition of 
growth and reducing phosphorylation of FLT3 and other downstream target proteins in the 
presence or absence of FL when compared to 32D FLT3-WT or FLT3-D835Y cells. 
Although both FLT3-T820N and FLT3-D835Y mutations conferred a proliferative 
advantage to 32D cells, they resulted in very different responses to AC220. The crystal 
structure of FLT3 in the absence of FL suggests that the receptor adopts an inactive 
conformation whereby the activation loop folds back into the ATP-binding cleft, blocking 
the loading of substrates (Griffith et al., 2004). In this conformation, the Asp829-Phe830-
Gly831 (DFG) motif, which resides at the amino-terminal within the activating loop domain, 
is flipped away from the active site (DFG-OUT). To activate FLT3, the activating loop needs 
to be removed from the active site while the DFG motif needs to flip inward towards the 
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active site (DFG-IN). Modelling of AC220 binding to FLT3 suggests that it is a type II 
kinase inhibitor demonstrating preferential binding to the inactive receptor (DFG-OUT) 
(Wodicka et al., 2010;Smith et al., 2012). This suggests that AC220 would have a lower 
affinity for the active conformation (DFG-IN). Specific amino acid residues are thought to 
stabilise the inactive conformation of the ALD, including D835 and Y842, and it has been 
proposed that mutations at these residues destabilise the inactive conformation, shifting the 
equilibrium to the active state and therefore preventing effective AC220 binding (Smith et 
al., 2012). This is consistent with the results presented here as 32D FLT3-D835Y cells were 
more resistant to AC220 in terms of inhibition of growth, cell killing and reducing 
phosphorylation of FLT3 in the presence or absence of FL in comparison to 32D FLT3-WT 
and FLT3-T820N cells. A similar response to AC220 has been observed in Ba/F3 cells 
expressing FLT3-D835Y which demonstrated that 100-1000nM AC200 was required to 
potently inhibit cell growth and reduce phosphorylation of FLT3 (Pauwels et al., 2012).  
Although the response of 32D FLT3-D835Y cells to AC220 is consistent with other 
published data, the response of 32D FLT3-T820N cells was more complex. The FLT3-
T820N mutation constitutively activated FLT3 and was most sensitive to AC220 compared 
to cells expressing FLT3-D835Y and FLT3-WT. This suggests that AC220 may bind to 
alternative kinase conformations, other than the currently known inactive configuration, 
when the activation loop is phosphorylated (DFG-IN). In support of this, AC220 has 
demonstrated potent anti-tumour activity against FLT3-ITD mutations, both in AML cell 
lines, primary AML cells and in in vivo mouse models (Zarrinkar et al., 2009;Pietschmann et 
al., 2012). This reiterates that AC220 must be able to bind to alternative conformations when 
there is an activating FLT3 mutation. Of note, all of the FLT3-expressing cell lines were 
more sensitive to AC220 in the absence of FL, supporting the notion that AC220 
preferentially binds to the inactive conformation of FLT3. Currently the mechanism of how 
type II inhibitors such as AC220 bind to the activation loop region when phosphorylated is 
unknown (Liu & Gray, 2006). 
To assess whether the response of the FLT3-expressing cells to AC220 was specific to this 
inhibitor, they were treated with another type II FLT3 inhibitor ponatinib. Ponatinib has 
demonstrated potent inhibition of FLT3 and cellular proliferation in in vitro and in vivo 
FLT3-ITD AML models (Gozgit et al., 2011). 32D FLT3-T820N and FLT3-WT cells treated 
with ponatinib in the presence of FL showed no discernible differences between growth 
inhibition or cell killing, whereas in the absence of FL the FLT3-T820N expressing cells 
were more sensitive to ponatinib. 32D FLT3-D835Y cells were the most resistant to 
ponatinib-mediated inhibition of growth and cell killing compared to either 32D FLT3-WT 
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or FLT3-T820N cells. Current binding models suggest, that like AC220, ponatinib binds to 
the DFG-OUT, inactive FLT3 conformation (Smith et al., 2013). The D835Y mutation is 
thought to destabilise this structure and therefore prevent ponatinib binding to FLT3, which 
explains the reduced toxicity observed when 32D FLT3-D835Y cells were treated with 
ponatinib. However, this cannot be the only mechanism of ponatinib binding to FLT3. 
FLT3-T820N cells were the most sensitive, in the absence of FL, to ponatinib. This suggests 
that the T820N mutation, although activating, generates a configuration that can more 
readily bind ponatinib. Of note, all of the FLT3-expressing cells were more resistant to 
ponatinib in the absence of FL, which is in stark contrast to what was observed under AC220 
treatment. This suggests that in the absence of FL ponatinib cannot bind as readily to the 
FLT3 receptor, regardless of mutational status. Overall, AC220 was more potent at inhibiting 
the FLT3-T820N mutation in comparison to ponatinib.  
FLT3-ITD mutations are reported to have increased endogenous levels of ROS, which has 
been associated with an increase in DNA damage and a decrease in end-joining fidelity 
(Sallmyr et al., 2008). Currently, FLT3-TKD mutations have not been associated with 
elevated ROS levels. In contrast, the presence of a FLT3-ITD mutation can lead to STAT5 
activation which can increase the level of ROS and contribute to driving cell proliferation 
(Sallmyr et al., 2008). As the FLT3-T820N mutation falls outside the TKD, led to factor-
independent growth and constitutively activated STAT5, it was hypothesised that ROS may 
be elevated in these cells. The basal level of ROS and response to H2O2 was assessed in each 
cell line. The basal level of endogenous ROS was equivalent across all the cell lines in the 
presence or absence of FL and there was no significant difference in response to H2O2 in the 
presence or absence of FL between the variant cell lines, suggesting that ROS do not play a 
significant role in cell growth in these cells.  
In summary, the data in this chapter report the identification of a novel FLT3-T820N point 
mutation in the ME-1 cell line. FLT3-T820N expressed in 32D cells conferred ligand-
independent growth and constitutively activated FLT3 in the absence of FL. 32D FLT3-
T820N cells were more sensitive to AC220 in regards to cell killing, inhibition of growth,  
reducing phosphorylation of FLT3 and downstream target proteins in comparison to FLT3- 
WT and FLT3-D835Y expressing cells. The same mutation has been identified by the 
Wellcome Trust Sanger Institute in the acute erythremia KMOE-2 AML cell line. Although 
the same mutation has been identified in two AML cell lines, the current MRC screening 
strategy for identifying FLT3-TKD mutations would encompass the T820 residue and the 
mutation would be detected by dHPLC but no such mutation has been detected in over a 
1000 patients screened (Rosemary Gale, personal communication). Therefore, as this 
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mutation has not been previously reported, it suggests that the T820N mutation is most likely 
a very rare mutation in AML.   
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5. Chapter 5: The impact of dasatinib and other small molecule 
inhibitors on AML cell lines and primary AML cells 
5.1 Introduction 
Activating mutations in c-KIT and FLT3 occur in 28% of CBFL and 30% of AML 
respectively and have been discussed in detail in chapters 3 and 4 (Kottaridis et al., 
2001;Mead et al., 2007;Allen et al., 2013). Mutations in c-KIT or FLT3 are associated with 
activation of key downstream signalling proteins including PI3K, AKT, mTOR and MEK. 
Activation of these signalling pathways is found in 50-90% of primary AML cells even in 
the absence of known RTK mutations, suggesting that these protein networks are intrinsic to 
the maintenance of AML cells (Xu et al., 2003;Grandage et al., 2005;Brandts et al., 
2005;Ricciardi et al., 2005). Targeting individual cell signalling molecules with small 
molecule inhibitors has elicited disappointing results in early clinical trials in AML and other 
malignancies (Rinehart et al., 2004;Yee et al., 2006;Cortes et al., 2012;Levis et al., 
2012;Zwaan et al., 2013).   
This chapter aimed to investigate the effect of combined RTK and AKT, mTOR, PI3K or 
PI3K + mTOR inhibition on cell growth, cell killing and signalling in AML cell lines and 




5.2 Materials and methods 
5.2.1 Cell lines 
Kasumi-1, SKNO.1, MV4-11, MOLM-13 and PL-21 cells were all grown in R2 media 
whereas HMC1.2 cells were cultured in R1 media, as described in chapter 2 section 2.1.6. 
Primary AML cells were thawed and left overnight in R3 media containing 20ng/mL of 
human SCF, FLT3, TPO and IL3. After 24 hours viable primary AML cells were isolated by 
density centrifugation, re-suspended in fresh R3, treated with small molecule inhibitors and 
incubated in a hypoxic atmosphere containing 5% CO2 and 5% O2 as described in chapter 2 
section 2.1.8.    
5.2.2 Screening of AML cell lines and primary AML cells for c-KIT and FLT3 
mutations  
PCR was used to amplify exons 14-15 and 20 of FLT3 and exons 8, 10-11 and 17 of c-KIT 
using primers listed in Table 4.1 as described in chapter 2 section 4.2.2. 
5.2.3 Annexin V/ PI assay  
Performed as described in chapter 2 section 2.4.2.    
 
5.2.4 Protein detection using western blotting 
Performed as described in chapter 2 section 2.3.4.     
5.2.5 Immunoprecipitation of FLT3 from MV4-11 and MOLM-13 cells 
MV4-11 and MOLM-13 cells (1x10
7 
cells/mL) were treated with AC220 for 4 hours. Cells 
were harvested and lysed in modified RIPA buffer (50mM TRIS HCL, 1% NP40, 0.25%  
sodium deoxycholate, 150mM NaCl, 1mM EGTA, 1mM PMSF, 1µg/mL leupeptin, 1µg/mL 
pepstatin A, 1mM NaF and 1mM Na3VO4). Harvested lysates were adjusted to contain 
equivalent amounts of protein using the DC
TM
 assay as described in chapter 2 section 2.3.3. 
They were then pre-cleared with a 50% slurry containing an equal volume of Protein G-
Sepharose 4 Fast Flow beads and RIPA lysis buffer for 1 hour at 4⁰C with end-over-end 
rotation. The beads were removed by centrifugation and the lysates were incubated with 2µg 
of FLT-3/Flk-2 antibody (C20) (Santa Cruz biotechnology) at 4⁰C over night with end-over-
end rotation. They were then incubated again with a 50% slurry containing an equal volume 
of Protein G-Sepharose 4 Fast Flow beads and RIPA lysis buffer for 2-3 hours at 4⁰C with 
end-over-end rotation. Protein bound to the beads were then washed 3 times with ice cold 
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lysis buffer and re-suspended in 50µL of NuPAGE® LDS Sample Buffer containing 10% 
NuPAGE® sample reducing agent. The samples were boiled for 5 minutes and 10µL was 
loaded onto a NuPAGE® Novex 7% Tris-Acetate Gel 1.0 mm. Gels were electrophoresed 
and transferred as described in chapter 2 section 2.3.4. 
5.2.6 Data analysis  
To examine if drug interactions were antagonistic, additive or synergistic at cell killing, the 
data was analysed using CalcuSyn software. This uses the Chou-Talalay method, which is 
based on the median-effect equation (Chou & Talalay, 1983;Chou & Talalay, 1984). The CI 




5.3.1 Confirmation of reported mutations in cell lines  
gDNA from HMC1.2, SKNO.1, Kasumi-1, MV4-11, MOLM-13 and PL-21 cell lines was 
screened for mutations in c-KIT (exons 8, 10, 11 and 17) and FLT3 (exons 14 and 15 [ITD] 
and 20 [TKD]) by sequencing and fragment size separation. The HMC1.2 cells had both a c-
KIT V560G and D816V mutation (Figure 5.1). The Kasumi-1 and the SKNO.1 cells both 
had the c-KIT N822K mutation (Figure 5.1). The MV4-11, MOLM-13 and PL-21 cells were 
WT for c-KIT. Only MV4-11, MOLM-13 and PL-21 cells lines had a FLT3-ITD mutation, 
shown in Figure 5.2 and quantified in Figure 5.3. Quantification of the FLT3-ITDs revealed 
that the MV4-11 cells only expressed the mutant allele which suggests complete loss of the 
FLT3-WT allele. The mutant level in the MOLM-13 and PL-21 cells was not equivalent to 
every cell having a heterozygous mutation i.e. 50:50. The reason for this is unclear. In the 
MOLM-13 cells a higher mutant level could indicate a proportion of the cells have lost the 
WT allele, whereas a lower mutant level in the PL-21 cells might suggest loss of the mutant 
allele in a proportion of cells. The HL60 cell line was included as a control which only 
expressed the WT allele. None of the cell lines examined had a mutation in exon 20 of FLT3. 
The mutations identified in each cell line are consistent with previous reports (Furitsu et al., 
1993;Quentmeier et al., 2003;Becker et al., 2008).   
5.3.2 Cytotoxic effects of dasatinib in Kasumi-1 and HMC1.2 cells  
To examine the cytotoxic effect of targeting c-KIT mutations, the Kasumi-1 and HMC1.2 
cells were treated with dasatinib. After 72 hours in the presence of dasatinib, Kasumi-1 cells 
showed a dose-dependent reduction in live cell number (IC50 = 9.2nM ± 0.57), and the 
percentage of live cells (IC50 = 21.4nM ± 2) (Figure 5.4 a,b). In contrast, HMC1.2 cells 
treated with dasatinib for 48 hours were more resistant to dasatinib-mediated growth 












HMC1.2 c-KIT 10+11  Forward 
HMC1.2 c-KIT 17  Reverse 
SKNO.1 c-KIT 17  Reverse 
Kasumi-1 c-KIT 17  Reverse 
Figure 5.1 Sequencing chromatograms showing the presence of c-KIT mutations in 

















Figure 5.2 Identification of FLT3-ITD mutations in MV4-11, MOLM-13 and PL-21 
cells. FLT3-ITD PCR products were amplified from HL60, MV4-11, MOLM-13 and PL-21 
cells and run on a agarose gel. The HL60 cell line was used as a WT control (WT PCR 
fragment size 328bp). 
 







HL60 FLT3 14-15 
 
100 0 
MV4-11 FLT3 14-15 
 
0 100 
MOLM-13 FLT3 14-15 
 
38 62 




Figure 5.3 Fragment analysis of FLT3–ITD mutations in the MV4-11, MOLM-13 and 
PL-21 cells. The HL60 cell line was used as a WT control. WT = Wild-type,  MUT = 













Figure 5.4 Response of Kasumi-1 cells to dasatinib after 72 hours (a) Total number of 
live cells. (b) Percentage of cells in the live cell fraction. Data shown is the mean ± SEM of 
three individual experiments. 
   Figure 5.5 Response of HMC1.2 cells to dasatinib after 48 hours (a) Total number of live 







5.3.3 The effect of dasatinib on signalling in c-KIT mutant cell lines 
As Kasumi-1 and HMC1.2 cells varied in their sensitivity to dasatinib-mediated growth 
inhibition and cell killing, the impact on targeting c-KIT and downstream signalling was 
assessed. Autophosphorylation of c-KIT was used as a measure of c-KIT activity as 
indicated by phosphorylation of residue Y719. Kasumi-1 cells treated with dasatinib for 4 
hours caused a dose-dependent reduction in phosphorylation of c-KIT at residue Y719 
between 20 and 80nM (Figure 5.6 a,b) There was also a corresponding reduction in 
phosphorylation of MAPK and S6 (Figure 5.6 a,b). The level of p-4E-BP1 was slightly 
reduced at dasatinib concentrations ≥ 40nM. In HMC1.2 cells, 0.3125-10µM dasatinib 
caused a dose-dependent reduction in phosphorylation of c-KIT corresponding with a 
reduction in phosphorylation of AKT, MAPK and S6 (Figure 5.7 a,b). Although c-KIT 
phosphorylation was potently reduced at concentrations between 0.3125µM and 1.25µM, the 
level of phosphorylation of AKT, MAPK and S6 remained disproportionately high. The 
level of p-4E-BP1 remained relatively unchanged following dasatinib treatment in the 
HMC.1.2 cells. A concentration of 2µM of imatinib did not reduce p-c-KIT levels in the 
HMC1.2 cell line.  
The capability of dasatinib to reduce autophosphorylation of c-KIT in HMC1.2 cells was 
explored further by extending the dose response range. Figure 5.8 illustrates after 4 hours a 
concentration greater than 0.08µM of dasatinib reduced phosphorylation of c-KIT. This 
suggests that although c-KIT activity is potently reduced other signalling molecules may 






Figure 5.6 Effect of dasatinib on signalling downstream of c-KIT in Kasumi-1 cells 




Figure 5.7 Effect of dasatinib on signalling downstream of c-KIT in HMC1.2 cells after 







Figure 5.8 Effect of expanded dose range of dasatinib on c-KIT phosphorylation in 
HMC1.2 cells after 4hours.  GAPDH was used as a loading control. 
5.3.4 Cytotoxic effect of combining dasatinib with other small molecule inhibitors in 
Kasumi-1 and HMC1.2 cells   
In Kasumi-1 cells, 40nM dasatinib completely blocked c-KIT phosphorylation and MEK but 
there was residual PI3K/mTOR signalling as indicated by the levels of p-4E-BP1 and p-S6 
(Figure 5.6 a,b). In HMC1.2 cells, dasatinib reduced c-KIT autophosphorylation fully at 
313nM, but there was also residual MEK, AKT, PI3K and mTOR signalling (Figure 5.7 a,b). 
Therefore, the effect of combining dasatinib with selective inhibitors of PI3K (ZSTK-474), 
mTOR (WYE-354), PI3K + mTOR (BEZ-235) and AKT (AZD5363) on cell survival and 
cell signalling was examined.  
Kasumi-1 cells were treated with selected inhibitors for 48 hours. As shown previously, 
dasatinib as a single agent was capable of killing Kasumi-1 cells at 80nM. Kasumi-1 cells 
were sensitive to ZSTK-474, WYE-354, BEZ-235 or AZD5363 alone as indicated by potent 
growth inhibition and cell killing (Figure 5.9 a,b). Treatment of Kasumi-1 cells with a 
combination of dasatinib and ZSTK-474, WYE-354, BEZ-235 or AZD5363 showed an 
enhanced reduction in cell growth and cell killing, particularly combinations of dasatinib and 
ZSTK-474, WYE-354 or BEZ-235 (Figure 5.9 a,b). In contrast, HMC1.2 cells required a 
concentration >1.25µM dasatinib to induce substantial cell killing. HMC1.2 cells were 
relatively sensitive to growth inhibition and cell killing mediated by ZSTK-474, WYE-354, 
BEZ-235 or AZD5363 alone (Figure 5.10 a,b). As the HMC1.2 cells were more resistant to 
dasatinib a higher dose range of 0.3125, 0.625, 1.25 and 5µM was used in combination with 
ZSTK-474, WYE-354, BEZ-235 or AZD5363. These drug combinations showed an 
enhanced reduction in cell growth and cell killing, particularly combinations of dasatinib and 
ZSTK-474, WYE-354 or BEZ-235 (Figure 5.10 a,b). The effect of the drug combinations 
was less striking in Kasumi-1 cells which may be due to a greater level of cell killing 





Figure 5.9 Response of Kasumi-1 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 after 48 hours. (a) Total number of live cells. (b) 




Figure 5.10 Response of HMC1.2 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 after 48 hours. (a) Total number of live cells. (b) 
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5.3.5  Evaluation of synergy between dasatinib and PI3K/mTOR inhibitors  
Kasumi-1 and HMC1.2 cells were treated with Dasatinib and PI3K/mTOR inhibitors to 
examine whether combinations of these drugs were additive or synergistic. Kasumi-1 cells 
were treated with a dose range of WYE-354, ZSTK-474 or BEZ-235 in combination with 
dasatinib for 72 hours. As shown in Figure 5.11 a-f BEZ-235 was the most potent 
PI3K/mTOR inhibitor at decreasing cell growth and inducing cell killing alone. Increasing 
concentrations of WYE-354, ZSTK-474 or BEZ-235 in combination with dasatinib, further 
inhibited cell growth and induced greater cell killing in comparison to either agent alone 
(Figure 5.11 a-f).  
HMC1.2 cells were treated with a dose range of WYE-354, ZSTK-474 or BEZ-235 in 
combination with dasatinib for 48 hours. As shown in Figure 5.12 a-f BEZ-235 was the most 
potent PI3K/mTOR inhibitor at reducing cell growth, however the effect of the various 
PI3K/mTOR inhibitors on cell killing was comparable. A combination of dasatinib and 
WYE-354, ZSTK-474 or BEZ-235 enhanced growth inhibition and cell killing in 
comparison to either drug alone (Figure 5.12 a-f). In particular dasatinib and ZSTK-474 or 
BEZ-235 had the most potent effects. The effect of dasatinib and the PI3K/mTOR inhibitors 
was less pronounced in Kasumi-1 cells which is most likely the result of these cells being 
more sensitive to dasatinib in comparison to HMC1.2 cells (Figure 5.11 a-f and Figure 5.12 
a-f).   
CalcuSyn software was used to examine if the interactions between dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 were synergistic at cell killing in each cell line (Table 5.1). In 
Kasumi-1 cells a combination of dasatinib and WYE-354, ZSTK-474 or BEZ-235 gave CI 
values at ED50 of <0.9, indicating that all drug combinations examined were synergistic 
(Table 5.1). In particular, dasatinib and the PI3K inhibitor ZSTK-474 showed the strongest 
synergy. In HMC1.2 cells, a combination of dasatinib plus WYE-354, ZSTK-474 or BEZ-
235 also gave CI values at ED50 of <0.9, indicating that all drug combinations examined 
were synergistic (Table 5.1). Of note, as seen in Kasumi-1 cells, a combination of dasatinib 






  Figure 5.11 Response of Kasumi-1 cells to combinations of dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 after 72 hours. (a,c,e) Total number of live cells. (b,d,f) Percentage 














Figure 5.12 Response of HMC1.2 cells to combinations of dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 after 48 hours. (a,c,e) Total number of live cells. (b,d,f) Percentage 









  CI Values at:  
Drug Combination Cell line  ED50 ED75 ED90 
Dasatinib + WYE-354 (1:25)  Kasumi-1 0.479 0.567 0.678 
Dasatinib + ZSTK-474 (1:25)  Kasumi-1 0.275 0.379 0.614 
Dasatinib +  BEZ-235 (1:25)  Kasumi-1 0.367 0.382 0.455 
Dasatinib + WYE-354 (1:4) HMC1.2 0.482 1.498 15.801 
Dasatinib + ZSTK-474 (1:4) HMC1.2 0.308 0.291 0.421 
Dasatinib + BEZ-235 (1:4) HMC1.2 0.562 0.432 0.533 
CI = Combination Index value, ED = Effective dose   
 
Table 5.1 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell killing data of Kasumi-1 and HMC1.2 cells treated with 





5.3.6 Impact of combined inhibition of c-KIT and PI3K/mTOR on downstream 
signalling in Kasumi-1 and HMC1.2 cells  
As combinations of dasatinib and WYE-354, ZSTK-474 or BEZ-235 showed synergistic cell 
killing (CI<0.9) in both Kasumi-1 and HMC1.2 cells, western blotting was used to examine 
the effect on downstream target proteins. Both cell lines were treated with inhibitory 
molecules for 4 hours. In Kasumi-1 cells, 40nM dasatinib potently reduced phosphorylation 
of c-KIT and MAPK. However, there was residual mTOR/PI3K signalling as indicated by 
levels of p-S6, p-p70-S6K and p-4E-BP1 (Figure 5.13a). WYE-354, ZSTK-474 or BEZ-235 
alone potently inhibited PI3K/mTOR targets but p-c-KIT and p-MAPK remained at levels 
equivalent to the control. Combining dasatinib with WYE-354, ZSTK-474 or BEZ-235 
markedly reduced residual PI3K and mTOR signalling compared with just dasatinib (Figure 
5.13a). This pattern was most striking when Kasumi-1 cells were treated with dasatinib and 
BEZ-235, as there was no residual p-p70 S6K, p-S6 or p-4E-BP1 expression.  
 
In HMC1.2 cells dasatinib alone potently reduced c-KIT autophosphorylation  however there 
was residual MEK, AKT, PI3K and mTOR signalling at a concentration of 0.625µM  
(Figure 5.13b). Treatment of HMC1.2 cells with WYE-354, ZSTK-474 or BEZ-235 alone 
potently inhibited mTOR/PI3K signalling indicated by a marked decrease in phosphorylation 
of p70 S6K, AKT, S6 and 4E-BP1 (Figure 5.13b). Combinations of dasatinib and WYE-354, 
ZSTK-474 or BEZ-235 significantly reduced the levels of p-p70 S6K, p-MAPK, p-AKT, p-
S6 and p-4E-BP1 compared to either drug alone. Of note, a combination of dasatinib and 
WYE-354 or BEZ-235 most potently decreased phosphorylation of downstream target 











Figure 5.13 Effect of dasatinib and WYE-354, ZSTK-474 or BEZ-235 on c-KIT and 
downstream signalling in Kasumi-1 and HMC1.2 cells after 4 hours. Western blotting of 
Kasumi-1(a) and HMC1.2 cells (b) treated with dasatinib and WYE-354, ZSTK-474 or BEZ-









5.3.7 A combination of dasatinib and inhibitors of PI3K/mTOR induces apoptosis  
The mechanism of cell killing in Kasumi-1 and HMC1.2 cells was examined further by 
screening of pro-apoptotic and anti-apoptotic Bcl-2 family members at 4, 24 and 48 hours of 
treatment. Cells were treated with dasatinib and WYE-354, ZSTK-474 or BEZ-235 for 4 and 
24 hours but showed little change in any apoptotic markers examined (data not shown). 
Therefore, cells were treated with inhibitor combinations for 48 hours. In Kasumi-1 cells 
treated with dasatinib alone there was no significant change in expression of the Bcl-2 family 
member proteins, pro-caspase 3 or PARP (Figure 5.14a). Treatment of Kasumi-1 cells with 
ZSTK-474 or BEZ-235 alone decreased expression of Mcl-1 corresponding with an increase 
in PARP cleavage but had a minimal effect on the other apoptotic proteins examined. WYE-
354 alone did not decrease expression of Mcl-1 or Bcl-2 however there was an increase in 
PARP cleavage suggesting other Bcl-2 family proteins might be involved in driving 
apoptosis through this inhibitor. Combinations of dasatinib and WYE-354, ZSTK-474 or 
BEZ-235 led to a significant decrease in Mcl-1. Combining dasatinib and BEZ-235 also 
reduced expression of Bcl-2. Only a combination of dasatinib and BEZ-235 led to a decrease 
in pro-caspase 3 however all drug combinations induced PARP cleavage (Figure 5.14a). The 
level of BIM did not change under any of the drug combinations in Kasumi-1 cells. 
HMC1.2 cells treated with dasatinib, WYE-354, ZSTK-474 or BEZ-235 alone did not 
significantly alter the expression of the Bcl-2 family member proteins examined and did not 
decrease expression of pro-caspases 3 or 9 (Figure 5.14b).  Only a combination of dasatinib 
and ZSTK-474 or BEZ-235 significantly decreased both Mcl-1 and Bcl-x. These drug 
combinations also led to a decrease in pro-caspases 3 and 9 and an increase in PARP 
cleavage (Figure 5.14b). Dasatinib and WYE-354 did not decrease levels of Mcl-1 or Bcl-2 
however there was an increase in PARP cleavage which suggests other proteins may be 
involved in driving cell killing through this drug combination. The effect of the drug 
combinations on BIM is inconclusive. Bcl-2 was not detected in HMC1.2 cells and Bcl-x 
and pro-caspase 9 were not detected in Kasumi-1 cells. Both Kasumi-1 and HMC1.2 cells 
were screened for changes in phosphorylation at residues S112 and S136 of the pro-apoptotic 
protein BAD however neither were detected in either cell line (data not shown). A 









Figure 5.14 Effect of dasatinib and WYE-354, ZSTK-474 or BEZ-235 on apoptotic 
regulators in Kasumi-1 and HMC1.2 cells after 48 hours of treatment. Western blotting 
of Kasumi-1(a) and HMC1.2 cells (b) treated with dasatinib and WYE-354, ZSTK-474 or 







5.3.8 Time course effect of dasatinib on c-KIT autophosphorylation in Kasumi-1 and 
HMC1.2 cells  
Kasumi-1 and HMC1.2 cells were cultured with dasatinib for 4, 8, 24 and 48 hours to assess 
if dasatinib could reduce phosphorylation of c-KIT in a sustained of transient manner. 
Treatment of Kasumi-1 cells with 40nM dasatinib reduced the level of p-c-KIT at 4 and 8 
hours which was completely decreased after 8 hours (Figure 5.15). The reduction in p-c-KIT 
corresponded with a complete decrease in phosphorylation of MAPK and S6. The level of p-
4E-BP1 expression only appeared to decrease more substantially after 24 or 48 hours, in 
accordance with the cells beginning to die.  
In HMC1.2 cells, 5µM dasatinib reduced c-KIT autophosphorylation at 4 and 8 hours of 
drug treatment and corresponded with a decrease in phosphorylation of AKT, MAPK and to 
a lesser extent S6. After 8 hours the level of c-KIT phosphorylation began to increase and by 
48 hours there was detectable phosphorylation of AKT, MAPK and an increase in 
phosphorylation of S6. It is unclear why this occurs but it could be due dasatinib being more 
rapidly metabolised in these cells.  
  
Figure 5.15 Time course effect of dasatinib on c-KIT autophosphorylation and 
downstream target proteins in Kasumi-1 and HMC1.2 cells. GAPDH was used as a 





5.3.9 Cytotoxic effect of dasatinib in SKNO.1 cells 
The SKNO.1 cell line expresses RUNX1/RUNX1T1 and bears a homozygous c-KIT N822K 
mutation. As SKNO.1 cells have similar genetic abnormalities to the Kasumi-1 cells it was 
of interest to assess the response of these cells to dasatinib. After 48 hours of treatment, 
dasatinib marginally decreased the number of live cells, in the presence or absence of GM-
CSF (Figure 5.16 a,c). Conversely, dasatinib did not induce cell killing in the presence or 
absence of GM-CSF (Figure 5.16 b,d). SKNO.1 cells were subsequently treated with 
dasatinib in combination with ZSTK-474, WYE-354, BEZ-235 or AZD5363 for 72 hours in 
the absence of GM-CSF (Figure 5.17 a,b). None of the inhibitor combinations reduced the 
live cell number below 50% of the control (Figure 5.17a) or decreased the percentage of 
cells in the live fraction below 70% of the control (Figure 5.17b).  
5.3.10 Effect of dasatinib on signalling in SKNO.1 cells 
As SKNO.1 cells showed no cytotoxic effect following dasatinib treatment, western blotting 
was used to assess the impact of dasatinib on c-KIT and downstream target proteins. 
SKNO.1 cells did not express any detectable c-KIT phosphorylation at residue Y719 and 
only expressed the unglycosylated c-KIT isoform (120KDa), not the fully glycosylated c-
KIT isoform (145KDa).  Treatment of the SKNO.1 cells with 1.25µM or 5µM dasatinib did 
not show any reduction in phosphorylation of AKT (Figure 5.18). This suggests that in 
SKNO.1 cells, c-KIT is not the driver mutation and therefore the cells are not a good model 













Figure 5.16 Response of SKNO.1 cells to dasatinib in the presence or absence of 
10ng/mL GM-CSF for 48 hours. (a) Total number of live cells. (b) Percentage of cells in 











Figure 5.17 Response of SKNO.1 cells to combinations of dasatinib and ZSTK-474, 
WYE-354, BEZ-235 or AZD5363 in the absence of GM-CSF after 48 hours (a) Total 
number of live cells. (b) Percentage of cells in the live cell fraction. Data shown is the mean 
± SEM of three individual experiments. 
 
 
Figure 5.18 Effect of dasatinib on c-KIT and downstream signalling in SKNO.1 cells 









5.3.11 Synergistic cell killing meditated by c-KIT and PI3K/mTOR blockade is limited 
to c-KIT mutant cells 
Combined inhibition of c-KIT autophosphorylation and constitutively active PI3K/mTOR 
led to synergistic cell killing in Kasumi-1 and HMC1.2 cells. To demonstrate that the 
enhanced cell killing observed was specific to targeting mutant c-KIT and its downstream 
targets, three c-KIT-WT cell lines (PL-21, MV4-11 and MOLM-13) were treated with 
dasatinib in combination with BEZ-235. BEZ-235 was selected as it was the most potent of 
the inhibitors studied at decreasing phosphorylation of mTOR and P13K targets, and 
combinations of dasatinib and BEZ-235 showed the most striking impact on apoptotic 
regulators in Kasumi-1 and HMC1.2 cells. Dasatinib and BEZ-235 did not show synergistic 
cell killing in the PL-21, MV4-11 or MOLM-13 cells (Figure 5.19 a-f). However, MV4-11 
and MOLM-13 cell lines were sensitive to BEZ-235 alone in regards to growth inhibition 
and cell killing (Figure 5.19 c-f).  The effect of dasatinib and BEZ-235 on cell killing in PL-
21, MV4-11 and MOLM-13 cells gave CI values at an ED50 of >1.1 indicating that drug 
interactions were antagonistic (Table 5.2).  
  CI Values at:  
Drug Combination Cell line  ED50 ED75 ED90 
Dasatinib + BEZ-235 (2.5:1)  PL-21 1.268 1.224 1.186 
Dasatinib + BEZ-235 (2.5:1)  MV4-11 1.137 1.588 2.220 
Dasatinib + BEZ-235 (2.5:1) MOLM-13 2.075 2.841 4.000 
    CI = Combination Index value, ED = Effective dose   
Table 5.2 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell 






   
  
 
  Figure 5.19 Response of PL-21, MV4-11 and MOLM-13 cells to combinations of 
dasatinib and BEZ-235 after 72 hours. (a,c,e) Total number of live cells. (b,d,f) Percentage 











5.3.12 MV4-11 and MOLM-13 cells treated with AC220 
It was hypothesised that cell lines expressing FLT3-ITD mutations treated with AC220 and 
BEZ-235 may show a similar synergistic cell killing profile as observed when targeting c-
KIT and PI3K/mTOR in c-KIT mutant cells. MV4-11 and MOLM-13 cells were treated with 
AC220 alone to ascertain a concentration range to use in combination with BEZ-235. MV4-
11 and MOLM-13 cells treated with AC220 for 72 hours showed a dose dependent reduction 
in cell growth (IC50 1.4nM and 2.6nM respectively) and cell killing (IC50 4.5nM and 8nM 
respectively) (Figures 4.6 a,b). In accordance with this, 12.5-100nM AC220 potently 
reduced phosphorylation of FLT3, MAPK and S6 in MV4-11 cells (Figure 5.20a). The 
MOLM-13 cell line also showed a dose-dependent reduction in the level of p-FLT3 between 
12.5 and 100nM AC220 (Figure 5.20b). The level of p-MAPK is very low in the MOLM-13 
cells making any reduction in phosphorylation difficult to ascertain. The levels of p-4E-BP1 
remained unchanged under AC220 treatment in both MV4-11 and MOLM-13 cells 
supporting the hypothesis that targeting PI3K and mTOR proteins in combination with 
AC220 may enhance cell killing. 
 
 
IP = Immunoprecipitation, α-PY = Anti-phosphotyrosine antibody 
Figure 5.20 Effect of AC220 on phosphorylation of FLT3 and downstream target 
proteins in MV4-11 and MOLM-13 cells. IP of FLT3 and western blotting of (a) MV4-11 
and (b) MOLM-13 cells treated with AC220 for 4 hours. GAPDH was used as a loading 






5.3.13 Cytotoxic effect of combining AC220 and BEZ-235 in FLT3-ITD mutant cells 
To examine the cytotoxic effects of targeting mutant FLT3 and constitutively active 
PI3K/mTOR, MV4-11, MOLM-13 and PL-21 cells were treated with AC220 and BEZ-235. 
As seen previously MV4-11 and MOLM-13 cells were sensitive to growth inhibition and cell 
killing mediated by AC220 or BEZ-235 alone (Figure 5.21 a-d). A combination of AC220 
and BEZ-235 showed an increase in growth inhibition and cell killing compared to either 
drug alone (Figure 5.21 a-d). MOLM-13 cells were particularly sensitive to this drug 
combination (Figure 5.21 c-d). PL-21 cells were considerably more resistant to AC220 as 
demonstrated by only a small decrease in growth inhibition and very little cell killing (Figure 
5.21 e,f). PL-21 cells were also relatively resistant to BEZ-235 requiring 1µM to 
significantly inhibit cell growth and induce some cell killing.  A combination of AC220 and 
BEZ-235 only slightly enhanced growth inhibition and cell killing in comparison to either 
agent alone (Figure 5.21 e,f). The lack of response to AC220 in the PL-21 cells may be due 
to total FLT3 levels being undetectable (Figure 4.7). 
A combination of AC220 and BEZ-235 were synergistic at cell killing in MV4-11 and 
MOLM-13 cells (CI values at ED50 of <0.9 for both cell lines) (Table 5.3). In contrast, 
AC220 and BEZ-235 were antagonistic in PL-21 cells CI value at ED50 of >1.1 (Table 5.3). 
 
   CI Values at:  
Drug Combination Cell line  ED50 ED75 ED90 
AC220 + BEZ-235 (1:100)  MV4-11 0.888 0.771 0.678 
AC220 + BEZ-235 (1:100)  MOLM-13 0.586 0.53041 0.484 
AC220 + BEZ-235 (2.5:1) PL-21 1.661 1.661 1.661 
    CI = Combination Index value, ED = Effective dose   
Table 5.3 CalcuSyn data providing the CI values at ED50, ED75 and ED90 from cell 









  Figure 5.21 Response of MV4-11, MOLM-13 and PL-21 cells to combinations of AC220 
and BEZ-235 after 72 hours. (a,c,e) Total number of live cells. (b,d,f) Percentage of cells in 











5.3.14  Impact of combined FLT3 and PI3K/mTOR blockade on cell signalling   
As AC220 and BEZ-235 were synergistic at cell killing in MOLM-13 and MV4-11 cells, 
western blotting was used to investigate the impact on downstream signalling. In MV4-11 
cells, AC220 (10nM) reduced phosphorylation of FLT3, MAPK and S6 whereas levels of p-
4E-BP1 remained unchanged (Figure 5.22). A combination of AC220 and BEZ-235 
inhibited FLT3 autophosphorylation and potently reduced phosphorylation of MAPK, S6 
and 4E-BP1. In MOLM-13 cells, AC220 (10nM) reduced p-FLT3 (Figure 5.22). A 
combination of AC220 and BEZ-235 reduced phosphorylation of FLT3 and 4E-BP1.  
 
IP = Immunoprecipitation, α-PY = Anti-phosphotyrosine antibody 
Figure 5.22 Effect of AC220 and BEZ-235 on phosphorylation of FLT3 and 
downstream target proteins in MV4-11 and MOLM-13 cells after 4 hours. GAPDH was 






5.3.15 Primary CBFL cells  
To assess the impact of targeting c-KIT and PI3K/mTOR further CBFL primary cells were 
treated with dasatinib and BEZ-235. A total of 27 primary CBFL cells were thawed of which 
20 had inv(16) and 7 had t(8;21). Following the overnight recovery step only 13 samples 
survived. Of the samples that did not recover 2 had the t(8;21) translocation and a c-KIT 
N822K mutation.  Of the 13 samples that survived 11 had inv(16) and 2 had t(8:21). A total 
of 5 samples provided both cell killing and western blotting data, 4 samples only provided 
cell killing data due to insufficient cells for western blotting, 3 samples only had western 
blotting data due to cells not surviving long enough in liquid culture to assess the impact on 
cell killing and 1 sample did not provide any information. From the cells that thawed one 
was a relapse sample and only one sample had a c-KIT mutation. The reason for the poor 
number of c-KIT mutant samples is due to the variability in how CBFL cells thawed and the 
ability of the cells to survive long enough in liquid culture to access the impact of the drugs 
on growth inhibition and cell killing.   
5.3.16 Impact of dasatinib and BEZ-235 on cell growth and cell survival in primary 
CBFL cells  
As dasatinib and BEZ-235 resulted in synergistic cell killing, eliminated c-KIT auto-
phosphorylation and markedly reduced residual MEK, AKT, PI3K and mTOR signalling in 
c-KIT mutant cell lines, it was hypothesised that a combination of dasatinib and BEZ-235 
may enhance cell killing in primary CBFL cells, in particular those with a c-KIT mutation. A 
total of nine primary CBFL cells had a cell viability ≥ 45% at 48 hours following Annexin/PI 
staining, shown in Figure 5.23 a-r. The remaining four patients were <10% viable upon 
analysis at 48 hours and therefore excluded.  All nine of the CBFL samples evaluable were 
c-KIT-WT. Dasatinib alone had a limited impact on inhibiting proliferation in the majority of 
samples however samples 1, 7, 8, 9 and 9 relapse did show a reduction in cell growth (Figure 
5.23 a, g, i, k and m). In contrast, dasatinib alone did not induce a significant level of 
apoptosis in any of the samples examined (Figure 5.23 a-r). The response of the primary 
cells to BEZ-235 alone was varied. All samples except 10 or 11 demonstrated that BEZ-235 
inhibited cell growth (Figure 5.23 a, c, e, g, i, k and m) with a modest effect on cell killing 
(Figure 5.23 b, d, f, h, j, l and n). A combination of dasatinib and BEZ-235 did not enhance 




































Figure 5.23 Response of primary CBFL samples to combinations of dasatinib and BEZ-
235 after 48 hours. (a,c,e,g,i,k,m,o,q) Total number of live cells. (b,d,f,h,j,l,n,p,r) 
Percentage of cells in the live cell fraction. 
(r) (q) 
(p) (o) 





5.3.17 The effect of dasatinib and BEZ-235 on downstream signalling in primary 
CBFL cells 
Primary CBFL cells were cultured in the presence of dasatinib, BEZ-235, dasatinib and 
BEZ-235 or with no inhibitor for 4 hours. Total lysates were subsequently probed for 
phospho-specific antibodies against AKT, MAPK, 4E-BP1, S6 and p-70 S6K. Western 
blotting data was available for 8 patients, the other 4 samples did not have sufficient cell 
numbers for western blotting analysis.  Seven patients had constitutive activation of MAPK, 
as indicated by p-MAPK, and all patients had constitutive activation of the mTOR pathway 
as shown by p-p70-S6K, p-S6 and p-4EB-P1 expression (Figure 5.24). Only 3 patients had 
constitutive activation of AKT. When the CBFL cells were cultured in the presence of 
dasatinib, there was a reduction in p-MAPK in 4 samples (patients 2, 4, 9, and 11) 
corresponding with a reduction in p-p-70-S6K and p-S6. BEZ-235 alone potently reduced 
phosphorylation of p-70 S6K, S6 and 4E-BP1 in 7 samples (patients 1, 2, 3, 4, 6, 11 and 12). 
A combination of dasatinib and BEZ-235 had a variable impact in the CBFL primary cells 
examined. Patients 2 and 11 showed a decrease in constitutive activation of p70 S6K, MAPK, 
S6, and 4E-BP1 in the presence of both dasatinib and BEZ-235 in comparison to either drug 
alone. In comparison, patients 1 and 4 showed an increase in p-S6 expression following dual 
inhibitor treatment. Patient 12 was the only sample with a c-KIT mutation, D816V. Dasatinib 
did not inhibit phosphorylation of AKT or PI3K/mTOR target proteins in this sample. In 
contrast patient 12 did show potent inhibition of p-p70 S6K, p-S6 and p-4E-BP1 when 
treated with BEZ-235 alone or dasatinib and BEZ-235. There were insufficient cells for 






Figure 5.24 Impact of dasatinib and BEZ-235 on cell signalling in primary CBFL samples after 4 hours.  Top panel treated with a lower dasatinib 






5.4  Discussion 
The use of small molecule inhibitors against mutated RTKs or activated signalling molecules 
has elicited a limited clinical response in AML (Rinehart et al., 2004;Yee et al., 2006;Cortes 
et al., 2012;Levis et al., 2012;Zwaan et al., 2013). Therefore this chapter aimed to evaluate 
the response of AML cell lines and primary CBFL cells to inhibitors targeting either c-KIT 
or FLT3 in combination with inhibitors of downstream signalling molecules.   
AML cell lines were first screened for mutations in c-KIT and FLT3 and confirmed the 
presence of c-KIT N822K in Kasumi-1 and SKNO.1 cells, c-KIT V560G and D816V in 
HMC1.2 cells and the presence of FLT3-ITD mutations in MV4-11, MOLM-13 and PL-21 
cells. The mutations identified in each cell line were consistent with previous reports (Furitsu 
et al., 1993;Quentmeier et al., 2003;Becker et al., 2008). Quantification of the FLT3-ITD 
mutations in the MOLM-13 and PL-21 cells indicated there was not a heterozygous mutation 
in every cell. The higher FLT3-ITD level in the MOLM-13 cells could indicate a proportion 
of the cells are homozygous for the FLT3-ITD mutation. Cells with a homozygous mutation 
may have a greater proliferative advantage compared to those cells with a heterozygous 
mutation and might have begun to out compete those with the heterozygous mutation. In 
contrast a proportion of the PL-21 cells appear to have lost the FLT3-ITD. This may be due 
to the FLT3-ITD becoming redundant in these cells as data presented in chapter 4 showed 
there was no detectable FLT3 or any response to AC220. To investigate this further each cell 
line could be single cell sorted, expanded and the mutant level of each clone analysed. This 
would identify if some of the MOLM-13 cells have a homozygous FLT3-ITD or if a 
proportion of the PL-21 cells have lost the FLT3-ITD mutation.    
Initial experiments showed that dasatinib was capable of potently inhibiting c-KIT 
phosphorylation in Kasumi-1(40nM) and HMC1.2 (157nM) cells, which  corresponded to 
potent cell killing in the Kasumi-1 cells (IC50 21.4nM ± 2) whereas the HMC1.2 cells were 
more resistant to cell killing (IC50 3.1µM ±0.6). This is consistent with previous reports 
(Schittenhelm et al., 2006;Mpakou et al., 2013). HMC1.2 cells were more resistant to 
dasatinib-mediated inhibition of c-KIT phosphorylation which could be due to the presence 
of both the V560G and D816V mutations. Alternatively this may just be due to the presence 





expressing c-KIT-D816V were the most resistant to dasatinib-mediated inhibition of c-KIT 
phosphorylation in comparison to the other mutant expressing cells, including UT-7 c-KIT-
N822K cells. HMC1.2 cells may be more resistant to dasatinib-mediated cell killing due to a 
high expression of p-AKT, p-S6 and p-MAPK even when c-KIT activity is eliminated 
(Figure 5.7). Activation of these proteins is associated with promoting cell survival and 
proliferation; therefore residual activation might be sufficient to keep the cells alive. 
Stimulation of AKT, S6 and MAPK, in the absence of c-KIT activity, also suggests other 
signalling molecules may activate these proteins. Of note the dose response observed 
between 1.25µM-10µM dasatinib in regards to the decrease in phosphorylation of AKT, 
MAPK and S6 is most likely mediated by off target effects.  
HMC1.2 cells were also treated with imatinib however there was no decrease in c-KIT 
autophosphorylation or phosphorylation of downstream target proteins. Previous reports 
have shown that imatinib can inhibit c-KIT autophosphorylation in cells harbouring the c-
KIT V560G mutation but not cells with the c-KIT D816V mutation (Frost et al., 2002;Shah 
et al., 2006). The c-KIT D816V mutation might therefore dominate over the V560G 
mutation in the HMC1.2 cells which might explain why there was no decrease in c-KIT 
activity or downstream target proteins.   
SKNO.1 cells also express the c-KIT N822K mutation, however in this study there was no 
detectable phosphorylation of c-KIT. This may explain why dasatinib did not induce 
significant levels of apoptosis alone or in combination with other small molecule inhibitors 
in these cells. Dasatinib did inhibit cell growth in the absence of GM-CSF at concentrations 
<0.3125µM however this was not observed at higher concentrations. This is supported by a 
report that showed dasatinib significantly inhibited proliferation of SKNO.1 cells at 10nM 
concentration (Han et al., 2010). The response observed might be mediated by dasatinib 
targeting Src tyrosine-protein kinase proteins which is only effective at nanomolar 
concentrations or it could be due to off target effects. As c-KIT did not appear to be the 
driver mutation in SKNO.1 cells, it was not considered a good model for assessing the 
effects of dasatinib against mutant c-KIT and these cells were not further investigated.  
In both Kasumi-1 and HMC1.2 cells, combinations of dasatinib and inhibitors of PI3K, 





reduction in residual constitutive activation of MEK, AKT, PI3K and mTOR target proteins. 
This indicates that both c-KIT and PI3K/mTOR signalling is essential for the survival of 
these cells. The most potent effects were observed with combinations of dasatinib and BEZ-
235. There are several possible reasons why this drug combination was the most effective. 
Firstly, BEZ-235 simultaneously targets mTOR and P13K whereas the other inhibitors 
examined only target mTOR or PI3K. This is advantageous as previous reports have shown 
that mTORC1 can be activated independently of PI3K, and inhibition of mTOR can lead to 
complex compensatory feedback loops activating AKT and P13K (Tamburini et al., 2008). 
Secondly, BEZ-235 was most potent at inhibiting phosphorylation of PI3K/mTOR target 
proteins in both cell lines compared to the other inhibitors examined. Thirdly, BEZ-235 
alone decreased autophosphorylation of c-KIT in Kasumi-1 cells and dasatinib and BEZ-235 
most strongly inhibited c-KIT activity in HMC1.2 cells (Figure 5.13). This could indicate a 
downstream feedback mechanism, mediated by BEZ-235 that could lead to an enhanced 
reduction in c-KIT activity. Finally, dasatinib and BEZ-235 was the only drug combination 
to significantly reduce expression of anti-apoptotic Bcl-2 family member proteins and 
decrease levels of caspase proteins in both cell lines.  
Subsequently, the same approach was adapted to targeting mutant FLT3 and PI3K/mTOR in 
PL-21, MV4-11 and MOLM-13 cells. Treatment of MV4-11 and MOLM-13 cells with 
AC220 inhibited autophosphorylation of FLT3 at 12.5nM, which corresponded with potent 
cell killing, IC50 4.5nM and 8nM respectively, and is consistent with other reports 
(Zarrinkar et al., 2009;Gunawardane et al., 2013). AC220 and BEZ-235 did not enhance 
inhibition of cell growth or induce cell killing in PL-21 cells. As previously discussed in 
chapter 4, the poor response to AC220 is most likely due to an absence of FLT3 expression 
in PL-21 cells. In contrast, AC220 and BEZ-235 induced synergistic cell killing and reduced 
residual mTOR signalling in MV4-11 and MOLM-13 cells. In support of this, recently 
published data has shown that simultaneous blockade of FLT3 and PI3K with small 
molecule inhibitors in FLT3-ITD AML cell lines enhanced apoptosis in comparison to the 
individual agents in hypoxic and normoxic conditions (Jin et al., 2013). In accordance with 
this finding, another study demonstrated that inhibition of FLT3 and AKT in FLT3-mutant 
cell lines and primary AML cells could synergistically inhibit cell growth in the presence or 
absence of stroma (Weisberg et al., 2013). It would be of interest to examine the response of 





combination might have a therapeutic benefit. AC220 has already been used in several 
clinical trials and has shown particular promise in patients with FLT3 mutations whereas 
BEZ-235 is just beginning to enter phase I clinical trials in acute leukaemias (Cortes et al., 
2012;Levis et al., 2012) (trial NCT01756118).   
As a result of the promising data obtained from targeting c-KIT and mTOR/PI3K in c-KIT 
mutant cell lines, a cohort of primary CBFL cells were treated with dasatinib and BEZ-235. 
Of the CBFL samples examined all but one were wild-type for c-KIT. The reason for the low 
number of c-KIT mutant samples investigated was due to the variability in how individual 
patient samples thawed and the ability to maintain the AML samples long enough in culture 
to assess the impact of the drugs.  The effects of dasatinib and BEZ-235 in primary c-KIT 
mutant CBFL cells therefore could not be assessed fully. However, as dasatinib can inhibit 
the kinase activity of the WT receptor at nanomolar concentrations and c-KIT is highly 
expressed on 60-80% of myeloblasts (Beghini et al., 2004;Schittenhelm et al., 2006), it did 
provide an opportunity to assess the impact of targeting the WT receptor in conjunction with 
PI3K and mTOR. Dasatinib alone inhibited cell growth in 5 samples but did not induce 
significant cell killing in any samples. BEZ-235 alone inhibited cell growth in 7 samples as 
well as having a modest impact on cell killing. None of the primary CBFL cells treated with 
dasatinib and BEZ-235 showed synergistic or additive effects on inhibiting cell growth or 
inducing cell killing. This indicates that dasatinib and BEZ-235 may not be an effective 
therapeutic approach for killing CBFL cells with WT c-KIT. These observations support the 
effects seen in c-KIT-WT cell lines treated with dasatinib and BEZ-235 (Figure 5.19). Of 
note, patient samples 2 and 11 showed dasatinib and BEZ-235 could reduce p-MAPK, p-S6 
and p-4E-BP1 further than either drug alone but did not result in cell killing. This suggests 
that other signalling pathways may contribute to the survival of the leukaemic cells. A phase 
I dose escalation study in paediatric patients aged 1-21 with relapsed or refractory AML and 
c-KIT-WT showed no clinical responses to dasatinib. This may indicate that dasatinib alone 
has a limited impact in c-KIT-WT expressing patients. The data presented in this chapter 
provides evidence that combining dasatinib and BEZ-235 in c-KIT-WT AML cell lines or 






In summary, a combination of dasatinib and ZSTK-474, WYE-354 or BEZ-235 were 
synergistic in c-KIT mutant cell lines at cell killing, with similar results observed with 
AC220 and BEZ-235 in FLT3-ITD AML cell lines. The response of primary CBFL cells to 
dasatinib and BEZ-235 was limited to those with c-KIT-WT due to low numbers of samples 
having a c-KIT mutation. Primary CBFL cells with c-KIT-WT showed a limited response to 
dasatinib, BEZ-235 or a combination of dasatinib and BEZ-235.  Further work is required to 
investigate the therapeutic potential of dasatinib and BEZ-235 in c-KIT mutant primary 
CBFL cells in conjunction with assessing the effect of AC220 and BEZ-235 in primary 















6. Conclusions and future directions  
Although there have been improvements in therapeutics and supportive care, the majority of 
patients with AML eventually succumb to the disease. This has led to the development of 
new therapeutic options for AML. One such approach is the use of small molecule inhibitors 
against frequently mutated RTKs or dysregulated signalling pathways. In AML RTKs such 
as c-KIT and FLT3 are frequently mutated and key signalling pathways including 
PI3K/AKT, mTOR and MEK are constitutively activated in a large proportion of patients 
(Gilliland & Griffin, 2002;Grandage et al., 2005;Frohling et al., 2007;Allen et al., 2013). 
Numerous reports have tried to exploit this by using small molecule inhibitors to target 
individual signalling proteins but clinical responses have primarily been cytostatic and not 
cytotoxic  (Rinehart et al., 2004;Yee et al., 2006;Cortes et al., 2012;Levis et al., 2012;Zwaan 
et al., 2013). The data in this thesis aimed to evaluate if all c-KIT mutations should be 
considered equivalent and to evaluate the efficacy of small molecule inhibitors against RTK 
mutations and activated downstream signalling molecules. 
Clinical data has shown that patients with CBFL and a c-KIT mutation have an increased RR 
(Paschka et al., 2006;Cairoli et al., 2006;Allen et al., 2013). Several studies have shown that 
c-KIT mutations, occurring across the receptor, can lead to constitutive activation of c-KIT 
and confer factor independent growth in cell line models (Ning et al., 2001;Growney et al., 
2005;Schittenhelm et al., 2006;Wang et al., 2011). Data in chapter 3 showed that expression 
of c-KIT-Δ417-419>Y and c-KIT-D816V in UT-7 cells led to autophosphorylation of c-KIT 
and ligand independent growth. This suggested that c-KIT could be an attractive therapeutic 
target for patients with a c-KIT mutation. UT-7 cells engineered to express c-KIT mutations 
in different domains and cell lines with endogenous c-KIT mutations showed differential 
sensitivities to dasatinib-mediated growth inhibition, cell killing and inhibition of c-KIT 
phosphorylation (chapter 3 and 5). The c-KIT-D816V mutation was identified as being more 
resistant to dasatinib-mediated inhibition of c-KIT phosphorylation in engineered UT-7 c-
KIT D816V cells and in the HMC1.2 AML cell line that has a naturally occurring D816V 
mutation. Although dasatinib was potent at inhibiting c-KIT phosphorylation there was 
residual mTOR and/or PI3K/AKT signalling in both UT-7 transduced cells and c-KIT mutant 
cell lines. A combination of c-KIT and PI3K/mTOR blockade reduced residual mTOR 





with endogenous c-KIT mutations. This drug combination was particularly potent against 
cells expressing c-KIT-D816V. In the primary CBFL samples examined all but one were 
wild-type for c-KIT. In these samples c-KIT and PI3K/mTOR blockade did not significantly 
inhibit cell growth or induce cell killing. This suggests the therapeutic efficacy of targeting 
c-KIT and PI3K/mTOR may be limited to patients with a c-KIT mutation.  
Examining the effects of dasatinib and BEZ-235 in primary CBFL cells with c-KIT 
mutations was affected by difficulties in thawing and maintaining primary AML cells in 
culture. Further work would require investigating a greater number of samples with c-KIT 
mutations to evaluate if dasatinib and BEZ-235 is effective at inducing cell killing. The 
culture conditions used to maintain primary AML cells would need to be improved and one 
possible method would be to culture cells on murine MS-5 stroma. This method has 
previously been shown to decrease apoptosis (Konopleva et al., 2002). To further investigate 
the effects of c-KIT mutations on AML progression a mouse model could be generated by 
transducing murine BM cells with constructs expressing c-KIT-WT, c-KIT-Δ417-419>Y, c-
KIT-L576P, c-KIT-D816V or c-KIT-N822K in conjunction with constructs expressing either 
RUNX1-RUNX1T1 or CBFβ-MYH11. This would allow a direct comparison between mice 
expressing the same c-KIT mutation in the presence of t(8;21) or inv(16). This may show 
differences in disease biology and disease progression as certain mutations such as those in 
the ECD are more frequently found in patients with inv(16) (Care et al., 2003) whereas ALD 
mutations are more frequently found in patients with t(8;21) (Park et al., 2011b). It would 
also provide a model system to examine the efficacy of dasatinib and BEZ-235 in vivo. The 
effects of dasatinib, BEZ-235 or dasatinib and BEZ-235 would also need to be assessed in 
normal CD34 progenitor cells using long term colony formation assays, by the impact on 
engraftment in NOD/SCID mice and by characterising the effects on normal murine BM 
cells in the in vivo model of inhibitor treatment.  
Identifying the domain in which c-KIT mutations occur will be important clinically, as 
different mutants have varying responses to c-KIT inhibitors. For example the c-KIT-D816V 
mutation has been reported to be resistant to imatinib (Growney et al., 2005) and data in 
chapter 3 showed that UT-7 cells expressing c-KIT-D816V and c-KIT-N822K were 
relatively resistant to dasatinib and masitinib. This indicates that the region in which the c-





examining c-KIT mutational status in paired presentation and relapse CBFL patients showed 
that 6 of 13 patients with a c-KIT mutation lost or changed their c-KIT mutation at relapse 
(Allen et al., 2013). This shows that in some patients the acquisition of a c-KIT mutation is 
likely to be a secondary event and has implications for the use of c-KIT inhibitors.  
FLT3-mutant AML cell lines treated with the FLT3 TK inhibitor AC220 and the 
PI3K/mTOR inhibitor BEZ-235 also showed a similar synergistic cell killing profile as c-
KIT mutant cells treated with dasatinib and BEZ-235 (chapter 5).  To explore this drug 
combination further primary AML cells both with and without FLT3 activating mutations 
would need to be treated with AC220 and BEZ-235 to examine if this drug combination 
could enhance cell killing in samples with a FLT3 mutation.  
Chapter 4 reported the identification and functional consequence of the FLT3-T820N 
mutation in ME-1, a patient derived, AML cell line. Although the FLT3-T820N mutation 
autophosphorylated FLT3 and resulted in ligand-independent growth, the mutation has not 
been detected in approximately 1000 primary AML samples (Rosemary Gale, personal 
communication). This indicates this mutation occurs infrequently in AML. However, 32D 
FLT3-T820N cells were more sensitive to AC220-mediated inhibition of FLT3 
phosphorylation and induction of cell killing in comparison to 32D cells expressing FLT3-
WT and FLT3-D835Y. This reiterates that mutations outside the classical mutational 
hotspots can respond to FLT3 inhibitors. Therefore, as screening strategies improve, patients 
with AML and infrequent FLT3 mutations could be eligible for clinical trials using FLT3 
inhibitors.  
In summary, this thesis examined the impact of AML specific c-KIT mutations, occurring 
across the receptor, showing that each mutation varied in its ability to activate c-KIT and its 
downstream targets. Dasatinib had variable effects on cells harbouring distinct c-KIT 
mutations and simultaneous blockade of mutated RTKs and PI3K/mTOR enhanced cell 
killing in AML cell lines. These observations may provide the basis for novel therapeutic 
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